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ABSTRACT
Background
Direct-to-consumer advertising (DTCA) of prescription medicines is prohibited in
Australia, but pharmaceutical companies can provide information about the health
condition for which they manufacture a prescription product – commonly referred to
as disease awareness advertising (DAA). The pharmaceutical industry purports that
DAA provides education regarding health conditions and different treatment options,
and may encourage early diagnosis and treatment. However consumer and public
health advocates are concerned that DAA has the potential to inflate the perceived
prevalence of disease, increase consumer anxiety, and result in unnecessary visits to
doctors. They believe it provides an indirect method of advertising prescription
medicines to consumers, and has the potential to increase the uptake of newer
medicines whose risk profiles are not fully understood. While studies overseas have
demonstrated that DAA can increase consultations regarding the advertised disease,
as well as prescriptions for the advertiser’s product, there has been no research
conducted in Australia regarding DAA, or consumers’ attitudes toward this form of
advertising.

Method
This research project examined recent cases of pharmaceutical industry-sponsored
DAA in Australia, and undertook a content analysis of advertisements in popular
women’s magazines. To determine how Australian consumers perceive DAA, and
how this compared to their perceptions of DTCA, a survey was conducted using
matched DAA and DTCA as stimuli. General attitudes to DAA were compared with
results from a similar study conducted in New Zealand exploring attitudes to DTCA.
Finally, an intercept survey explored attitudes of older Australian women towards
hypothetical DAA for two health conditions. Sponsor logos and the amount of
disease information were manipulated in the advertisement stimuli.

Results
Pharmaceutical companies use a range of persuasive techniques in DAA, and while
the name of the product is not included, other branding techniques, such as spokescharacters and campaign names, may convey the identity of the product. The most
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common type of information found in DAA in popular Australian women’s
magazines (which included advertisements sponsored by government and non-profit
organisations) was treatment information, and industry advertisements more often
provided information about treatment and prevalence.

In the survey research, despite pharmaceutical company branding on the DAA
stimuli, most participants did not attribute a direct commercial intent (to sell a
treatment or product) to the advertisements. They perceived the advertisements were
designed to provide information and to make them more proactive about their health.
Similar to New Zealand consumers considering DTCA, Australian consumers valued
DAA for the information it provides about health conditions and treatment options;
however they may have been considering DAA sponsored by government and/or
non-profit organisations. Participants perceived DAA to be useful in discussions with
their doctor, but were ambivalent as to whether it helped them in making health
decisions.

Following exposure to DAA stimuli, most participants agreed that they would talk
about the condition with their doctor or talk about a treatment with their doctor, and
up to half expressed an intention to ask for a prescription or referral. In the intercept
survey, older women exposed to advertisements with less disease information were
less likely to be satisfied that adequate information was provided, but were more
likely to express an intention to ask their doctor for a prescription or a referral.

Discussion
The results suggest that DAA, particularly advertisements with limited disease
information, can stimulate demand for prescription medicines. Despite purporting an
educational function, most industry DAA focus on treatment information and many
utilise persuasive techniques which may convey the identity of the product. This has
implications for regulators of pharmaceutical advertising in Australia, as activities
which encourage patients to seek a prescription for a specific product are prohibited.

The results demonstrate the commercial intent (and potential commercial success) of
industry DAA. However, it is concerning that most consumers (our research
indicates up to 90%) do not recognise this intent, and they may be less critical in

ix

evaluating advertisements. While consumers value the information provided in DAA,
many advertisements fail to provide detailed or comprehensive disease information.
The regulation of DAA requires strengthening, with specific recommendations
regarding the amount and breadth of disease information to be included.

x
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1.

CHAPTER 1: INTRODUCTION AND AIMS

Pharmaceutical industry promotion of medicine and disease has targeted consumers
for hundreds of years (Baudot, 1991; Donohue, 2006). However these promotions,
particularly for prescription medicine products, have become more common over the
past 20 years with the advent of direct-to-consumer advertising (DTCA) of
prescription medicines in the United States (US) and New Zealand. In Australia,
where DTCA is prohibited, companies are limited to promoting awareness about the
diseases or health conditions for which they manufacture a prescription medicine
product. This form of advertising is commonly referred to as disease awareness
advertising (DAA) and can include information on the disease (such as the
symptoms), but cannot include the name or brand of a prescription medicine product.
This introductory chapter provides a brief background of DTCA and DAA, and the
regulation of pharmaceutical advertising for prescription medicines in Australia. It
identifies that limited research has been conducted into DAA, and outlines the series
of studies conducted for this thesis which aimed to increase understanding of the
types, content, and consumer perceptions, of pharmaceutical promotions.

1. 1 Background
Western culture is becoming increasingly medicalised, with previously non-medical
problems redefined as health conditions requiring pharmacological treatment
(Conrad and Leiter, 2004; Finlayson and Mullner, 2005). A related phenomenon is
the ‘pharmaceuticalisation’ of health, where resources are increasingly provided for
research, education and promotion of pharmacological remedies over other potential
solutions (Toop and Mangin, 2002). For some conditions where previously the only
approach was behaviour change strategies (such as diet/exercise to reduce obesity)
there is now a range of prescription, over-the-counter and complementary medicines.

A range of stake-holders have contributed to the increasing medicalisation of society
including doctors and other health professionals, pharmaceutical companies,
governments, health insurers, and advocate groups, as well as consumers themselves
(Conrad and Leiter, 2004; Dear and Webb, 2006). Pharmaceutical companies serve
to gain by creating new markets, or expanding existing markets, for their products
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and thus increasing profits (Moynihan, et al., 2002). The media are also important
agents of medicalisation in informing consumers of new diseases or symptoms as
well as new or emerging treatments (Woloshin and Schwartz, 2006). Since the
patients’ rights movement of the 1970s, consumers themselves have challenged the
autonomy of doctors and health authorities and have demanded access to information
regarding treatment options (Donohue, 2006; Mackenzie et al., 2007). More recent
advances in technology since the 1990s (including the Internet) have further enabled
consumers to inform themselves about diseases and potential treatments and become
more actively involved in their health care decisions (Donohue, 2006).
1.1.1

Prescription Medicines

The increasing demand for, and reliance on, medicines within western societies has
significant economic and social implications. This is particularly the case for
prescription medicines as they are deemed by regulatory authorities as having higher
risk, and can only be obtained with the written consent of a health professional
(Australian Government Department of Health and Ageing, 2007a). While it is
generally acknowledged that medicines can significantly improve individual and
public health, there are also potential negative outcomes, such as the lack of efficacy
of a product, adverse side effects, and poly-pharmacy (the use of five or more
medicines, commonly associated with sub optimal prescribing and increased risk of
negative outcomes for the patient (Hilmer, 2008)).

Improving standards of living coupled with the ageing of populations in western
societies has led to heightened consumer expectations about their health and
longevity (Heath, 2006). Consumers are increasingly looking toward pharmaceutical
solutions for what may previously have been considered elements of a natural ageing
process (such as balding) or for complex social and behavioural problems (Conrad
and Leiter, 2004; Heath, 2006). For example, Viagra has been promoted to treat any
degree of erectile dysfunction (Lexchin, 2006). In some instances, patients may
perceive prescription medicines to be more effective than over-the-counter
alternatives, or may request prescription medicines inappropriately. For example, a
study has shown that patients experiencing upper-respiratory tract infection often
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request antibiotics from their doctor, but actually require pain relief for their
symptoms (van Driel et al., 2006).

In countries such as Australia that provide national health cover (where the cost of
approved pharmaceutical products is subsidised) increasing reliance and over-use of
medicines comes at a cost to the tax-payer, as well as to the individual. The
Australian Government’s Pharmaceutical Benefits Scheme (PBS) has subsidised the
cost of prescription medicines for over 60 years. The cost of the PBS is reported as
approximately $7 billion per year, but is estimated to reach $8.2 billion in 2009/10
(Australian Government Department of Health and Ageing, 2009a). In an effort to
improve the rational use of medicines, the Australian Government instigated the
National Medicines Policy in 1999 (National Prescribing Service, 2009). Key
objectives included: timely and affordable access to medicines; medicines meeting
standards of quality, safety and efficacy; the Quality Use of Medicines (QUM); and
maintaining a responsible and viable medicines industry. The objectives called for
accurate information about medicines and their use to be available for consumers and
health professionals, as well as responsible advertising that will enhance public
health (Australian Government Department of Health and Ageing, 2009b).

However Lofgren and de Boer (2004) describe that while the Australian government
was concerned most with affordability and access of pharmaceuticals prior to the
1980s, the neo-liberal governments since that time have increasingly considered the
interests of the pharmaceutical industry. Heath (2006) recognises that governments
have to balance support for industry with a sustainable health care system. However
she suggests the ongoing focus on the treatment of disease is also an effort of
governments to alleviate potentially more difficult responsibilities of disease
prevention or addressing social causes (Heath, 2006). While the pharmaceutical
industry in Australia claims to support QUM (Medicines Australia, 2009), others
argue that the industry may prioritise its commercial duty to shareholders over its
social duty (Vitry, 2004).

Following the large-scale development and success of penicillin during the late
1930’s, the pharmaceutical industry has dramatically evolved with the establishment
of in-house research and development programs and rapid rates of discovery and
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introduction of new drugs (Malerba and Osrsenigo, 2002). The industry has become
increasingly successful and powerful on a global scale, with impressive growth rates
and profits throughout the 1990s. The past decade, however, has brought new
challenges including shorter patent periods and increasing competition from generics
(Moss and Schuiling, 2003). The increasing cost of research and development, with
fewer returns by way of innovative or ‘block-buster’ pharmaceutical products, has
resulted in a shift in focus from research and development to aggressive marketing
practices, many of which have attracted criticism (Angell, 2006).

Pharmaceutical companies have been accused of playing an active part in disease
mongering (Mintzes, 2006; Moynihan and Cassels, 2005), which is defined as
“widening boundaries of treatable illness in order to expand markets for those who
profit from treatments” (Moynihan, et al., 2002 p. 886). The influence of the industry
on the medical profession has been heavily criticised, and marketing practices such
as providing gifts and continuing medical education activities, as well as
pharmaceutical representative visits to doctors, are linked to increased and
unnecessary prescribing (Australian Consumers' Association, 2008b; Breen, 2004).
Other marketing practices of the pharmaceutical industry that target the general
public, including direct-to-consumer advertising and public relations activities, have
also been criticised as having adverse effects and resulting in outcomes that are
contrary to QUM (Brown, 2009; Vitry, 2004).
1.1.2

Advertising of Prescription Medicines to Consumers

Direct-to-consumer advertising (DTCA) of prescription medicines is currently
prohibited in Australia by the Therapeutic Goods Act (Australian Government
Department of Health and Ageing, 2007b). However, the practice does occur in the
neighbouring country of New Zealand, as well as in the US. There is ongoing debate
regarding the potential benefits and harms of DTCA in these two countries, as well
as nations that have considered its adoption (including Canada and Europe).
Pharmaceutical companies and proponents argue that DTCA provides consumers
with important information regarding medicines and health conditions, and that it can
assist in earlier diagnosis and treatment, improved doctor/patient relationships, and
medication compliance (Auton, 2007; Bonaccorso and Sturchio, 2002). Opponents
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argue that DTCA is about increasing profit rather than improving public health, and
that it can lead to over-prescribing of unnecessary, costly and potentially harmful
pharmaceutical products (Lyles, 2002; Mintzes, 2002). For example, the
manufacturers of the product Vioxx, Merck Sharp and Dohme, are still facing public
criticism, lawsuits and class action after undertaking aggressive DTCA in the US
without adequately disclosing that the product increased rates of myocardial
infarctions and stroke (Consumers International 2006, Topol 2004). The company
had annual sales of more than $US1 billion for Vioxx, and was spending more than
$US100 million on DTCA despite mounting evidence of the risks. More than 80
million patients had taken the medicine by September 2004 when the drug was
withdrawn and it is estimated that tens of thousands of patients had major adverse
events as a result of taking Vioxx (Topol 2004). There is concern that while DTCA is
persuasive, it often lacks educational value (Kaphingst and DeJong, 2004; Woloshin
et al., 2001) and this may result in tension between doctors and patients requesting a
prescription, or a misuse of consultation time as the doctor attempts to re-educate
patients regarding the suitability or risks of the prescription product (Toop and
Mangin, 2006).

The advertising of prescription medicine in Australia is currently regulated by the
pharmaceutical industry body Medicines Australia (MA) via a Code of Conduct.
Edition 15 of the Code of Conduct was in effect from 2007 until the end of 2009
(Medicines Australia, 2006). Sections of the Code relevant to marketing directly to
consumers included Section 9.4 (Promotion to the General Public) and Section 9.5
(Patient Education). These sections allowed for the advertising of health conditions
or diseases, and general information on the broad range of treatments that may be
available, but prohibited the naming of a particular product or brand (Medicines
Australia, 2006). This form of marketing is commonly called ‘disease awareness
advertising’ (DAA), but is referred to as ‘help-seeking advertising’ in the US and
Canada, and ‘disease awareness campaigns’ or DACs in the United Kingdom (UK).

A national review of the Australian Drugs, Poisons and Controlled Substances
Legislations in 2000 examined literature from New Zealand and the US with regard
to DTCA, and weighed up the potential costs and benefits to the Government,
consumers and the pharmaceutical industry. The review did not support a relaxation
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of the current prohibition (Galbally, 2000). The Review considered “unbranded
product advertising” but concluded that permitting such advertising for prescription
medicines would potentially have similar negative outcomes as for DTCA. DAA was
also considered, and identified as a form of advertising that circumvents the
prohibition of DTCA in Australia. The Review recommended that a Code of Practice
should be developed with specific requirements for DAA such that these
advertisements would benefit the community as a whole (Galbally, 2000).

Since the Review, there has been speculation about the potential introduction of
DTCA in Australia with the establishment of the Australian New Zealand
Therapeutic Products Authority (ANZTPA) in 2003 and in the prelude to the Free
Trade Agreement with the US in 2004 (Harvey et al., 2004). The Therapeutic
Products Advertising Code drafted as part of the establishment of ANZTPA
recognised and defined DAA as “…information that aims to raise awareness
regarding specific diseases, including public health campaigns…” (ANZTPA, 2005
p. 9). The ANZTPA code also recognised unbranded product advertising, and stated
that it “promotes the use and supply of a product by inviting the consumer to seek
information about symptoms or conditions and/or their treatment or management
while not referring overtly to any particular branded product,” (ANZTPA, 2005 p. 9).
However, the Code was not explicit as to whether this type of advertising was
permissible for prescription medicines. The establishment of ANZTPA stalled in the
New Zealand Parliament in 2007, however there is potential that the process will be
resumed (ANZTPA, 2007).
1.1.3

Disease Awareness Advertising

Much of the debate that surrounds DTCA is relevant to industry-sponsored DAA.
The pharmaceutical industry claims that it provides an important educational
function, particularly for health conditions that are under-diagnosed, and may help
consumers to identify symptoms and seek help. However, like DTCA, DAA has also
been identified as a form of ‘disease mongering’, and some pharmaceutical
campaigns have been criticised for encouraging consumers to identify with the
symptoms or risk factors of an advertised condition in order to increase the potential
market for a prescription medicine (Moynihan and Cassels, 2005). Further, there is
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concern that DAA may encourage consumer reliance on medications to solve what
may be social or behavioural problems, has the potential to increase consumer fear
and anxiety, and may potentially drive consumers to visit their doctors unnecessarily
(Mintzes, 2006; Moynihan and Henry, 2006).

Only two studies, one in the US and one in the Netherlands, have been identified that
considered the influence of DAA on consumers. Both demonstrated the capacity of
DAA to increase consultations for the advertised conditions, and prescriptions for the
advertiser’s products (Basara, 1996; t'Jong et al., 2004). While exploratory research
in Australia has considered consumer attitudes towards DTCA (Jones and Mullan,
2006; Miller and Waller, 2004; Vatjanapukka, 2004), there is no identified research
into consumers’ attitudes towards DAA, or whether attitudes towards DAA and
DTCA differ. Further, while case studies of DAA have been identified across a range
of media (Australian Consumers' Association, 2008a; Hughes and Minchin, 2003),
no studies have attempted to quantify the prevalence of DAA in Australian media.

Despite the recommendations of the National Review, a specific code of conduct to
regulate the content of pharmaceutical company DAA has not been developed in
Australia. This differs from other countries such as the UK and the US where there
are specific guidelines for industry in the provision of DAA to consumers (Food and
Drug Administration, 2004; MHRA, 2005). In Australia, the growing awareness of
controversial cases of DAA (Efrat, 2004; Hall, 2008; Hughes and Minchin, 2003)
and complaints to Medicines Australia with regard to potential breaches of the Code
of Conduct suggest that regulation of DAA in Australia could be strengthened.

1. 2 Aims
This research project aimed to contribute to knowledge regarding pharmaceutical
company advertising of medicines and disease in Australia, and to determine
consumer responses to this advertising in order to inform future advertising
regulation in the interest of public health.

Specific aims of the research included:
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1. To determine the extent and nature of pharmaceutical company-sponsored
advertisements in the Australian mass media, and specifically in Australian
magazines, including:


The provision of disease information in advertisements;



The sponsors of advertisements; and



The use of branding and other persuasive techniques.

2. To determine Australian consumer responses to DAA, including:


Their behavioural intentions as a result of viewing advertisements;



Their perceptions of advertisements generally, and specifically their
perceptions of targeted disease awareness advertisements and adequacy of
disease information;



Their perceptions of DAA compared with their perceptions of DTCA
(including Australian and New Zealand consumers’ perceptions); and



Their attitudes towards the sponsors of DAA including their perceptions
of the intent of the advertisement and advertiser.

1. 3 Structure of the Thesis
This thesis is submitted in fulfilment of the requirements of a Doctor of Philosophy
in Public Health in Style 2, where chapters are prepared as journal articles. Chapters
2 through to 8 comprise seven articles, three of which have been published, and the
remainder submitted for editorial review. Please note, that while the articles are
formatted according to the guidelines of each journal, the referencing has been
changed to Harvard style for consistency within the thesis.

Chapter 2 provides a review of literature on the use of branding techniques by
pharmaceutical companies in the promotion of prescription medicine. It describes
some recent cases of pharmaceutical sponsored promotions and discusses the
implications for public health and advertising regulation. This article was written by
the candidate with co-author Professor Sandra Jones, and was published by the
Australasian Marketing Journal in 2007.
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Chapter 3 describes results of a mail survey that was conducted to elicit Australian
consumers’ perceptions of DAA. The results are compared with results from a New
Zealand study, to determine how Australian perceptions of DAA differ to New
Zealand perceptions of DTCA1. This article was written by the candidate with coauthors Professors Sandra Jones and Janet Hoek. Professor Hoek supervised the
conduct of the New Zealand survey, analysed and reported on the New Zealand data,
and contributed to the literature review and discussion. This article was submitted to
the Australasian Marketing Journal in November 2009 and is under review.

Chapter 4 describes an additional component of the mail survey which explored
Australian consumers’ attitudes towards New Zealand magazine advertisements for
prescription medicines (DTCA) and matched Australian pharmaceutical companysponsored advertisements. This survey explored what consumers valued in the
advertisements and their reported behavioural intentions after exposure. The article
was written by the candidate with co-author Professor Sandra Jones, and was
published by the Australian New Zealand Journal of Public Health in 2008.

Chapter 5 describes a content analysis of disease advertisements that appeared in six
popular women’s magazines over a 12 month period. The analysis sought to
categorise the types of advertisements and their sponsors, as well as exploring the
types of disease information provided and the use of persuasive techniques. The
article was written by the candidate with co-authors Professors Sandra Jones and
Don Iverson, and was published by the Medical Journal of Australia in 2009.

The results of the content analysis informed the final research study which was an
intercept survey of older Australian women who were shown hypothetical DAA for
two relatively unknown health conditions. The intercept survey results are reported
in Chapters 6, 7 and 8. Participants were allocated one of eight different stimuli as
their first advertisement, and then received the second advertisement for the other
health condition with the same sponsor and information manipulation as the first
advertisement. A web-based randomising resource was used to generate a list of
stimuli combinations to be assigned to participants in order. Research assistants
1

Please note that the candidate was not involved in the conduct of the New Zealand survey.
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underwent training, and were instructed to allocate the advertisements to participants
in the order that they appeared on the list.

Chapter 6 describes the behavioural intentions of the women following exposure to
the DAA, and what they perceived to be the intention of the advertisements. The
article was written by the candidate with co-authors Professors Sandra Jones and
Don Iverson, and was submitted to the Australian Health Review in February 2010.

Chapter 7 describes results of the intercept survey relevant to older Australian
women’s perceptions of the adequacy of disease information in advertisement stimuli
and whether this influenced their attitude towards the advertisement. The article was
written by the candidate with co-authors Professors Sandra Jones and Don Iverson,
and was submitted to the Australian New Zealand Journal of Public Health in
November 2009.

Chapter 8 describes the results of the intercept survey relevant to older Australian
women’s attitudes towards varying sponsors. The article was written by the
candidate with co-authors Professors Sandra Jones and Don Iverson, and was
submitted to the Health Education in March 2010.

The final chapter (Chapter 9) provides a summary and comparison of the findings of
the research including the types and content of pharmaceutical advertising in
Australia, consumer perceptions of advertising, and its potential effects on their
behaviour. This chapter provides suggestions for improved regulation of
pharmaceutical advertising in Australia, and recommendations for future research.
1.3.1

Health Conditions Addressed in the Thesis

Within the studies reported in the thesis, disease advertisements cover a wide range
of health conditions, however the advertisement stimuli in Chapter 4 are for
Alzheimer’s disease and weight loss, while the advertisement stimuli for Chapters 6,
7 and 8 are for osteopenia and fibromyalgia. This section describes the treatment of
these conditions with prescription medicines in the Australian context, and the
potential for disease advertising.

11

Alzheimer’s disease
Alzheimer’s is the development of multiple cognitive deficits including memory
impairment, but also language and/or motor impairment and disturbance in
organisational skills which causes significant loss of occupational and social
functioning (NSW Health 2003). There is a gradual onset and progressive decline.
Alzheimer’s disease most often occurs over 65 years, but can occur as early as 40
years. In Australia, there are clinical criteria for the diagnosis of Alzheimer’s disease
(NSW Health 2003); management includes behavioural and social modifications for
sufferers and their carers as well as pharmacotherapy (acetyl cholinesterase
inhibitors). There are currently three products in Australia including Galantamine
Hydrobromide (Reminyl), Revastigmine (Exelon) which was the subject of a New
Zealand DTCA used as stimuli in the study described in Chapter 4, and Donepezil
Hydrochloride (Aricept) which was the subject of an Australian DAA in Chapter 4.
There is evidence for the use of acetyl cholinesterase inhibitors to treat the symptoms
of Alzheimer’s disease, and some evidence for improved outcomes with early
treatment (Alzheimer’s Australia 2006). There is also PBS criteria for the
prescription of acetyl cholinesterase inhibitors (Pond & Brodaty 2004).

Weight loss
In 2005 it was estimated that 47 % (7.5 million) of Australians aged over 15 years
were overweight, and approximately one third of these were obese (AIHW 2010).
People who are overweight and particularly people who are obese are at greater risk
of experiencing cardiovascular disease, high blood pressure, Type 2 diabetes, and a
range of other health problems for women (AIHW 2010). The Australian “Clinical
Practice Guidelines for the Management of Overweight and Obesity in Adults” states
that pharmacotherapy treatment should only be considered for patients who have
been unsuccessful in losing weight in other ways, including education, counselling
and dietary and/or physical activity interventions, and have impaired health due to
their weight (Commonwealth of Australia 2003). There are prescription medications
available with some evidence for efficacy, including orlistat (Xenical) which is now
an OTC medication but was previously prescription only (Egger 2008), and during
that time was the subject of DAA campaigns in Australia and New Zealand which
attracted some controversy (Vitry, 2004; Coney 2001). Other weight loss
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prescription medicines include phentermine (Duromine) which is an adrenergic
stimulant, and sibutramine (Reductil) which is an appetite suppressant and was the
subject of the advertising stimuli (both Australian and New Zealand) in the study
described in Chapter 4.

Osteopenia
Osteopenia refers to a state of lower bone density which can potentially increase the
risk of developing osteoporosis (Osteoporosis Australia 2007). Clinical guidelines in
Australia recommend that women aged 45 years and over be assessed for risk factors
for osteoporosis (RACGP 2010) and that bone mineral densitometry occur every two
years for postmenopausal women over 65 years or those over 45 years with other risk
factors. There are three potential prescription medicine categories for the prevention
of osteoporosis in post menopausal women, and Australian clinical guidelines
recommend the use of two in reducing the risk of osteoporotic fractures by increasing
bone mineral density in postmenopausal women at risk (RACGP 2010). As such, it is
feasible that pharmaceutical companies in Australia would sponsor awareness
advertising about osteopenia to encourage women to undertake bone density testing
and preventative treatment as has occurred in the US (Alonso-Coello et al., 2008).

Fibromyalgia
Fibromyalgia is a condition characterised by widespread pain, fatigue and sleep
disturbances but can be difficult to diagnose (Arthritis Australia, 2009). There are no
Australian-specific guidelines for diagnosis, and as such, the American College of
Rheumatology classification criteria are the most commonly used (Ee, 2008). There
is some evidence for treatment with prescription medicines including amiriptyline,
fluoxetine as well as serotonin and norepinephrine reuptake inhibitors; however a
multidisciplinary approach including patient education is recommended (Ee, 2008).
Prescription medicine advertising for the treatment of fibromyalgia has occurred in
the US (for example ‘Lyrica’ or pregabalin); the growing recognition of the
condition in Australia suggests that disease advertising by pharmaceutical companies
may also occur here.
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This research project aims to improve understanding of pharmaceutical advertising
targeting Australian consumers to address a gap in knowledge and to generate new
information to inform future regulation and health policy. It is hoped that this
research will ultimately improve the provision of information about disease and
medicines in Australia to better educate consumers and benefit public health.
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2. 1 Executive Summary: Implications for Policy Makers
With the rise of generics, and limited periods in which to exploit patent monopoly
and recoup expenditure on research and development, pharmaceutical companies are
under pressure to develop enduring trademarks and brand power. There is increasing
recognition within the industry that strong brands and brand names are remembered,
and that both doctors and consumers remain loyal to them, even after patent
expiration (Blackett and Harrison, 2001; Schuiling and Moss, 2004).

Brand development and brand management in the pharmaceutical sector is complex
due to the specific nature of pharmaceutical products as well as the regulation of
promotional activity. Building brand value directly with consumers can be achieved
through a variety of marketing strategies, including emotional appeals via direct-toconsumer advertising (DTCA) in the countries where it is permitted. In countries
such as Australia where DTCA is not allowed, pharmaceutical companies target most
of their branding activities to doctors or health care professionals, however some
activities such as disease awareness campaigns (DACs) can be used to generate
awareness among consumers.

In Australia, the marketing of prescription pharmaceutical products is self-regulated
via the Medicines Australia Code of Conduct (Medicines Australia, 2006a). This
paper explores some recent cases of DACs, and other advertisements for prescription
pharmaceuticals, that have many elements of branding or use pseudo brands (without
actually naming the product). For policy makers, it is important to be aware of such
brand-building techniques within the pharmaceutical industry, and to consider
whether current sections of the Code of Conduct regarding promotion to consumers
provide adequate guidance for industry, or whether more specific regulation is
required.
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2. 2 Abstract
Brand development and brand management is complex in the pharmaceutical sector
due to the specific nature of pharmaceutical products and their life-cycles, as well as
the regulation of promotional activity. The building of strong brands is becoming
increasingly important for the industry, and consideration is being given to
developing more expressive or emotional values of brands over traditional functional
values and attributes. In Australia, brand-building activity for prescription
pharmaceuticals primarily targets the medical profession in an effort to achieve brand
recognition, brand preference and brand loyalty and, in turn, increase prescriptions.
Despite direct-to-consumer-advertising of prescription pharmaceuticals not being
allowed in Australia, there have been cases of unnamed product advertisements and
disease awareness campaigns that serve to increase consumer awareness of brands.
This paper provides a review of issues influencing brand building in the
pharmaceutical sector as well as recent examples of brand-building activities that
target Australian consumers.
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2. 3 Introduction
Kotler, Adam, Brown and Armstrong (2003) define a brand as a “name, term, sign,
symbol or design, or a combination of these, intended to identify the goods or
services of one seller or group of sellers and to differentiate them from those of
competitors” (p.631). The brand helps customers to make choices by delineating the
unique qualities and value that the product or service provides to the customer
(VanAuken, 2003 p.xi). Brands are argued to assist customers to make purchase
decisions in increasingly cluttered retail environments, providing a useful cue as to
product quality, attributes and ‘personality’ (Aaker, 1997; Maheswaran et al., 1992;
Park and Srinivasan, 1994). Brands can offer intangible benefits that go beyond the
functional benefits of a product (Schuiling and Moss, 2004).

There are numerous factors that constrain branding activity and other marketing
practices in the pharmaceutical sector when compared with the traditional consumer
goods sector. Prescription pharmaceutical products by nature are high risk and
emotionally charged, and in some instances they may have life or death implications
(Chandler and Owen, 2002). Pharmaceutical products have relatively short lifecycles – they have short-term patent protection and usually only hold exclusivity for
15 years in the major world markets (Blackett and Harrison, 2001; Moss, 2001). The
pharmaceutical industry is one of the most regulated industries globally, and unlike
other product categories, pharmaceutical brands cannot be transferred to a new
product following patent expiration (Moss and Schuiling, 2004). In the past,
pharmaceutical marketing has tended to concentrate on research and development
(R&D), and the creation of the ‘blockbuster product’ rather than the building of
brands. As such, pharmaceutical companies have, until recently, focused their
branding activities around products and product attributes as well as engaging in
some corporate branding (Moss, 2001).

Direct-to-consumer advertising (DTCA) of prescription medicines is legal only in the
United States (US) and New Zealand, and there is active debate over the impact of
DTCA within these countries as well as other countries considering its adoption
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(Hoek and Gendall, 2002; Hoek and Gendall, 2004; Lyles, 2002). Some of the
argued benefits include the provision of health information to consumers, involving
consumers in health decision-making, and potentially improving patient compliance
(Auton, 2007; Harker and Harker, 2007). Some of the concerns over DTCA include
the focus on profit to the pharmaceutical industry as opposed to public health, the
potential for disease mongering, the creation of a ‘pill for every ill’ mentality, and a
possible negative impact on doctor/patient interactions (Coney, 2002; Mintzes et al.,
2002).

Prescription pharmaceutical marketing activities in countries where DTCA is not
allowed (including Australia) tend to target the doctor or health care professional,
rather than the actual consumer of the product (Chandler and Owen, 2002). While
personal sales or drug detailing has dominated pharmaceutical marketing to doctors,
a range of other brand-building activities are evident, including advertising in
journals, sponsoring educational events, educational materials, promotional
merchandise and even advertising via medical administration software.
Pharmaceutical sponsored activities that target consumers directly also utilise brands,
albeit usually corporate brands, including public relations activities, disease
awareness campaigns (DACs), educational events and materials.

Marketing practices, particularly for prescription pharmaceutical activities, are
heavily regulated in most Western nations. In Australia, they are self-regulated by
the pharmaceutical industry via Medicines Australia. Medicines Australia’s Code of
Conduct provides standards for prescription pharmaceutical advertising and other
promotions including the behaviour of the medical sales force. The Code of Conduct
was first established in 1960, and Edition 15 of the Code recently took effect
(Medicines Australia, 2006a). Two committees oversee the Code of Conduct. The
Code of Conduct Committee provides an adjudication function for complaints that
arise regarding pharmaceutical promotional, however there have been few
complaints with regard to activities targeting consumers – the majority of complaints
are made by pharmaceutical companies regarding competitor activity (Medicines
Australia, 2005). The Monitoring Committee provides “proactive monitoring” of
promotional activities (Medicines Australia, 2006a), however there is no provision
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for pre-vetting of advertisements (as currently occurs in New Zealand) to improve
compliance prior to production or release.

This paper examines ways in which companies develop brands for prescription
pharmaceutical products, as well as factors that impact upon or constrain brand
building, in particular branding that targets Australian consumers. It also examines
how, despite current advertising regulation and the prohibition of DTCA,
pharmaceutical companies are building brand awareness for prescription medicines
among Australian consumers; illustrated with recent examples of unnamed product
advertisements and DACs.

2. 4 Literature Review
Branding in the pharmaceutical industry has experienced considerable transformation
over the past 15 years, primarily due to the advent of generic drugs which by the
early 1990s had infiltrated almost every product category (Blackett, 1992). Earlier
research tended to focus on brand development and effects in relation to prescribers.
For example, Stern and Ehrenberg (1995) undertook studies of prescribing habits of
240 general practitioners (GPs) in the UK during 1986 and found that market share
(as opposed to individual brand attributes) provided a strong predictor of prescribing
habits and brand loyalty. They also found that the degree of prescribing loyalty for a
particular brand only varied slightly between brands, and that generics attracted
similar loyalty to named brands (Stern and Ehrenberg, 1995). Stern (2000) reports on
behavioural data from 1998 of a sample of 290 GPs in the UK, and found that
contrary to pharmaceutical industry perceptions, GPs are not either prescribers of
generics or prescribers of brands, but instead prescribe both forms – and often for the
same drug. The work of Stern and Ehrenberg (1995) demonstrated a lack of brand
preference among GPs in the UK, and this conceivably is one of the factors that led
pharmaceutical companies to target consumers in building brand value, as patient
requests for specific brands would potentially influence prescribing behaviour.

Since the dramatic increase of DTCA in the US in the mid 1990s (Donohue, 2006)
research into prescription pharmaceuticals has considered the impact of branding on
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consumers, for example the influence of DTCA and patient’s requests for
prescription medicines on prescribing decisions (e.g., Mintzes et al., 2002). In a
survey of 288 US residents, Singh and Smith (2005) found that behavioural
intentions (intention to discuss advertisements with their physician and intention to
ask about a specific brand) were influenced by a greater awareness of specific
branded drugs via DTCA. In addition, consumer surveys in the US have consistently
found that DTCA increases the likelihood of consumers requesting and receiving
prescriptions for a specific brand-name pharmaceutical (Heinrich, 2002). Heinrich
(2002) estimated that in 2000, as a result of seeing or hearing a DTCA, 8.5 million
US consumers requested and received a prescription for a branded medicine from
their doctor.

While brand development has not been a major focus of the industry in the past, the
rise of generics and the gradual decline in product breakthroughs (Angell, 2006) have
placed pharmaceutical companies under pressure to develop enduring trademarks and
brand power. Other threats for manufacturers of prescription pharmaceuticals include
the push from governments and private health funds to subsidise generics, and the
growing availability of generics via the Internet (Schuiling and Moss, 2004; SpenceStone, 2002). Pharmaceutical companies are gradually recognising the benefits of
brand-building, particularly in the post-patent stage of a product’s life (Blackett and
Harrison, 2001; Schuiling and Moss, 2004). There is increasing recognition within
the industry that strong brands and brand names are remembered, and doctors (as
well as consumers) remain loyal to them even after patent expiration (Blackett and
Harrison, 2001; Schuiling and Moss, 2004). Rotfeld (2005) agrees that
pharmaceutical brand names retain value initially after patent expiration, and
describes how companies attempt to extend patents prior to expiration by releasing
slight variations of the product such as higher dose rates or time release variations, or
combinations with other products. There is also the opportunity for some products to
achieve brand success by moving from prescription-only status to over-the-counter
availability post-patent (Chandler and Owen, 2002).

There is increasing evidence of the power of the corporate brand in creating trust and
conveying credibility (Moss, 2001; Schuiling and Moss, 2004), and Schroff (2003)
describes corporate branding in the pharmaceutical industry as “an opportunity
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waiting to happen” (p.58). Moss and Schuiling (2004) recommend that product brand
names be linked to corporate brand names and describe that doctors as well as
consumers look for reassurance of quality and safety in a pharmaceutical brand, and
are influenced by the image of the company. It has even been suggested that
pharmaceutical companies can become more competitive and develop greater brand
equity via socially responsible actions such as providing essential pharmaceutical
products to the least developed nations at low cost (Ross-Wooldridge et al., 2004).

In recent years, challenges for corporate branding in the pharmaceutical sector
include merger activity and consequent changes to corporate names and identities,
for example the merger of Ciba-Geigy and Sandoz to form Novartis. When
developing a strong association between the corporate brand and the product brand,
there is also the risk that if the latter falls into disrepute it may negatively impact on
the corporate brand (Schuiling and Moss, 2004). For example, the Merck corporate
brand was negatively effected following the withdrawal of its arthritis medication
Vioxx in 2004; Merck was ranked 30 and 32 in the Business Week ‘100 Top Brands’
in 2003 and 2004 respectively; however the company did not make the 100 Top
Brands in 2005 or 2006 (Business Week, 2004, 2005, 2006). When the safety of
Pfizer’s cox-2 inhibitor, Celebrex, also came into question, the company chose not to
withdraw their product, although they did suspend advertising of the product to
consumers (Arnold and Hyde, 2005). Pfizer suffered an initial drop in stock prices as
well as declines in new prescriptions for Celebrex, however the overall brand rating
in the 100 Top Brands only fell from 29 in 2004 to 31 in 2005 (Business Week,
2004, 2005).

As well as some corporate branding, the pharmaceutical industry has focused on
product-attribute branding, which can be defined as the promotion of functional
values of the product (Blackett and Harrison, 2001; Schuiling and Moss, 2004).
Importantly for pharmaceutical products, these values include safety (for example,
minimal side effects) and efficacy (for example, improvement in condition compared
with no treatment or other product). Other functional values include convenience
(complexity of dosage) and cost effectiveness. In a content analysis of 320 DTCA
from 1989 to 1998 in the US, Bell, et al. (2000) found that the most common appeals
used were effectiveness, symptom control, innovativeness and convenience. An
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example of product-attribute branding is a recent US advertisement for Relpax, a
migraine medicine, which emphasised efficacy: “Replax works fast. For some people
it starts to work in 30 minutes. Most get back to their day in 2 hours. Clinical studies
prove that with Relpax more people got relief with just one dose than those taking
Imitrex” (Pfizer, 2005).

There has been criticism that pharmaceutical branding in the past has focused too
much on product attributes and functional values of the brand (e.g., Blackett and
Harrison, 2001; Moss, 2001), and that it should build more expressive or emotional
values that the consumer or prescriber can identify with. These authors recommend
that pharmaceutical marketing should reinforce the benefits, personality and ‘human’
values of their product. In a content analysis of 208 DTCA from the US, Roth (2003)
found that transformational messages that emphasised benefits such as happiness or
social approval created greater brand awareness than informational messages, but
stated that transformational messages are “used the least (relative to informational
messages) and are being used less often over time” (p.189). There is considerable
concern that the more emotive style of promotion for prescription pharmaceutical
products will manipulate consumers, play on their vulnerabilities and encourage a
‘pill for every ill’ mentality (Coney, 2001; Mansfield et al., 2005). This concern is
also held for doctors and health professionals – for example, a recent study into
pharmaceutical marketing practices in the UK (Devlin et al., 2005) concluded that
“brands are designed and marketed to satisfy emotional as well as rational benefits
and there is a desire by the industry to exploit health professionals’ emotional needs
and vulnerabilities” (p.11).

There is argument within the pharmaceutical industry that branding will never
achieve for pharmaceuticals the results it has for the consumer goods sector (Lerer,
2005; Schroff, 2003). These authors argue that personal selling is still the
cornerstone of pharmaceutical marketing and that a separate branding paradigm is
required for this sector. They elucidate that branding in the pharmaceutical sector
needs to take into account the diverse audiences of pharmaceutical promotion –
including the patient, the doctor, and other health professionals such as pharmacists,
as well as regulators and government departments – as they all potentially influence
the purchase decision. Schroff (2003) also argues that pharmaceutical product
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benefits are the same regardless of product or therapy area (that is, the benefit is
improved health and well-being for the patient), and that this makes pharmaceutical
marketing very different to consumer packaged goods in that the latter can be more
easily differentiated by benefits. Schroff (2003) and Lerer (2005) agree that the
nature of pharmaceutical marketing is complex and dynamic, and that the
pharmaceutical industry needs to be proactive and innovative to respond to constant
changes such as government or health fund decisions regarding subsidisations of
certain products.
2.4.1

Developing a Pharma ‘Superbrand’

The building of brands can be achieved through a variety of marketing strategies,
including emotional appeals via DTCA (in the countries where it is permitted) as
well as unnamed product advertising, DACs, public relations activities, and regular
sales and educational activities targeting GPs and other health professionals.
Increasingly, brand building has been suggested as the solution to the many
marketing issues faced by pharmaceutical companies (Blackett and Harrison, 2001;
Moss, 2001; Schuiling and Moss, 2004). It has been suggested that pharma
‘superbrands’ are capable of surviving patent expiration and can achieve “a bond
with the consumer at a level which transcends mere functional performance”
(Weston, 1999 p.3). Brand development includes the steps of developing brand
value, brand personality, and brand identity (or how the brand appears to its
audience) (Blackett and Harrison, 2001; VanAuken, 2003).

Brand value is the essence of what the brand delivers to the consumer. Important to
brand value are the unique attributes of the brand that support the value and provide
differentiation from other brands. These can be functional or emotional elements, but
traditionally within the pharmaceutical market there should be considerable scientific
evidence to support claims. A television advertisement by Roche for Xenical (weight
loss drug) was criticised in New Zealand for providing too much focus on the
emotional benefits of the brand (50 seconds of the 60 second commercial) such as
being attractive, carefree and spontaneous, and too little on the functional benefits
(remaining 10 seconds); and their failure to mention important information such as
side effects (Coney, 2002).
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Brand personality is the emotional qualities of the brand that the target market can
identify with. Blackett and Harrison (2001) describe brand personality as the
‘expressive values’ of a brand or what the brand says about the consumer. Brand
personality is often achieved through visual imagery; the use of celebrity
endorsements (for example actor Gary Sweet promoting Levitra in Australia)
(Australian Consumers' Association, 2008); or the use of a spokes-character to make
consumers more comfortable with, or to humanise, a product. Spokes-characters are
also effective in helping consumers to associate with particular functional values of a
brand. For example, they might represent qualities of the brand such as being
powerful, strong or gentle, or they might represent the disease that the brand is
treating. GlaxoSmithKline targeted Australian GPs over a two-year period with a
campaign featuring ‘Puff’, a dragon spokes-character for an asthma medication
(Seretide). This campaign won a national marketing award as it succeeded in
increasing brand recognition among GPs by 16%, and sales achieved 115% of
forecast (National Marketing Institute, 2002).

Brand identity combines the sensory components of the brand that create recognition
and convey the positioning, personality and values of the brand. Brand names, logos,
colours, shapes, images, fonts, jingles, tag-lines and packaging all contribute to the
brand identity. Brand names in the pharmaceutical sector are fundamentally different
to most consumer products in that they have two names – the product brand name
(for example, Coversyl), and the generic name (for example, perindopril) (Schuiling
and Moss, 2004). Brand names are often developed based on the chemical substances
the product is derived from (for example, Temaze from temazepam), the disease the
product will treat (for example, the name Lariam was derived from the word
malaria), the drug class (for example, Lipostat from the statin class of drugs), the
corporate name (for example, Scheriproct from Scherring Pharmaceuticals) or a
newly invented name.

Brand names carry with them a range of associations, whether these come from
concrete references or lexical meanings (O'Shaughnessy and O'Shaughnessy, 2004).
Weston (1999) describes the importance of developing a user-friendly brand name
that “evokes wellness rather than illness” and has “global appeal” (p. 4). Prescription
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medicines used to treat erectile dysfunction provide some good examples. The name
Levitra was derived from elevate, but also ‘Le’ suggests masculinity and ‘vitra’ is
similar to vitality and virility. Similarly, Pfizer named their product ‘Viagra’ to
suggest vigour and strength, while rhyming with Niagara and evoking images of free
and forceful flow (Anonymous, 2003), although in recent times some have suggested
that these connotations may be beyond the thought processes of the target audience
(O'Shaughnessy and O'Shaughnessy, 2004). The letter X is commonly used in drug
nomenclature as it is often associated with technology and innovation, and the letters
Z, C and D are also used to imply potency of a drug (McNeil, 2003).

The development of trade-marks and logos is fundamental to building a memorable
brand, as is consistency of design and colours. For example, the Levitra flame has
become a well known trademark and is commonly used in DTCA in the US without
reference to the drug name (Angell, 2006). Packaging may be closely aligned to the
trademark and to the shape and colour of the drug itself; for example, Viagra’s blue
diamond-shape trademark featured on GP advertising in Australia is also the colour
and shape of the Viagra tablet itself. Parry (2003) refers to the effectiveness and
versatility of packaging, citing the example of Sarafem which is in fact another drug
– Prozac. Prozac, which is made by Lilly and used to treat depression and mood
disorders, was nearing patent expiration, so Lilly re-marketed the same active
ingredient as a lavender coloured pill, complete with new packaging and promotion
featuring sunflowers. This ‘new’ product, Sarafem, had been developed to treat
Premenstrual Dysphoric Disorder – a rare and extreme form of premenstrual
syndrome in women.
2.4.2

Branding Disease

The concept of branding a condition was explored by Parry (2003) with the view that
“if you can define a particular condition and its associated symptoms in the minds of
physicians and patients, you can also predicate the best treatment for that condition”
(p.43). Parry (2003) identifies three different strategies that can be used to brand a
condition and associate it with a product:


increasing the importance of a disease (see example of onychomycosis
described below);
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re-defining or reducing stigma relating to a disease (for example, erectile
dysfunction or weight loss advertisements); or



developing a new condition to create recognition of an unmet need, then
introducing the product to meet that need (for example, the case of restless
legs syndrome in the US – see Woloshin and Schwartz 2006).

The primary technique used by pharmaceutical companies to brand diseases is
DACs, however DACs pose ethical issues for pharmaceutical companies; as
Consumers International (2006) describe this style of advertising, it is “often
disguised as corporate social responsibility, and has been shown to create a subtle
need among consumers to demand drugs for the conditions, while giving consumers
a sense of trust in the pharmaceutical companies” (p.25). One particular criticism of
pharmaceutical sponsored DACs is that they create awareness and increase the
importance of diseases where there are larger and more lucrative markets, such as
lifestyle conditions rather than potentially more serious, life-threatening illnesses
(Consumers International, 2006; Glatter, 2004). However, it could be argued that
DACs for more life-threatening conditions have greater ethical implications. For
example, a DAC in the US regarding breast cancer risk, sponsored by Astra Zeneca,
was followed by branded advertisements for Nolvadex (a product to reduce the risk
of breast cancer), also sponsored by Astra Zeneca (Hogle, 2001). Consumer groups
expressed concern about this advertising campaign, in particular the presentation of
relative risk rather than absolute risk which was potentially misleading for
consumers; but also that information regarding breast cancer was provided for
commercial gain (Hogle, 2001).

DACs may take the shape of advertisements in the mass media, or other techniques
such as advertorials or magazine articles coupled with pamphlets and other
promotional materials including posters, often on display at the point of decision
making (doctor’s waiting rooms). Industry representatives describe DACs as
effective in growing the market and increasing product uptake, and are reported as
being particularly beneficial for products that are market leaders (Carpenter, 2003;
Pharma in Focus, 2004). While there is limited research into consumer responses to
DACs, Hall and Jones (2007) found Australian consumers were more likely to find a
DAC to be valuable than both unnamed product and named product advertisements
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(DTCA). Consumers were also more likely to perceive the DAC as trying to provide
information about a medical condition, as opposed to trying to sell a product or
treatment – which was commonly selected for the other advertisements.
2.4.3

Regulation in Australia

As previously mentioned, DTCA is not legal in Australia; as such, the majority of
pharmaceutical marketing, including advertising and branding, is directed at health
care professionals and/or prescribers. This activity is currently self-regulated by the
pharmaceutical industry via the Medicines Australia Code of Conduct, Edition 15.
DACs and unnamed product advertisements that target consumers are legal in
Australia and are also self-regulated via the Code of Conduct.

Section 9 of the Code (Medicines Australia, 2006a) details how the pharmaceutical
industry should interact with the general public in Australia; it specifically covers
“Promotion to the General Public” (9.4) and “Patient Education” (9.5). These
sections of the Code prohibit the promotion of a prescription medicine product
directly to consumers, or the provision of any encouragement for consumers to seek
a prescription for a product. The code, however, does allow for educational
information on medical conditions and the range of treatments that may be
prescribed by a consumer’s GP (Medicines Australia, 2006a).

Medicines Australia provides limited guidance as to what defines an advertisement
for prescription medicines, other than reiterating the current Therapeutic Goods
Association (TGA) definition, and suggesting that media releases as well as
information published on the Internet are included in the definition of advertising
(Medicines Australia, 2006b). Specific guidelines regarding what can and cannot be
included in DACs are limited, especially when compared with guidelines of other
nations, including the UK and US (Food and Drug Administration, 2004; Macias et
al., 2007; MHRA, 2005; PhRMA, 2005). The Australia New Zealand Therapeutic
Products Authority (ANZTPA), which is in the process of establishing a Trans
Tasman regulatory scheme for therapeutic products, provides a definition in its draft
advertising code. ANZTPA state that DACs must not identify the therapeutic
product, but can contain “information that aims to raise awareness regarding specific
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diseases, including public health campaigns, [and] must be factual and balanced and
support consumers in making informed healthcare choices” (ANZTPA, 2005, p.9).

2. 5 Case Studies

2.5.1

Disease Awareness Campaigns (DACs)

A recent Australian example of a DAC was the promotion of onychomycosis (a
usually benign fungal infection of toe and/or fingernails) by Novartis, the makers of
Lamisil, a treatment for onychomycosis. Their DAC (including television and print
advertising) featured an extremely unattractive spokes-character that personified the
fungus, and introduced himself to consumers as “Hi, I’m Digger…I’m a
Dermatophyte and I love living under your nails!” Australian GPs were concurrently
targeted with identically branded advertisements featuring ‘Digger’; however these
urged GPs to “check diabetic patients’ feet for onychomycosis, which can lead to
serious complications.” It is noteworthy that the GP-targeted advertisements focused
on patients with diabetes, whereas the consumer-targeted advertisements appeared to
be directed at all consumers. Campaigns of a similar nature were also held in the US
(Langreth and Herper, 2006), the UK (Jackson, 2003) and the Netherlands (Sheldon,
2002). A study in the Netherlands (t'Jong et al., 2004) analysed changes in
consultation and prescribing patterns prior to and following the commencement of
the DAC. It was found that prescription rates for Lamisil and onychomycosis-related
consultations increased considerably following the launch and throughout the
campaign, while prescriptions for the competitor product decreased. However, the
authors are critical of the impact of the campaign on the workload of doctors and
describe how the Dutch Society of General Practitioners opposed the campaign as
“an unnecessary focus on an unimportant health problem” (t'Jong et al., 2004, p.931).

Another recent example of branding used in an Australian DAC was the Baxtersponsored advertisement for meningococcal C vaccine. This print-based
advertisement featured an image of the feet of a dead person lying on a mortuary
bench, with a detachable tag stuck to a toe providing the following information:
“Almost one in two meningococcal C cases are adults. Two in ten infected lose toes,
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fingers or limbs. One in ten die. Meningococcal C can strike out of the blue. Don’t
wait to VacCinate. Take this to your GP and ask about vaccination today.” This
advertisement attracted a complaint to Medicines Australia and was found to be in
breach of the Code of Conduct Section 9.5 (Patient Education) as it did not provide
balanced information regarding prevalence of the disease and the message was
presented in a way that could cause community alarm. The Complaints Committee
took issue with the tear-off portion to be taken to the GP as these potentially
encouraged prescriptions of Neiss Vax C. There was also concern regarding the
prominence of the manufacturer’s name as well as other branding techniques, such as
the colouring and capitalisation of the letter C, which clearly linked the
advertisement to their product despite the fact that the product’s name was not
mentioned (Medicines Australia, 2004). This example suggests that more specific
detail in the Medicines Australia Code of Conduct would be useful in guiding
pharmaceutical companies regarding branding techniques that can and cannot be
used in DACs.
2.5.2

‘Unbranded’ Product Advertisements and the Pseudo Brand

The draft Australia New Zealand Therapeutic Products Advertising Code has defined
several types of advertisements that are relevant for prescription medicines including
‘unbranded advertisements’ (ANZTPA, 2005), previously referred to in this paper as
“unnamed product advertisements”. Unbranded advertisements are described as an
advertisement that “promotes the use or supply of a product by inviting the consumer
to seek further information about symptoms or conditions and/or their treatment or
management while not referring overtly to any particular branded product,”
(ANZTPA, 2005, p.9). These are clearly differentiated from DACs which raise
awareness regarding specific diseases and may discuss symptoms plus a range of
treatment options. ANZTPA’s definition of an ‘unbranded advertisements’ provides
recognition of a new type of advertisement that is emerging in Australia as well as
other countries where DTCA is prohibited (Hall, and Jones, 2006; Mansfield et al.,
2005; Mintzes, 2006; Pharma in Focus, 2004). However we question the term
‘unbranded’ as there are many elements of branding within recent advertisements of
this genre, illustrated by recent cases described below.
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Recent examples of ‘unbranded’ product print advertisements targeting consumers in
Australia include the Levitra When?/Now and the Viagra Welcome Back Tiger
campaigns for products used to treat erectile dysfunction. These campaigns ran in
popular magazines including Australian Readers Digest which has an older
readership, and the advertisements encouraged consumers to ask their doctors
regarding treatment. The makers of Viagra and Levitra, Pfizer and Bayer Healthcare
respectively, were simultaneously advertising with identical advertisements to GPs in
the medical press but the version for doctors featured the product names and the
requisite product information. The Viagra campaign utilised a spokes-character
(tiger) as well as consistent colours and fonts, and the positive imagery of a mature
man (with tiger head) and seemingly satisfied woman sitting together on a couch.
Interestingly, the tiger character has been prominent in subsequent campaigns and
appears as both a character and a trademark (or logo) in consumer advertisements,
making it synonymous with the product. As such, Pfizer are creating a virtual or
pseudo brand for the product Viagra that can be used directly with consumers to
convey the identity of the brand without naming the product.

A similar series of ‘unbranded’ product advertisements by Abbott Australasia
(manufacturers of Reductil – a weight loss drug) featured close-up images of
attractive and seemingly confident overweight men and women. Each advertisement
featured the text or trademark i decide, and used branding techniques such as
consistency of fonts and colours. The emotive and positive nature of the text in these
advertisements (as with those previously described) could be classified as
‘transformational messages’ (Rossiter and Percy, 1997). Transformational messages
focus on positive end states and desired emotions. For example, in the i decide series
the text reads: “Today I decided to stop being fat…Losing weight means you’ll feel
much happier about your body, wear the clothes you love and feel great about
yourself too…”. As previously mentioned, the use of transformational messages in
pharmaceutical advertising has been shown to generate greater brand awareness with
consumers in the US (Roth, 2003). Hall and Jones (2007), however, found
considerable differences among consumers as to who they thought the advertiser was
when they viewed the ‘unbranded’ advertisement for Reductil described above. Of
the 102 participants who viewed an ‘unbranded’ advertisement, 22% thought the
advertiser was i decide (the campaign name), while 18% thought the advertiser was
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the Government or a Medical Association and only 15% correctly identified Abbott
Laboratories. There were also considerable differences among participants who
viewed a similar but ‘branded’ version (i.e., the product was named) of the
advertisement intended for a New Zealand audience. Of the 98 participants in this
condition, 43% identified the advertiser as Reductil (the product name), 21%
identified a pharmaceutical company, and only 13% correctly identify Abbott
Laboratories. From these results, it appeared that consumers perceived the most
prominent logo in the advertisement (i decide in the Australian version and Reductil
in the New Zealand version) to be the advertiser of the product, and suggests that the
use of a campaign name with a logo such as ‘I decide’ may also act as a pseudo
brand for the product.

The prevalence and the effects of these ‘unbranded’ product advertisements on
consumers and their interactions with GPs in Australia requires further research and
exploration, particularly when similarly branded campaigns target GPs concurrently.
A criticism of these advertisements is that they do not appear to support the ‘spirit’ of
the Medicines Australia Code of Conduct, in that they allude to a particular
prescription product by using elements of branding or pseudo brands. As yet
however, there have been no rulings in relation to this form of pharmaceutical
advertising in Australia, and aside from the draft ANZTPA Advertising Code, there
is limited acknowledgement of their existence and no specific guidelines to better
regulate their content. Medicines Australia has the opportunity to provide stricter
guidelines to prevent the use of pseudo brands in the next revision of the Code of
Conduct. Until that time, the Monitoring Committee as well as independent
researchers could determine if this type of branding of prescription medicines is
increasing in Australia, and what effect it has on consumers. In Canada, while DTCA
is not legal, reminder advertisements which provide the name of a product without
stating its use, as well as disease state awareness advertisements, are allowed
(Gardner et al., 2003). There has been considerable concern regarding instances
where these two types of advertisements are aired concurrently: one for a product,
and another for the disease it is designed to treat; particularly when aspects of the
brand identity such as colours, logos, fonts, characters are evident in both
advertisements (Mintzes, 2006).
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2. 6 Conclusion and Future Implications
Brand building for prescription pharmaceutical products has traditionally focused on
classical product or functional attribute promotion, however pharmaceutical
companies are increasingly concentrating on the emotional concerns of prescribers
and consumers, and reinforcing the benefits, ‘personality’ and ‘human’ values of
their products. In countries more liberal in health care marketing and branding such
as the US, there is an increase in DTCA (Elliott, 2004) plus DACs to consumers
(Thomaselli, 2004), and considerable debate over whether this adversely affects
public health. In Australia, while DTCA is not allowed, recent cases illustrate that
brand building activity for prescription pharmaceuticals is targeting consumers as
well as (and often in conjunction with) the traditional audience of doctors and other
health professionals. Pharmaceutical companies’ use of branding techniques in
DACs and ‘unbranded’ product advertisements such as using trademarks, logos,
campaign names and spokes-characters can be seen as pseudo branding – conveying
the identity of the product while not actually naming it. Further research is needed in
Australia to determine how consumers perceive pharmaceutical company sponsored
advertising and pseudo brands for prescription medicines. The cases described in this
paper indicate that regulation of promotion of branded prescription medicines to
consumers in Australia is deficient. Further analysis of the current regulatory system,
as well as the assessment of potential alternative approaches such as government
regulation, is required.
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3. 1 Executive Summary
Australia and New Zealand and have close economic relations and their governments
have actively promoted stronger trade relationships, however the countries have
differing positions regarding pharmaceutical industry advertising of prescription
medicines. In New Zealand, direct-to-consumer advertising (DTCA) of prescription
medicines is permitted, while in Australia, pharmaceutical companies are limited to
advertising about the diseases or conditions for which they manufacture a treatment,
referred to as disease awareness advertising (DAA).

This study found that consumers from Australia and New Zealand held similar views
regarding DTCA and DAA. Perceived benefits included increased awareness of
conditions and treatment options, and improved discussions with doctors, benefits
that proponents of DTCA have argued will eventuate (Auton, 2007; Bonaccorso and
Sturchio, 2002). While Australian consumers were ambivalent about whether DAA
assisted them to make better health decisions, New Zealanders perceived more
negative outcomes resulting from DTCA. These outcomes included unbalanced
information, inappropriate requests to doctors, increased reliance on medications,
and confusion, and reflect arguments outlined by those opposed to DTCA (Mintzes,
2002; Toop et al., 2003).

These findings suggest countries currently considering rescinding bans on DTCA
should act cautiously as the risks may outweigh the benefits. Further, it appears that
consumers see DAA as fulfilling a similar purpose to DTCA, and producing
analogous benefits.

Interestingly, the New Zealand survey found considerable support for a neutral
information service that would replace DTCA, an idea first tested by Toop et al.
(2003). Although the form this service might take was not examined in either the
Australian or the New Zealand survey, providing consumers with dispassionate
information could simultaneously satisfy their desire for knowledge while also
addressing the concerns they have raised about commercial information.
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3. 2 Abstract
At present, only the United States and New Zealand allow direct-to-consumer
advertising (DTCA) of prescription medicine. In other countries where DTCA is not
allowed, including Australia and the United Kingdom, pharmaceutical companies
undertake disease awareness advertising (DAA). In DAA, advertisements do not
name a drug directly, but provide general information about diseases and treatments,
and encourage consumers to talk to their doctor. Similar debate surrounds these two
forms of advertising, yet while past research has explored consumers’ attitudes and
behaviour in response to DTCA, little consideration has been given to DAA. This
paper compares Australian consumers’ perceptions of DAA with New Zealand
consumers’ perceptions of DTCA. Despite differences in the type and extent of
advertising, respondents perceived similar benefits including heightened awareness
of treatment options and improved discussions with doctors. However, New Zealand
respondents associated many negative outcomes with DTCA including unbalanced
information, inappropriate requests to doctors and consumer confusion.
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3. 3 Introduction
Direct-to-consumer advertising (DTCA) occurs when pharmaceutical companies
promote prescription medicine brands to the general public, via mass media or other
media including the Internet. An alternative, disease awareness advertising (DAA),
occurs when pharmaceutical companies or other organisations (including the
government and non-profit organisations) promote diseases or conditions, rather than
named treatments (ANZTPA, 2005). Pharmaceutical companies use DAA to promote
diseases or conditions for which they produce a treatment, and typically do so in
jurisdictions where DTCA is prohibited (Mintzes, 2006).

DTCA is currently legal in only two countries within the Organisation for Economic
Cooperation and Development (OECD), the United States (US) and New Zealand.
There is on-going debate in both countries about the benefits of DTCA, growing
concern about the potential harms it may cause (Moynihan and Bay, 2007; Toop et
al., 2003), and speculation about its future (Royne and Myers, 2008). Other
countries, including Canada, European Union, and Australia, have considered
introducing DTCA, and it remains a topical regulatory question in many countries
(Gardner et al., 2003; Toop and Mangin, 2006, 2007).

Questions about the benefits delivered by DTCA have focused attention on its
origins and effects. Mandese (2005) suggested that the key beneficiaries of DTCA
were media and advertising groups, both of which played important roles in its
introduction, and have lobbied for more relaxed regulatory oversight. However,
Donohue (2006) suggested DTCA had its genesis in the patients’ rights movement of
the 1970s where it reflected a change from the ‘learned intermediary’ model of
healthcare to a partnership model. She suggested that DTCA capitalizes on
consumers’ desire for empowerment, a point recognized by pharmaceutical
companies, which have funded patient advocacy groups (Jacobson, 2005). Yet, while
DTCA provides information, its profit motive continues to trouble medical and social
researchers (Coney, 2002).
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Proponents of DTCA argue that it educates consumers about new medicines and the
diseases these treat (Auton, 2004, 2007; Bonaccorso and Sturchio, 2002). Other
benefits thought to accrue from DTCA include earlier diagnosis, more informed
discussions with doctors, and increased compliance with treatment regimens (Auton,
2007). Recent studies suggest that DTCA also provides information to groups with
lower health literacy, and so may help reduce health inequities (Kaphingst, et al.,
2005). However, Mintzes (2002) concludes that DTCA may mislead consumers by
inflating the likely benefits they will receive from taking a treatment and
downplaying the risks and side effects. Toop et al. (2003) extend this point and argue
that DTCA creates an over-reliance on medications when behavioural or lifestyle
changes may achieve better long-term outcomes. DTCA may not only promote less
optimal treatment paths, but Toop and Mangin (2006) also suggest it may damage
doctor-patient relationships by stimulating requests for advertised drugs that do not
suit patients’ overall health profile. They conclude that the difficulty of dealing with
poorly-informed requests could reduce the high level of trust required between
doctors and patients and result in misallocation of consultation time.

In many countries where DTCA is not permitted, consumers are exposed to
pharmaceutical company-sponsored DAA, which is designed to create awareness of
diseases and the availability of treatments. For DAA, a similar debate over its ethics
and effects has occurred (Glatter, 2004; Mintzes, 2006). Moynihan and Henry (2006)
argue that, like DTCA, DAA will encourage healthy people to believe they may
require potentially unnecessary tests or medication. Furthermore, Mackenzie et al.
(2007) suggest DAA disguises itself as a community service by obscuring its
commercial intention, a point noted also by Hall and Jones (2007) who suggested
that DAA uses branding techniques that circumvent the ban on DTCA. By contrast,
proponents argue that DAA educates consumers about diseases and conditions,
enables them to keep up to date with new treatments, and encourages those who are
potentially at risk to visit their doctor (Angelmar et al., 2007; Wielondek, 2005).
These arguments clearly reflect themes evident in the long-running debate over
DTCA and raise questions about consumers’ perceptions of these different forms of
pharmaceutical advertising. The current study examined Australian and New Zealand
consumers’ perceptions of DAA and DTCA respectively. The findings provide the
first insights into how consumers respond to DAA, enable a comparison of
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consumers’ perceptions of DAA and DTCA, and may help to inform regulatory
decisions about pharmaceutical promotions facing many developed nations.
3.3.1

Advertising Expenditure and Media Exposure

Glatter (2004) suggests DTCA offers potential returns to manufacturers and Toop et
al. (2003) recorded sharp spikes in prescriptions following DTCA campaigns. The
US Government Accountability Office (GAO) reported a trend of increasing
expenditure on DTCA. Although promotion to physicians still outweighed spending
on DTCA, television and magazine DTCA increased at twice the rate of detailing to
doctors during the 1997 to 2005 period (US GAO, 2006). However, more recent data
have indicated a slight drop in US spend on DTCA between 2006 and 2007
($US4.81 billion to $US4.77 billion) (IMS Health, 2008). New Zealand data reflect
these patterns; pharmaceutical companies spent an estimated $NZ38 million
($US30.5 million) on DTCA in 2006; this represented the largest category of
advertising spending on therapeutic products (Ministry of Health, 2006) and was a
217% increase on the $NZ17.5 million spent on DTCA in 1999.

Growth in expenditure on DTCA has been paralleled by an increase in consumer
awareness. A recent US poll reported that 91% of respondents had heard or seen
prescription drug advertisements (USA Today et al., 2008). Exposure occurs
predominantly via television, which remains the dominant DTCA medium, although
print media are also important (Brownfield et al., 2004; Frosch et al., 2007; Hoek et
al., 2004). Wijesinghe and Norris (2008) reported that the frequency of medicine
advertisements during 4pm – 8pm on New Zealand television in 2001 and 2006 had
increased from .72 advertisements per hour to 1.14 advertisements per hour. DTCA
promotions declined as a proportion of medicine advertisements from 28% in 2001
to 17% in 2006, although this appears to reflect an increase in the number of overthe-counter (OTC) and complementary medicine promotions.

In 2006, pharmaceutical companies in Australia spent an estimated $AUD190 -200
million on mass media advertising (Nielsen Media Research AdEx, 2006), however
it is difficult to ascertain how much of this was spent on DAA as this figure includes
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OTC advertising. In Europe, it was estimated that spending on DAA would grow to
$US345.5 million in 2008 (Mintzes, 2006).

Despite the limited literature on consumers’ responses to DAA, there is some
evidence that this advertising increases awareness of the advertised health conditions
and prescriptions of the sponsor’s product (Basara, 1996; t'Jong et al., 2004). A
recent content analysis examined the prevalence of DAA in top circulating
Australian women’s magazines and concluded it constituted approximately 12% of
all therapeutic advertisements (Hall et al., 2009); this finding suggests its potential
exposure is at least moderate.
3.3.2

Advertising Regulation

The US Food and Drug Administration (FDA) regulates and oversees DTCA. The
FDA has an explicit ‘fair balance’ criterion that requires information about a drug’s
benefits be balanced by information about its potential risks and side effects (Hoek et
al., 2004). Despite this criterion, recent content analyses have questioned whether
this balance is achieved, particularly in television advertisements (Kaphingst, et al.,
2004; Macias et al., 2007), and the GAO had doubts about the adequacy of consumer
protection FDA regulation afforded (US GAO, 2006).

Critics of the US regulatory model suggest self-regulation is more efficient than
government regulation and makes no demands on tax payer funds (Calfee, 2002).
New Zealand relies on such a system and the advertising industry is responsible for
developing codes of practice and administering the complaints body that adjudicates
complaints (Hoek and Gendall, 2002). The New Zealand system evolved rapidly in
response to concerns raised by politicians and health professionals following
DTCA’s emergence in the late 1980s, and rapid growth during the late 1990s.
Following the development of a self-regulatory code, the Advertising Standards
Authority devised a pre-vetting system to improve compliance with the code. New
Zealand regulation does not require the same extent of risk/benefit information as the
US (Hoek et al., 2004), and risk/side-effect information tends to occupy a third of a
print page of advertising, whereas in the US, usually a full page or more is required.
Complaints about all advertising can be made to the Advertising Standards
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Complaints Board, which adjudicates these (Advertising Standards Authority New
Zealand, 2008).

Despite these measures, DTCA has generated considerable concern and leading
health professionals called on the New Zealand Minister of Health to review the
regulatory lacunae that enabled DTCA to flourish. Two reviews conducted by the
New Zealand Ministry for Health (Ministry of Health, 2000, 2006) received
polarized submissions. While the advertising and pharmaceutical industries favoured
retaining DTCA under a liberal self-regulatory system, health professionals and
consumer groups, which constituted the majority of submitters, supported a complete
ban on DTCA.

In Australia, the Therapeutic Goods Act prohibits advertising of prescription
medicines directly to consumers (Australian Government Department of Health and
Ageing, 2007). However, the development of a Trans-Tasman regulatory scheme for
therapeutic products with New Zealand (the Australian New Zealand Therapeutic
Products Authority or ANZTPA) led to speculation that Australia would allow
DTCA, although this has not yet eventuated. Currently, Australian pharmaceutical
companies target consumers via DAA and unbranded product advertisements, neither
of which include the brand name of the prescription medicine indicated for the
disease or health condition (Hall and Jones, 2007). Disease awareness advertising
can be sponsored by government and other organisations as well as the
pharmaceutical industry and usually provides information on the condition itself,
whereas industry-sponsored unbranded product advertisements promote the use or
supply of a product without referring directly to a brand (ANZTPA, 2005).
Medicines Australia, an industry body, monitors this advertising and provides a
complaints service, but does not vet or otherwise restrict placement of DAA
(Medicines Australia, 2006).

The fact that pharmaceutical advertising has emerged in different guises, is subject to
different regulatory systems, and yet stimulates similar debate, suggests that further
research exploring consumers’ perceptions of pharmaceutical promotions would
provide regulators with a more robust evidence base to inform their decisions. The
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following section reviews existing evidence on US and New Zealand consumers’
views of DTCA.
3.3.3

Consumer Perceptions

Existing research suggests US and New Zealand consumers hold generally positive
attitudes toward DTCA and believe it provides them with useful information about
health conditions and treatments, and facilitates discussions with doctors (Deshpande
et al., 2004; Hoek et al., 2004; Mehta and Purvis, 2003). However, consumers are
more ambivalent about the overall worth of DTCA, particularly its role in improving
the decisions they make about their health (Hoek et al., 2004; USA Today et al.,
2008). Recent surveys in the US have found growing negative attitudes towards
DTCA, including a dislike of advertisement content and the perceived ubiquity of
DTCA (Friedman and Gould, 2007a; USA Today et al., 2008).

A US survey of 1,695 adults found that 67% of respondents felt DTCA provided
education about treatments and encouraged people to seek help for conditions or
diseases about which they had been previously unaware (USA Today et al., 2008).
These findings are generally similar to those reported in New Zealand, where a
survey of 625 residents found that 91% believed DTCA helped make people aware
of new medicines (Hoek et al., 2004). Between half and two thirds of New Zealand
respondents found DTCA useful (61%), and thought it helped people have better
discussions with their doctors (64%); however, only half felt it helped people to
make better decisions about their health (52%).

Friedman and Gould (2007a) surveyed 321 US residents and reported high awareness
of DTCA (96%), but noted some negativity towards it; over half reported that they
disliked seeing advertisements for prescription drugs. Nevertheless, 59% still agreed
that, overall, DTCA was a good thing (Friedman and Gould, 2007a). In a USA
Today survey, 53% of adults thought prescription drug advertising was a good thing,
however 68% felt that DTCA appeared too frequently on television and 66% felt it
encouraged people to take medications that they did not really need (USA Today et
al., 2008).
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Studies of more specific population groups have reported similar findings. DeLorme,
Huh and Reid (2007) conducted in-depth interviews with older Americans (n=25) to
explore their views of DTCA. While these participants thought DTCA affected
others more than themselves, they nevertheless paid attention to DTCA, and believed
it helped them learn about drug benefits and risks, and assisted them to locate further
information. However, they noted that DTCA lacked balance, portrayed unrealistic
outcomes and created pressure on viewers to talk with their doctors. Respondents
also complained about the quantity and frequency of DTCA (DeLorme et al., 2007).

Because DTCA does not exist in Australia, work exploring consumers’ likely
responses has been hypothetical. Miller and Waller (2004) surveyed 619 individuals
and reported that 53% felt DTCA would provide useful information while 58% felt it
would make the public more aware of the benefits prescription medicines could offer
(Miller and Waller, 2004). However, only 32% agreed that it was proper for
prescription medicines to be advertised, and almost half (48%) felt that DTCA would
not improve the quality of prescription medicines available in the future (Miller and
Waller, 2004). These findings are consistent with Vatjanapukka and Waryszak
(2004) who reported mixed responses to DTCA, particularly among those more
knowledgeable about prescription medicines. Jones and Mullan’s (2006) analysis of
older Australians’ views also concluded that participants held ambivalent views
about DTCA; while they recognized it could inform their discussions with doctors,
they also thought it could be confusing and promote reliance on medications.

To date, no studies have compared whether consumers exposed to DTCA differ in
their perceptions and behaviours from those exposed to DAA. This omission is
serious, since global trade and economic alliances are becoming more prevalent and
assume a high level of regulatory congruence. New Zealand and Australia have close
economic relations and their governments have actively promoted stronger trade
relationships. Advertising of prescription medicines in both countries is selfregulated via industry codes of conduct and a complaints process (Advertising
Standards Authority New Zealand, 2009; Medicines Australia, 2006). Despite their
physical proximity, New Zealand and Australia have very little cross-border
advertising, thus the media environments are largely insulated from each other.
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The current study examined Australian and New Zealand consumers’ general
perceptions of DAA and DTCA respectively and determined perceived benefits or
weaknesses of these advertising formats. The natural experiment created by New
Zealand and Australia’s differing stance on DTCA enables development of an
evidence base that may be useful for countries currently reviewing their position on
prescription pharmaceutical advertising, such as Canada and Europe.

3. 4 Methodology
The Australian survey questionnaire was conducted in 2006 and questions were
based on surveys previously developed and tested by Hoek et al. (2004) and Hoek
and Gendall (2004) to elicit consumer responses to DTCA in New Zealand in 2002
and 2003 respectively1,2. The New Zealand questionnaire was part of a broader
survey conducted in 2006 to examine New Zealanders’ views on advertising and
how this should be regulated. The questions relating to prescription medicine were
based on those previously used by Hoek et al. (2004) and Hoek and Gendall (2004).
Although both surveys were based on existing instruments, there were minor
differences in the question wording and the scales used.

The Australian sampling frame was a purchased database of mail addresses for a
metropolitan area in New South Wales. A total of 2800 addresses were randomly
sampled, and a pre-test was administered randomly to 400 of these addresses. The
pre-test resulted in 56 responses (response rate of 14%), following which minor
modifications were made to the wording of one question. The remaining 2400
addresses were sent the revised survey questionnaire with an information sheet3.

1

Refer to Question 13 of Appendix A for the Australian questionnaire

2

Note that the Australian survey was part of a larger survey designed to elicit consumer responses to

New Zealand DTCA and matched Australian DAA, the results of which are reported in Chapter 4
(Hall and Jones 2008).
3

Refer to Appendix B
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The New Zealand sample were 2000 people randomly selected from the electoral roll
(registration to vote is mandatory in New Zealand, thus the electoral roll is a
comprehensive database of adults aged 18 years and over).

3. 5 Results
For the Australian survey, a total of 357 surveys were returned (representing a
response rate of 15%); all responses were used along with those from the pre-test,
resulting in a total of 413 responses. For the New Zealand survey, a total of 998
respondents completed and returned their survey (after deducting ineligible and
gone-no-address returns, this represents a valid response rate of 56%). Data from
both surveys were weighted so the samples’ age-sex distributions matched census
data; the Australian data matched the metropolitan area1 from which the sample was
drawn and is similar to the national age-gender profile, while the New Zealand data
matched the national age-gender profile. The following section reports on Australian
and New Zealand consumers’ perceptions of DAA and DTCA respectively.
3.5.1 Australian Perceptions of DAA
Australian participants were asked whether they agreed or disagreed with nine
general statements about DAA (see Table 3.1) on a five point agree-disagree scale.
Agree and strongly agree responses were aggregated. Most respondents (80%)
agreed that DAA makes people aware of disease/conditions and different treatment
options and almost two thirds agreed that DAA helps people to have better
discussions with their doctors. While 62% agreed that DAA is designed to increase
positive health behaviours such as diet and exercise, some respondents may have
considered government public health and non-government sponsored advertisements
as well as those sponsored by pharmaceutical companies; thus this estimate may be
higher than if respondents had considered only pharmaceutical company sponsored

1

however of the participants in the current study 24.4% were born overseas whereas 2006 census data

shows 21.5% born overseas, and in the current study 35.5% had bachelor degree qualification or
higher whereas census data shows only 13.9%.
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DAA. Just over half (52%) felt that DAA helps them to make better decisions about
their health.

When considering DAA’s intent, 72.2% agreed that this advertising was designed to
sell more medicine or medical products, and around 40% agreed that it was to make
the disease itself seem more important or to increase visits to doctors. Over a third
(36%) felt that DAA confuses people about what diseases they may be at risk of
developing, while just over one quarter (26%) felt that advertisements about diseases
and conditions are often difficult to understand.
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Table 3.1: Australian responses to statements regarding DAA
% Agreement (inc.
Statements1

strongly agree +
agree) (n=413)

Advertisements help make people aware of disease/conditions
and different treatment options
Advertisements alert people to disease in order to sell more
medicine or medical products
Advertisements about diseases/ conditions help people have
better discussions with their doctor
Advertisements alert people to disease in order to increase
positive health behaviours such as diet or exercise
Advertisements about diseases/ conditions help people make
better decisions about their health
Advertisements alert people to disease in order to make the
disease itself more important
Advertisements alert people to disease in order to increase
visits to doctors or other health professionals
Advertisements about diseases/ conditions confuse people
about what disease they may be at risk of developing
Advertisements about diseases/ conditions are often difficult
to understand
1.

Emphasis used in original instrument

80

72

65

62

52

43

40

36

26
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3.5.2

New Zealand Perceptions of DTCA

To explore respondents’ views on DTCA, New Zealand participants were asked the
extent to which they agreed or disagreed with eleven general statements (see Table
3.2) on a four point agree-disagree scale. Agree and strongly agree responses were
aggregated. Most respondents (84%) agreed that DTCA overemphasises drug
benefits and most thought DTCA does not provide balanced information about the
risks and benefits of the medicine. Half agreed that people probably feel by confused
by the information given in DTCA. The majority (78%) believed that prescription
medicine advertising makes people more aware of options to treat their health
problems, however over 80% considered that most people lack the technical
knowledge required to tell whether an advertised medicine is safe for them. Nearly
two thirds agreed that advertising for prescription medicines helps people have more
informed discussions with their doctor; however, a similar proportion thought DTCA
leads people to ask their doctor for medicines that may not suit them. Over half
believed that DTCA makes people rely more on medicines to treat their health
conditions, though only 12% thought it harms the relationship that patients have with
their doctor.
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Table 3.2: New Zealand responses to statements regarding DTCA
% Agreement (inc.
Statements

strongly agree +
agree) (n=998)

Prescription medicine advertisements over-emphasise the
benefits and don't explain the risks enough
Most people lack the technical knowledge to tell whether an
advertised medicine is safe
Advertising for prescription medicines makes people more
aware of options that could treat their health problems
Advertising for prescription medicines leads people to ask
their doctor for medicines that may not be suitable
Advertising for prescription medicines helps people have
more informed discussions with their doctor

83

81

77

67

64

It would be better if money spent on regulating prescription
medicine advertising was used to provide a neutral
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information service
Advertising for prescription medicines makes people rely
more on medicines to treat health conditions
Most people probably understand the information in
advertisements for prescription medicines
Most people probably feel confused by the information in
advertisements for prescription medicines
Prescription medicine advertisements provide balanced
information about a medicine's risks and benefits
Advertising for prescription medicines harms the relationship
patients have with doctors

54

48

47

26

12
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Sixty percent of New Zealand respondents agreed that it would be better to spend the
money that is used to regulate prescription medicine advertising on a neutral
information service. There was a strong preference for a government agency to
manage regulation of prescription medicine advertising (33%), followed by an
independent group (15%), the advertisers and the media (6%) and just under a fifth
(17%) of New Zealand respondents thought that the advertising of prescription
medicines should not be allowed; the remainder were either unsure (8%) or in favour
of a combination of a government agency, independent group and advertisers and the
media to manage prescription medicine advertising (21%).

3.5.3

Responses to Similar Questions

Four questions within the respective surveys were similar and the results of
Australian and New Zealand respondents to these questions is compared in Table
3.3.
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Table 3.3 Comparison of Australian and New Zealand responses

Statements

% Agreement

% Agreement

New Zealand

Australia

(n=998)

(n=413)

Advertising for prescription medicines makes
people more aware of options that could treat
their health problems /
Advertisements help make people aware of

77

disease/conditions and different treatment

80

options
Advertising for prescription medicines helps
people have more informed discussions with
their doctor /

64

Advertisements about diseases/ conditions help
people have better discussions with their doctor

65

Most people probably understand the
information in advertisements for prescription
medicines /

48

Advertisements about diseases/ conditions are
often difficult to understand

26

Most people probably feel confused by the
information in advertisements for prescription
medicines /
Advertisements about diseases/ conditions

47

confuse people about what disease they may be
at risk of developing

36

63

3. 6 Discussion
Despite the differences in the questions and scales of the surveys conducted in either
country, as well as differences in the types of pharmaceutical advertising, there are
several similarities between the Australian and New Zealand results.
3.6.1

Generating Awareness

Very similar proportions of both samples agreed that the purpose of DAA and DTCA
is to make people aware of health conditions and treatment options. These findings
are similar to US surveys, which reported high levels of agreement with the
proposition that DTCA helps increase awareness of options or new medicines (Hoek
et al., 2004; USA Today et al., 2008). Similar proportions of Australian and New
Zealand respondents reported feeling informed about treatment options, irrespective
of whether they saw DAA or DTCA. This suggests that in Australia, even unbranded
promotions create high levels of treatment awareness.
3.6.2

Health Decisions and Health Behaviour

Australians were ambivalent about whether disease awareness advertisements help
them to make better health decisions, which is similar to results relating to DTCA
from earlier New Zealand and US consumer surveys (see Hoek et al., 2004). More
recent findings suggest views towards DTCA as an information source have become
more negative in the US; for example, Friedman and Gould (2007a) reported that
only 41% of their respondents agreed that DTCA helped them to make better
decisions about their health (Friedman and Gould, 2007a). Furthermore, only 19% of
physicians thought DTCA assisted their patients to make better health decisions
(Friedman and Gould, 2007b).

While the results revealed some similar patterns, important differences were also
evident. For example, while 55% of New Zealand respondents felt that DTCA makes
people rely more on medicines to treat medical conditions, 62% of Australian
respondents felt that DAA is designed to increase other positive health behaviours
such as diet and exercise. Although New Zealand respondents were not asked about
the potential lifestyle benefits that DTCA might promote, the proportion who felt
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DTCA offered a ‘pill for every ill’ suggests fewer would be likely to agree that
DTCA brought wider benefits. Only 40% of Australian respondents felt that DAA
was designed to encourage consumers to visit a doctor or health professional, even
though Medicines Australia stipulates that this information must be included in DAA
(Medicines Australia, 2006). A high proportion of New Zealand respondents agreed
that DTCA would prompt consumers to ask for drugs that may not suit them. This
implies that studies examining the influence of pharmaceutical promotions on
interactions with health professionals should also explore the types of requests that
would be made and the likely health benefits that would ensue.
3.6.3

Interaction with Doctor

The majority of respondents in both countries (65%) agreed that pharmaceutical
advertising improves discussions with their doctor. These proportions are similar to
those reported in earlier New Zealand surveys, which in turn are very similar to US
survey results. Just under two thirds of respondents in these countries (64% New
Zealand and 61% US) felt that DTCA helps people to have better discussions with
their doctor about their health (Hoek et al., 2004). Murray et al. (2004) surveyed
3209 US residents and found DTCA encourages patients to disclose health concerns
to their doctors and helps some to feel more confident and in control of their
consultation. While studies into US physicians’ attitudes concur that DTCA may
help patients to initiate discussions with their doctor (Murray et al., 2003; Weissman
et al., 2004), Friedman and Gould (2007b) found, only 27% of the 416 physicians
they surveyed felt DTCA gave patients adequate information to decide whether to
discuss a drug with their doctor.

Over two thirds of the New Zealand respondents (68%) felt DTCA led to requests to
doctors for medicines that may not be appropriate, an identical finding to the 2008
USA Today poll. Studies of US physicians’ attitudes have found that around 80%
felt DTCA led to inappropriate requests for unnecessary prescriptions (Friedman and
Gould, 2007b; Weissman et al., 2004). Toop et al. (2007) argue that responding to
such requests and re-educating patients can detract from valuable consultation time;
this problem requires further research to assess whether other adverse outcomes
result. Twelve percent of New Zealand respondents agreed that DTCA harms the
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doctor-patient relationship; this is a higher proportion than Murray et al. (2004)
reported; their US work estimated that only 5% of respondents who took DTCA
information to their doctors thought this had negatively affected their relationship.
3.6.4

Consumer Understanding of Advertising

Nearly three quarters of Australian respondents (72%) agreed that DAA aimed to sell
more treatments (or medical products). These results imply Australians are aware
that DAA has a profit motive and may allay concerns that consumers falsely perceive
DAA to be a community service. However, further research is required to determine
how Australian consumers respond to actual DAA with varying sponsors before
these concerns can be put aside. Similar research could be undertaken in New
Zealand, particularly given that 60% of respondents felt resources spent on
regulating DTCA could be better spent providing neutral drug information.

With regard to the confusion caused by advertisements, 48% of New Zealand
respondents thought that most people felt confused by the information in DTCA. By
contrast, 36% of Australian respondents felt that DAA confused people about the
disease they may be at risk of developing. However, New Zealand respondents were
almost twice as likely to report difficulties in understanding DTCA (49%) than
Australians (26%). This result may reflect the more detailed product information
required in DTCA, which includes technical details that lay people are unlikely to
understand; this interpretation is supported by the finding that 81% of New Zealand
respondents agreed most people lacked the technical knowledge to judge the safety
of an advertised product.

These findings are supported by previous studies identifying the potential of
pharmaceutical promotions to mislead or confuse consumers (Jones and Mullan,
2006; Kaphingst and DeJong, 2004). Our findings also support earlier
recommendations to improve DTCA, including requiring a more effective balance of
risk and benefit information (Kaphingst, et al., 2004) and presenting important risk
information in a stand-out window format (Stotka et al., 2007). Use of more
quantitative data to support benefit claims and reducing emotional appeals that
suggest a disease is more prevalent or a drug more efficacious than is really the case
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would also help to increase the ease with which lay consumers understand DTCA
(Woloshin and Schwartz, 2006; Woloshin et al., 2001). Finally, the use of consumer
friendly language is recommended to promote understanding and reduce the
demands on doctors (Handlin et al., 2003; Kaphingst, et al., 2004).

3. 7 Limitations
A significant limitation of the Australian survey is the low response rate which may
result in a level of non response bias. Unfortunately, due to resource limitations,
follow-up methods that have been shown to improve response rates, such as reminder
letters and telephone calls, were not possible. Another limitation is that Australian
respondents had viewed either New Zealand DTCA or Australian DAA within the
broader survey (results of which are reported in Chapter 4 (Hall and Jones 2008))
and this may have influenced their responses to the questions about advertising in
general. As previously mentioned Australian respondents may have considered
government or non-government sponsored DAA or even OTC advertising when
responding to the questions and there may have been a level of social desirability
bias as a consequence. It is feasible that responses specific to pharmaceutical
company sponsored DAA for prescription medicines would differ. Further, the
surveys only asked about perceptions of DTCA and DAA, and respondents may have
answered differently if asked about their behaviour intentions, or their actual
behaviour. The two surveys used different sampling methods, different measurement
scales and different questions; however, as the purpose of the research was to
compare general perceptions of DAA and DTCA, the questions needed to reflect the
different regulatory environments and the data were suitable for comparisons
outlined.

3. 8 Conclusion
Australian and New Zealand consumers value DAA and DTCA for generating
awareness of disease and treatment options and improving discussions with their
doctors. Overall, Australian consumers found DAA less confusing than New
Zealanders found DTCA, although further work is required to test how exposure to
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DAA and DTCA, respectively, influences consumers’ understanding and knowledge.
Respondents were ambivalent about whether pharmaceutical advertising improved
their decision making and a neutral information service may be a more effective
means of improving their knowledge of diseases and treatment options. Future work
examining information credibility, the trust respondents place in different sources,
and the likelihood they would use information from these, will also be important as
decisions regarding the adoption and continuation of DAA and DTCA are made.
Perhaps most critically, however, future research should also locate consumers’
views within the broader ethical and economic debate over prescription medicine
promotions and the optimal means of providing consumers with information that is
in their best interests.
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4. 1 Abstract
Objective: The current study aimed to elicit and compare the responses of Australian
consumers towards New Zealand direct-to-consumer-advertisements (DTCA) for
prescription medicines and matched pharmaceutical company-sponsored
advertisements from Australia.
Methods: A survey questionnaire was mailed to a random sample of residents in a
metropolitan area in NSW, Australia. Potential participants were randomized to
receive one of four different advertisements: two for weight loss and two for
Alzheimer’s disease. A total of 413 responses were received and analysed.
Results: Participants reported that they were not likely to ask for a prescription from
their doctor as a result of seeing any of the advertisements in the study. The
Australian disease awareness advertisement that did not refer to a medicinal
treatment was perceived as more valuable than the New Zealand DTCA or other
Australian advertisement. Overall, participants found it easier to make sense of the
more informational advertisements, and felt that there was insufficient information
regarding the disease/condition and treatments in the more emotive and
transformational advertisements.
Conclusions: While there is concern over potential negative effects of
pharmaceutical-sponsored disease awareness advertisements, this study found that
Australian consumers perceived an informational advertisement with a list of disease
symptoms to be valuable.
Implications: These findings contribute to current debate in New Zealand and
Australia regarding DTCA and disease awareness advertising, and have the potential
to inform guidelines relevant to the advertising of prescription medicine in each
country.
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4. 2 Background

4.2.1

Advertising of Prescription Medicines in Australia and New Zealand

Direct-to-consumer advertising (DTCA) can be defined as pharmaceutical-company
sponsored advertising of prescription medicines that directly targets consumers via
the mass media. Currently, DTCA is only legal in two countries within the
Organisation for Economic Cooperation and Development, the United States (US)
and New Zealand. DTCA was not anticipated in New Zealand, and it came about in
the early 1990s primarily because there was no specific legislation to prevent it. It is
currently regulated by the pharmaceutical industry, but underpinned by legislation
(The Medicines Act 1981 and The Medicines Regulations 1984). This regulation
includes a pre-vetting system, a separate monitoring system and a complaints
management process that involves lay-people in complaint adjudication (Hoek and
Gendall, 2002). In Australia, DTCA is prevented by the Therapeutic Goods Act
1989, and the advertising of prescription medicines is regulated by the
pharmaceutical industry via Medicines Australia (MA). Section 9 of the Medicines
Australia Code of Conduct (Medicines Australia, 2006) details how the
pharmaceutical industry should interact with the general public in Australia; it
specifically covers “Promotion to the General Public” and “Patient Education” (9.5).
These sections of the Code prohibit promotion of a specific prescription medicine
product to consumers or providing encouragement for consumers to seek a
prescription for a product. The code does, however, allow for educational
information on medical conditions (such as disease awareness advertisements) and
the range of treatments that may be prescribed by a doctor (Medicines Australia,
2006). Despite the ban on DTCA in Australia, there have been instances where
pharmaceutical advertisers have skirted current regulations by using advertising and
branding techniques to promote a specific prescription medicine product but without
mentioning the product’s name (Hall and Jones, 2007).
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4.2.2

Direct-to-consumer Advertising (DTCA) Debate

There is considerable argument regarding the risks and benefits of DTCA in the
countries that currently allow for it as well as countries that have considered its
potential adoption including Australia, Canada and the European Union (Hoek, 2008;
Lexchin and Mintzes, 2002; Mintzes, 2006). Arguments for DTCA which are usually
espoused by the pharmaceutical industry include: the provision of information
regarding symptoms, undiagnosed conditions and new treatments to consumers; the
involvement of consumers in their healthcare; and potential improvements to the
doctor patient relationship including compliance with medication regimes (Auton,
2004, 2007). Arguments against DTCA which are usually espoused by consumer
groups, medical professions and public health advocates include: it encourages
disease mongering; the emphasis on profit outweighs public health and education; it
has a negative impact on doctor/patient interactions and leads to inappropriate
prescribing; it encourages the consumption of new drugs which may have unforeseen
risks; and it leads to increased pharmaceutical costs for governments (Hoek, and
Gendall, 2002; Lexchin and Mintzes, 2002; Toop and Richards, 2002). There is
concern among general practitioners in New Zealand that DTCA generates
unnecessary visits and inappropriate requests for medications by patients and, as a
result, valuable consultation time is spent re-educating patients who have been
misinformed by advertisements (Toop and Mangin, 2007; Toop and Richards, 2002).
There is also the concern that DTCA will increase the mentality that all life’s
problems require pharmaceutical solutions, and that the resources of pharmaceutical
companies in marketing as well as research will overpower any other efforts to
improve health such as counseling or behaviour change interventions. Toop and
Richards (2002) refer to this concept as the ‘pharmaceuticalisation of health’ and
others as ‘disease mongering’ (Moynihan et al., 2002; Toop and Richards, 2002).
4.2.3

Disease Awareness Campaigns (DACs)

The Australia New Zealand Therapeutic Products Authority (ANZTPA) is in the
process of establishing a trans Tasman regulatory scheme for therapeutic products,
however this recently faltered in the New Zealand Parliament and developments are
currently suspended (ANZTPA, 2007). ANZTPA refer to DACs in their draft
advertising code, stating that they must not identify the therapeutic product but can
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contain “information that aims to raise awareness regarding specific diseases,
including public health campaigns, [and] must be factual and balanced and support
consumers in making informed healthcare choices,” (ANZTPA, 2005, p.9).
Pharmaceutical sponsored DACs may take the shape of advertisements via the mass
media or other techniques such as advertorials in magazines or newspapers, public
service announcements, pamphlets and other promotional material such as posters.
There is argument that this promotional activity is of particular concern as it purports
to provide a community service (i.e. provision of health information) while its real
purpose is to sell a product (Glatter, 2004; Mackenzie et al., 2007). For example
Mackenzie et al (2007) describe DACs in Australia as “infomercials” which “evade
the [DTC] advertising ban by masquerading as community education and not
mentioning the drug itself.” (p225).

Similar debate surrounds DACs as that surrounding DTCA. There is concern that
these advertisements will only be seen for diseases where there are larger and more
lucrative markets, such as lifestyle conditions (Consumers International, 2006;
Glatter, 2004). There are also claims that these advertisements generate unnecessary
fear and encourage disease mongering and greater reliance on medications to solve
social and behavioural problems (Mintzes, 2006; Moynihan and Henry, 2006).
However DACs can also be seen as providing important information that assists
consumers to identify symptoms and seek more information and/or treatment for
previously untreated conditions (Bonaccorso and Sturchio, 2002). It is considered
particularly important for diseases where there is considerable under-diagnosis (e.g.,
diabetes).

The provision of disease and prescription medicine information by pharmaceutical
companies is the subject of current review in Canada and Europe. In Canada,
concerns regarding DACs and similarly branded reminder advertisements (described
in Figure 4.1) led to a review in 2004 by the House of Commons Standing
Committee on Health. They recommended that Health Canada immediately enforce
the prohibition of DTCA and improve the monitoring and complaints process. It was
also recommended that publicly funded, independent information on prescription
medicines be made available to Canadians. The Health Council of Canada has also
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called for the repeal of a clause in the Food and Drug Act that allows for reminder
advertisements, as well a review of cross-border exposure to DTCA (Mintzes, 2006).

In Europe, the European Commission recently held a public consultation over a
Legal Proposal on Information to Patients regarding Prescription Medicines, to
which the majority of responses were that pharmaceutical companies were not
appropriate sources for such information (European Commission, 2008). The
European Commission had previously proposed to sanction DTCA in 2000 however
this was rejected in 2002 by the European parliament (Richards, 2008). While there
is international concern from government, health and consumer lobby groups
regarding the capacity of pharmaceutical companies to provide objective and nonpromotional information on prescription medicines and disease, it is of interest to
consider how consumers perceive and respond to this phenomena.
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Figure 4.1: Classification of pharmaceutical company-sponsored advertising for
prescription medicine targeting consumers
Advertisement

Other terms

Type

Countries

General Requirements

Applicable

Direct-to-

Product claim

US

Include product name and can

consumer

advertisement

New Zealand

include specific product benefits.

(DTCA)

Must also include details of costs,
risk and side effects (New Zealand).
Must include a fair balance of risk
and benefit information and a major
statement of the main risks (US).
Refer to (Hoek et al., 2004) for
further details.

Reminder

Price

Canada

Include the name of a product and

Advertisement

advertisement

US

cost/dosage information only.

Disease

Disease

Australia

Provide information generally on

Awareness

Awareness

Canada

diseases such as symptoms and

European

prevalence.

(DAA)

Union

May mention that treatments are

‘Help Seeking’

New Zealand

available but cannot name specific

advertisement

United

products.

Unbranded

Kingdom

Usually includes advice to “talk to

product

US

your doctor”.

Unbranded

Australia and

“…promotes the use or supply of

product

potentially

product by inviting the consumer to

advertisement

elsewhere

seek further information about

Campaign (DAC) Advertising

advertisement

symptoms or conditions and/or their
treatment or management while not
referring overtly to any particular
branded product,” (ANZTPA, 2005).
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4.2.4

Consumer Responses to DTCA and DACs

In Australia, a 2004 exploratory survey of 619 consumers in Sydney found that that
Australians do not have strong feelings for or against DTCA (Miller and Waller,
2004). Another 2004 study of 863 consumers (Vatjanapukka, 2004) found that 53%
were unaware that DTCA was not legal in Australia and only 37.8% felt that DTCA
would contain important information that patients needed to know regarding
prescription drugs. However in the same study, nearly half of the respondents felt
that DTCA could provide valuable information regarding the risks and benefits of
prescription medicines and over 45% felt DTCA would motivate them as well as
assist them to discuss conditions with their doctor. A study conducted in 2005 into
the responses of older Australians with regard to DTCA (2006) found that
participants reported limited perceived benefits but expressed concern that DTCA
may cause people to ask their doctor for inappropriate medicines, rely more on
medicines to solve their health problems, and become more confused. Consumer
surveys in the US have consistently found that DTCA increases the likelihood of
consumers requesting and receiving prescriptions for a specific brand-name
pharmaceutical (Heinrich, 2002).

There are limited studies regarding consumer responses to specific pharmaceutical
company sponsored DACs, however one study has been reported in the Netherlands
(t'Jong et al., 2004). The studied campaign provided information regarding
onychomycosis, a usually benign fungal infection of toe and/or fingernails. The
advertisement was sponsored by Novartis, the makers of Lamisil, a treatment for
onychomycosis. The authors analysed consultation and prescribing patterns prior to
and following the commencement of the campaign and found that onychomycosisrelated consultations increased considerably after the launch of the campaign, as did
prescription rates for Lamisil (2004). The campaign was criticized by the authors as
it increased the workload of doctors for what might be considered a minor health
problem, and potentially at the expense of more critical consultations. Similarly,
Pfizer’s disease awareness campaign for erectile dysfunction, coupled with DTCA in
the US, created considerable demand for their product (Viagra) but was criticized for
targeting younger men who are less likely to need the product, and for positioning
the product as a lifestyle drug (Lexchin, 2006).
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4.2.5

Advertising Strategy

An understanding of consumer perceptions and responses to DTCA and DACs can
be complemented by an understanding of advertising tactics that are commonly used
by pharmaceutical companies or their advertising agencies to elicit the desired
consumer attitudes and behaviour. The Rossiter-Percy grid (Rossiter and Percy,
1997) was initially developed to enhance creative execution tactics in advertising,
but can also be used in an analysis of advertising creative to determine the intentions
of advertisers. The grid categorises consumers’ attitudes in terms of type of decision
regarding the product (low involvement vs. high involvement) and the type of
motivation (informational for negatively originated motivation vs. transformational
for positive-ending motivation). Generally, advertisements for disease or prescription
medicines evoke problem avoidance or problem solving motivations and for that
reason, informational quadrant tactics are recommended (Rossiter and Bellman,
2005). However content analysis research has found transformational tactics are also
being employed by the pharmaceutical industry (Roth, 2003), and there is common
criticism that emotional appeals in DTCA create the perception that happiness and
wellbeing is just a prescription away (Frosch et al., 2007; Welch Cline and Young,
2004).

4. 3 Current Study
While there is considerable research into the responses and intentions of consumers
following exposure to DTCA in the countries where it is permitted, there is limited
research in countries such as Australia where DTCA is not allowed. There is also
limited research into Australian consumer’s responses to other forms of
pharmaceutical-sponsored advertising including unbranded product advertisements
(for prescription medicines) and DACs (refer to Figure 4.1 for descriptions). The
current study aimed to elicit and compare Australian consumer responses towards
DTCA from New Zealand and matched advertisements from Australia including
their ease of comprehension of advertisement information; their attitudes towards the
advertisement and their intentions to request further information/prescription.
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Two disease/condition types were selected for the study: Alzheimer’s disease and
obesity. Alzheimer’s disease is the most common form of dementia, and dementia is
reported as carrying 3.5% of Australia’s total disease burden (measured in disabilityadjusted life years) (Mathers et al., 1999). An estimated 4% of the total burden of
disease and injury in Australia is attributed to overweight and obesity (Mathers et al.,
1999). Consumer perceptions of the severity of these diseases/conditions however
may differ. In a study conducted with six focus groups in Western Australia,
participants were asked what they thought were the most serious diseases in
Australia, and what health problems or diseases they personally worry most about
getting (Carter et al., 2002). In response 13% identified obesity and only 4%
identified dementia as the most serious disease in Australia, but 17% identified
dementia as the disease they were personally most worried about contracting, while
obesity was not identified for this second question.

4. 4 Method
A direct-mail survey questionnaire1 was used based on surveys previously developed
and tested by Hoek et al (2004) and Hoek and Gendall (2004) to elicit consumer
responses to DTCA in New Zealand in 2002 and 2003 respectively. A purchased
database of addresses from the white pages directory for a metropolitan area was
used as the sampling frame. A total of 2800 addresses were randomly sampled, and a
pre-test was administered randomly to 400 of these addresses. Addresses randomly
received one of four different advertisements with the survey questionnaire. While
the advertisement differed, all other aspects of the questionnaire were identical. The
different advertisements (described in Figure 4.2)2 were:
1. A New Zealand weight loss treatment advertisement (NZW).
2. A matched Australian weight loss advertisement (AW).
3. A New Zealand Alzheimer’s disease advertisement (NZA) for a product used
to treat the disease.
4. A matched Australian Alzheimer’s disease advertisement (AA).

1

Refer to Appendix A.

2

Also refer to Appendix C
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Figure 4.2: Description of stimulus (pharmaceutical company-sponsored
advertisements)
Ad reference
Advertisement
Type

Product type

NZW

DTCA

Weight loss
treatment

NZA

DTCA

Alzheimer’s
disease
treatment

AW

AA

Unbranded

Disease

product

awareness

advertisement

advertisement

Weight loss
treatment

Alzheimer’s
disease
awareness

Product name

Product name

included and

included and

Product name

Product

requisite

requisite

not included but

No product or

identification/

information

information

featured

treatment

information

regarding

regarding

campaign name

information.

risks/side

risks/side

“idecide”

effects

effects
Face of elderly

Images

Face of an

Elderly woman

overweight

seated with a

woman

female carer

Face of an
overweight man

man embraced
by a young girl
(possibly his
granddaughter)

Do you, any of
When I met my
Headline

new man I
decided to stop
being fat

your family
members or
loved ones,
have

I decided to stop

How could I

eating too much

ever forget you?

Alzheimer’s
Disease?

The pre-test resulted in 56 responses (response rate of 14%), following which minor
modifications were made to the wording of one question. The remaining 2400
addresses were sent the revised survey questionnaire. There were 357 returned
surveys (response rate of 15%) and all responses were used along with those from
the pre-test, resulting in a total of 413 participants.
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4. 5 Results
The median age of participants was 49.5 years, with 70.3% female. This differs to
the demographic data for the sampling frame (and to the 2006 census data for
Australia) where the median age was 37 years with 50.7% female (Australian Bureau
of Statistics, 2007). The returned, anonymous responses were entered by a research
assistant using SPSS Version 15. Initial analysis was performed by cross-tabulating
responses to the four different advertisements for each of the questions on the survey
and performing Pearson’s Chi-Square analysis.
4.5.1

Attitudes Toward the Advertisement

When asked how valuable they found the advertisement (see Table 4.1), participants
viewing the AA advertisement were more likely to find the advertisement extremely
valuable or valuable than those viewing other advertisements (2=25.072, p<.001).
Participants viewing the NZW advertisement were more likely to find the
advertisement not very valuable or not at all valuable (2=56.805, p<.001).

Table 4.1: Perceived value of advertisements
Advertisement type viewed (n=343*)
NZW (%)

AW (%)

NZA (%)

AA (%)

n = 86

n = 85

n = 70

n = 102

Extremely valuable

3.5

16.5

12.9

21.6

Valuable

24.4

32.9

52.9

62.7

Neutral

22.1

29.4

15.7

9.8

Not very valuable

36.0

17.6

10.0

2.9

Not valuable at all

14.0

3.5

8.6

2.9

Mean Score1

3.33

2.59

2.49

2.03

1

on a 5 point scale where 1 = extremely valuable and 5 = not valuable at all

*does not include pre-test data as this question was modified in final survey.

85

When participants were asked about their perceptions of the advertisement’s intent
(see Table 4.2), they were more likely to perceive the AA advertisement as trying to
provide information about a medical condition as opposed to sell a product or
treatment which was more commonly selected for the other advertisements (2 =
175.545, p<.001). For the New Zealand advertisements (i.e. the DTCA) participants
were most likely to select sell a product or treatment.

Table 4.2: Perceived intent of advertisements

What do you think this advertisement

Advertisement type viewed (n = 393*)
NZW (%)

AW (%)

NZA (%)

AA (%)

(n=93)

(n=97)

(n=93)

(n=110)

Sell product or treatment

82.8

32.0

59.1

18.2

Provide information about treatment

8.6

22.7

19.4

5.5

Encourage talking to doctor

4.3

36.1

7.5

33.6

Provide information about medical condition

2.2

8.2

9.7

42.7

Encourage asking for prescription

2.2

1.0

4.3

0

is trying to do?

*due to missing responses

4.5.2

Comprehension and Provision of Information

Most participants (see Table 4.3) found the information in the Alzheimer’s
advertisements very easy to make sense of. For the AW advertisement, participants
generally found the information very easy or quite easy to make sense of. For the
NZW advertisement the majority of participants found the information quite easy
however participants viewing this advertisement were more likely to find the
information quite difficult to make sense of than those viewing other advertisements
(2=31.323, p<.001).
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Table 4.3: Perceived ease of understanding the advertisement information
Advertisement type viewed (n = 400*)

How easy was it to make sense

NZW (%)

AW (%)

NZA (%)

AA (%)

of the information?

n= 94

n = 100

n = 92

n = 114

Very easy

17.0

48.0

64.1

67.5

Quite easy

38.3

35.0

25.0

28.1

Neither easy nor difficult

23.4

11.0

4.3

3.5

Quite difficult

21.3

5.0

4.3

0.9

Very difficult

0

1.0

2.2

0

*due to missing responses

For information provided regarding the medical condition itself (see Table 4.4), the
majority of participants viewing Alzheimer advertisements felt that adequate
information was provided while the majority of those viewing the weight loss
advertisements felt that adequate information was not provided. For all
advertisements, but particularly for the Australian advertisements, participants felt
that there was not adequate information provided regarding the treatments available
or the risks associated with treatments. Most participants felt that there was not
adequate information provided regarding the benefits of treatment particularly for
AW and for NZA, Most participants felt there was adequate information provided
regarding how/where to get further information, especially so for NZA and AW.
Note that it is a requirement for DTCA in New Zealand to provide a source for
further information. Interestingly, participants were less likely to find adequate
information provided regarding how/where to get further information in the AA
advertisement compared with the other advertisements (2=19.427, p<.001). In the
AA advertisement there was a suggestion to “check with your doctor” rather than
providing a web address or 1800 number for further information as was offered in
the other advertisements.
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Table 4.4: Percentage of respondents agreeing that adequate information was
provided
Advertisement Type Viewed (n=392*)
NZW (%)

AW(%)

NZA(%)

AA(%)

(n = 93)

(n =95)

(n = 91)

(n = 113)

how/where to get further information?

80.4

93.8

91.2

74.3

the benefits of treatments?

45.7

19.8

20.9

43.1

the treatments available?

39.8

26.3

31.9

16.5

the risks of treatments?

34.4

2.1

29.3

7.5

the medical condition itself?

26.9

31.6

60.4

62.8

*due to missing responses

4.5.3

Behavioural Intentions

Participants were asked to imagine that the disease or condition was relevant to them
personally, and then asked questions regarding contact with their doctor. The
majority of participants for each advertisement agreed that they would talk about the
condition with their doctor (see Table 4.5), however this was significantly more
likely for participants in the Alzheimer’s advertisements (2=16.702, p<001). A
similar case was found for talking about the treatment with their doctor but
significantly more so for the Alzheimer’s advertisements (2=15.697, p<.001). The
majority of participants across all advertisements felt that they would not seek a
prescription from their doctor as a result of reading the advertisements, however the
participants viewing the Alzheimer’s advertisements were more likely to perceive
that they would do so than those viewing the weight loss advertisements (2=10.283,
p=.016) (see Table 4.5).

Note that participants were asked about their own health and the health of their
family, including experience with Alzheimer’s disease and overweight/obesity.
There were no significant differences in responses across the four advertisements. Of
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the participants that viewed the advertisements regarding Alzheimer’s disease only
one reported direct experience with Alzheimer’s disease and 19.6% reported having
a family member experience the disease. Of the participants that viewed the weight
loss advertisements, 49.2% reported being overweight, while 62.3 % reported a
family member being overweight.

Table 4.5: Percentage of people reporting that they would take specific actions after
reading the advertisement (if relevant to them or a family member)
Advertisement type viewed (n = 383*)
NZW (%)

AW(%)

NZA(%)

AA(%)

(n = 89)

(n = 92)

(n = 89)

(n = 113)

talk about the condition with doctor

60.7

55.4

89.9

95.6

talk about the treatment with doctor

57.3

61.6

93.0

95.3

seek a prescription from doctor

37.8

24.2

47.4

49.5

*due to missing responses

4. 6 Limitations
Limitations of the study include the relatively low response rate and small sample
size as well as the higher proportion of older and female participants in the survey,
making the data less able to be generalised to other populations. The matching of
advertisements was less than ideal, with the New Zealand weight loss advertisement
offering a pedometer as a give-away while the Australian advertisement did not.
While efforts were made to match the New Zealand advertisements as closely as
possible, the selected Australian Alzheimer’s advertisement was more of the genre of
a DAC. This particular advertisement may have been perceived as more credible
(and potentially more valuable) due to the renown of the sponsor company which has
consistently been ranked around 30 within the 100 top brands over the past five years
(Business Week, 2003, 2005, 2006). It is difficult, therefore, to confidently
extrapolate how consumers might respond to other disease awareness advertisements
sponsored by less well-known companies. Participants may have been more familiar
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with the Australian advertisements as these have appeared in popular Australian
magazines, while the New Zealand DTCA format with product and side-effect
disclosure may have appeared foreign. This may have resulted in an over- or underestimation of the likely effects in the event that these advertisements become widely
available in Australia. Other limitations include that participants were only shown
one advertisement on one occasion rather than measuring the effects of an
advertising campaign or seeing an advertisement in its usual context, and
comparisons could only be made between participant responses to one of four
advertisements rather than within-participant responses to all four advertisements.

4. 7 Discussion
Participants were significantly more likely to perceive the Australian advertisement
for Alzheimer’s disease to be extremely valuable or valuable compared with the
other advertisements. This advertisement could be classified as a disease awareness
advertisement as it provided information regarding the symptoms of Alzheimer’s
disease without promoting a particular product or treatment. Conversely, participants
found the DTCA (in particular the NZW advertisement) to be not very valuable or
not at all valuable. While there is considerable evidence in the countries that allow
DTCA that consumers find it of value (Deshpande et al., 2004; Hoek, et al., 2004;
Mehta and Purvis, 2003) these new results suggest they may find DACs to be more
valuable. It should be noted that the median age of participants in the study was 49.5
years which is higher than the general population, and would potentially be more
concerned about dementia than a younger sample.

Participants were more likely to perceive the AA advertisement as trying to provide
information about a medical condition as opposed to sell a product or treatment. This
finding – that participants were not more cynical regarding the intent of the disease
awareness advertisement – may alarm public health and consumer advocates,
particularly as this advertisement was perceived to be more valuable. The sponsor of
AA produces a product to treat Alzheimer’s disease, and presumably this would have
been a large part of their motivation in creating awareness of the disease. For the
New Zealand advertisements (DTCA) where the product name and requisite product
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information was evident, participants were most likely to identify the advertisement
as trying to sell a product or treatment. For the Australian advertisements, where
product name and information cannot be included, but each of the advertisements
encouraged readers to talk/check with their doctors, participants were more likely to
identify that the advertisement was encouraging them to talk to their doctor.

In the current study it was significantly more likely for participants receiving the
Alzheimer’s advertisements to consider talking with their doctor regarding the
disease, and about the treatment. While the majority of participants in the current
study did not consider seeking a prescription as a result of reading the
advertisements, they were most likely to do so for the Alzheimer’s advertisements. It
could be considered that while there are a variety of methods to prevent, treat and
manage obesity (such as physical activity and dietary changes, as well as
medication), there are limited and potentially only pharmacological options to treat
Alzheimer’s disease. This may in part be the cause of participants viewing the
Alzheimer’s advertisements being more likely to discuss the conditions and
treatments with their doctor. It could also be considered that patients feel more
comfortable talking with their doctor or with others about Alzheimer’s disease as it is
perceived as a medical condition which the sufferer has no control over, whereas
they may be less inclined to discuss being overweight or obese as it is perceived
more as a social issue with multiple, complex causation and associated stigma.

A greater percentage of participants had either themselves been overweight, or had
experience of a family member being overweight than had had experience with
Alzheimer’s disease, and this may have effected their processing of advertisement
information, their attitude toward the advertisement, and their reported intentions to
take action. While advertisement involvement was not measured in the current study,
there is evidence that participants suffering with a disease or condition have higher
involvement with advertisements regarding that disease/condition than non-sufferers,
particularly when exposed to high levels of risk information (Kavadas et al., 2007).

Participants viewing the Alzheimer’s advertisements found it easier to make sense of
the information than those viewing the weight loss advertisements which could be
attributed to the informational content of the former. The Alzheimer’s
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advertisements, particularly the AA advertisement, provided information on the
disease and symptoms, while the weight loss advertisements were more visual, with
limited text, and a focus on treatment. According to the Rossiter and Percy model
previously described, most DACs and DTCA are classified as informational because
they elicit a problem-solving or problem-avoidance motivation. However the weight
loss advertisements in the current study contained many emotional and
transformational elements as they focused on positive end states, they used a
seemingly confident and happy “expert user” as the presenter who was also someone
the target audience would aspire to or identify with (Rossiter and Percy, 1997).
Interestingly, when Roth (2003) examined message strategies in DTC print
advertisements and how they effect brand-level advertising he found that
advertisements conveying patient happiness as a result of using a drug were
associated with higher levels of advertisement awareness and that disease
information did not increase brand awareness levels (advertisements with symptom
information were associated with lower brand awareness). It is troubling that
pharmaceutical companies are increasingly using these persuasive techniques which
appear to be effective from a marketing viewpoint, while public health and consumer
advocates are calling for less emotional and more informational content in DTCA.

In terms of adequacy of information, the results of the current study demonstrate that
participants found the more transformational styles of advertising (the weight loss
advertisements) provided insufficient information regarding the condition itself and
treatments available. Interestingly, more participants viewing the NZW
advertisement felt that there was adequate information available regarding the
benefits of treatment than the risks (45.7% vs. 34.4%). This contrasts with the other
New Zealand DTCA (NZA) where more participants felt there was adequate
information about the risks of treatment than the benefits (29.3% vs. 20.9%). This
occurred despite both advertisements containing the requisite risk information panel
at the bottom of the advertisement. This is of interest as New Zealand DTCA
regulation does not include the same strict criteria for fair balance of risk/benefit
information as the US (Hoek et al., 2004). Potentially, the more emotional and
promotional style of the NZW advertisement (compared with the more informational
style of the NZA advertisement) achieved this contrasting result in the current study,
however it could also be related to the free Pedometer on offer in the NZW
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advertisement which may have been perceived as information on an additional
benefit of treatment. Participants viewing Australian advertisements felt there was
not enough information regarding the treatments available, nor the benefits/risks of
treatment. This was expected as the Australian advertisements are compliant with
Medicines Australia Code of Conduct requirements and do not mention a specific
product (Medicines Australia, 2006). Under the Code there is capacity for disease
awareness advertisers to provide the full range of treatment options, but in this
instance, the advertisers elected to provide only symptom information.

4. 8 Conclusion
Participants were not likely to report an intention to ask for a prescription from their
doctor as a result of seeing any of the advertisements in this study. Participants were
more likely to find the disease awareness advertisement to be valuable than the
unbranded product or DTC advertisements. While more research is required to
determine the persuasive effects of, and consumer responses to, a range of DACs,
this study suggests that consumers are less critical of pharmaceutical company
sponsored advertisements of this genre than DTCA and unbranded product
advertisements. It is evident from the study that participants found it easier to make
sense of the more informational style advertisements, and felt that there was
insufficient information regarding the condition and treatments in the more emotive
and transformational advertisements. These finding could inform future revisions to
the regulation of pharmaceutical sponsored advertisements for prescription
medicines in both Australia and New Zealand, and (if re-enacted) the ANZTPA
Advertising Code. In the interests of consumers and public health, advertising
guidelines should encourage more informational advertisements, and more
transparency regarding the intent of the advertiser particularly for DACs, such as a
generic disclosure that the advertisers make product(s) to treat the condition/disease
advertised.
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5. 1 Abstract
Objective: To examine the nature of disease awareness advertising (DAA).
Design: Therapeutic advertisements in six popular Australian women's magazines
were monitored between April 2006 and March 2007. A subset of advertisements
was included in the study based on criteria derived from a definition of DAA. Unique
advertisements were analysed by four independent coders.
Main outcome measures: Types of advertisements and their sponsors, the types of
disease information present, and the persuasive techniques utilised.
Results: Of 711 advertisements identified, 60 met the inclusion criteria for DAA,
and 30 of these were unique. Over one-third of the advertisements were classified as
“unbranded product advertisements”, which promote a product without referring
directly to a brand. DAA sponsored by pharmaceutical companies most often
provided treatment and prevalence information. Most (22/30) advertisements used
emotional appeals; 15 of these used “happiness/healthiness/wellbeing”.
Conclusions: The educational value of industry-sponsored DAA could be improved
if regulations and guidelines stipulated disease information requirements, such as
inclusion of risk-factor and symptom information. Regulators should provide
guidelines regarding "unbranded product advertisements", and the acceptability of
other persuasive techniques. Further research into DAA is required and should
consider advertisements in a range of media and behavioural responses.
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5. 2 Introduction
In countries where direct-to-consumer advertising (DTCA) of prescription medicine
is prohibited, pharmaceutical companies can indirectly promote medicines via
disease awareness advertising (DAA) (Hall and Jones, 2007; Mintzes, 2006). DAA
typically contains information on a disease and recommends that consumers speak to
a doctor for further information. Companies sponsor DAA for conditions for which
they manufacture a treatment, and often run concurrent branded advertising
campaigns that target general practitioners (Hall and Jones, 2007).

DAA sponsored by pharmaceutical companies may negatively influence consumers,
generate unnecessary fear, and create a greater reliance on medications to solve
social and behavioural problems (Mintzes, 2006; Moynihan and Henry, 2006). DAA
has been identified as a form of disease mongering or “widening the boundaries of
treatable illness in order to expand markets for those who sell and deliver treatments”
(Moynihan, et al., 2002). DAA is often directed at lifestyle conditions for which
there are large, lucrative markets (e.g., balding or erectile dysfunction) (Consumers
International, 2006; Glatter, 2004). A Dutch study found that a DAA campaign
increased disease-related consultations and prescriptions for the advertiser’s product
for what may be considered an unimportant health issue (t'Jong et al., 2004).

However, DAA can also provide information to help consumers identify symptoms
and seek information about and treatment for previously untreated conditions
(Wielondek, 2005). Advocates consider DAA to be particularly important for
diseases that are considerably under-diagnosed (e.g., diabetes). In Australia,
advertisers of therapeutic goods are bound by the Therapeutic Goods Act 1989 and
the Therapeutic Goods Administration (TGA) Therapeutic Goods Advertising Code
(Australian Government Department of Health and Ageing, 2007), which prohibit
DTCA. Although the definition and regulation of DAA is not explicit in the current
Code, this form of advertising was recognised in a review of the therapeutic goods
legislation (Galbally, 2000). The review identified pros and cons of industry DAA,
including its potential use as a method of skirting current regulations that prohibit
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DTCA. It called for the development of a code of practice with clear parameters for
DAA, with an aim to increase the potential benefits and decrease the potential
disadvantages. The formative Australia New Zealand Therapeutic Products Authority
(ANZTPA), which aims to establish a trans-Tasman regulatory scheme for
therapeutic products, defined DAA in its draft advertising code (ANZTPA, 2005).
The establishment of ANZTPA, however, faltered in New Zealand Parliament, and it
may not be re-instigated for some time.

In Australia, pharmaceutical company advertising for prescription medicines,
including DAA, currently falls under the jurisdiction of Medicines Australia, a selfregulatory industry body. The Medicines Australia Code of Conduct is designed to
complement the requirements of the Act and the TGA Code. Although prior approval
of advertisements is not required, there is a monitoring committee and member
companies may be required to submit promotional material for review at various
times (Medicines Australia, 2006). Section 9.5 of the Medicines Australia Code of
Conduct (15th edition) allows for “patient education”, including advertising or
provision of information on medical conditions and the broad range of treatments
that may be prescribed by doctors. The Code stipulates that patient education should:
be current, accurate, and balanced; not focus on a specific product or treatment;
include a statement directing consumers to seek further information about the
condition or range of treatments; not encourage patients to seek a prescription for a
product; not cause alarm or misunderstanding; and not raise patients’ hopes of
successful treatment (Medicines Australia, 2006).

We aimed to determine the nature of DAA in popular Australian magazines,
including the types of disease information provided and the use of persuasive
techniques, in an effort to inform future regulation of pharmaceutical industry DAA.

5. 3 Method
We used content analysis, as this method has been successfully employed in the
United States (US) to examine DTCA (Bell, Kravitz et al., 2000; Frosch et al., 2007;
Shah et al., 2003). We chose to study women’s magazines, as women have been
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identified as being more involved in health-related decisions, and studies in the US
have indicated a greater incidence of DTCA in women’s magazines (Bell, Kravitz et
al., 2000; Shah et al., 2003). The two highest-circulating monthly magazines, the
three highest-circulating weekly magazines that contained therapeutic
advertisements, and the highest-circulating health magazine were selected for the
study. Monitoring was conducted from April 2006 to March 2007.

Advertisements where the focus was a disease or condition were included for
analysis. We used the definitions in the ANZTPA draft advertising code. ANZTPA
describes DAA as “information that aims to raise awareness regarding specific
diseases, including public health campaigns, must be factual and balanced, and
support consumers in making informed healthcare choices”, and unbranded product
advertising promotes the use or supply of product by inviting the consumer to seek
further information about symptoms or conditions and/or their treatment or
management while not referring overtly to any particular branded product
(ANZTPA, 2005).

Advertisements regarding health behaviours or procedures (e.g., domestic violence
or eye checks) were not included unless they contained some mention of a disease
associated with these behaviours. Advertisements where a branded product or service
was promoted (e.g., over-the-counter products or government vaccination programs)
were excluded. Disease advertisements where a separate but potentially related overthe-counter product advertisement appeared on the same or adjacent page were
included, along with the original placement context, but coders were asked to focus
on the disease advertisement.

We employed directed content analysis for the study, where categories and codes
were derived from relevant theory and prior research (Hsieh and Shannon, 2005).
Three coders had qualifications and experience in marketing, and one had medical
qualifications and experience as a general practitioner. One of us (D.V.H) facilitated
individual training with each coder, as recommended by Kolbe and Burnett (1991).
Coders made decisions on the sponsors, type of disease information provided, target
audience, emotional appeal and use of branding techniques. Advertisements were
coded for the presence or absence of disease information, but coders did not analyse
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the accuracy of information. More detailed information regarding the establishment
of categories and codes is available from the authors1.

Following the completion of coding, data were entered into SPSS V.15. The level of
intercoder agreement was tested using the proportional reduction in loss (PRL)
approach, which is suited to qualitative data, particularly where subjective coder
judgements are made about marketing and promotional material (Rust and Cooil,
1994). The PRL is considered to be, under the assumptions of generalisability theory,
an equivalent measure to Cronbach’s  (Rust and Cooil, 1994). For the PRL, interrater agreement is calculated for each variable; the reliability score is then
established using tables provided by Rust and Cooil (1994). The score is contingent
on the number of coders and response categories. A minimum score of .7 is
considered adequate for exploratory work.

5. 4 Results
We identified 711 advertisements for 207 therapeutic products (including over-thecounter and natural products) in the initial monitoring process (see Figure 5.1).
Initially, 83 advertisements were identified as DAA; however, 23 were excluded as
they did not meet the inclusion criteria (see Figure 5.1). The remaining 60
advertisements were analysed for frequency by magazine source (see Table 5.1) and
disease or condition advertised (see Table 5.2).

1

Refer to Appendix D for coding sheet
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Figure 5.1: Disease awareness advertisements selected from initial sample
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Table 5.1: Magazine source of 60 disease awareness advertisements,
April 2006 to March 2007
Magazine

Size*

Circulation

Advertisements

Reader’s Digest

154

352 000

22

Good Medicine

162

70, 031

11

Woman’s Day

496

480 564

8

Australian Women’s Weekly

256

605 039

7

New Idea

456

391 388

6

Table 5.2: Number of times diseases or conditions were advertised in six magazines,
April 2006 to March 2007
Disease or condition

No.

Cervical cancer

13

Melanoma or skin cancer

9

Genital herpes

6

Erectile dysfunction

5

Asthma

4

Cramps

4

Multiple sclerosis

4

Skin conditions

2

Nasal congestion

2

Onychomycosis (foot fungal conditions)

2

Prostate problems

2

Whooping cough

2

Arthritis

1

Osteoporosis

1

Bruises

1

Muscle pain

1

Tinnitus and vertigo

1
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The most frequently advertised conditions were cervical cancer, melanoma or skin
cancer, genital herpes, and erectile dysfunction (see Table 5.2). These advertisements
were part of larger advertising campaigns that occurred across a range of media
during the monitoring period.

Of the 60 advertisements, 30 unique advertisements (i.e., with unique text or
imagery) were identified, and these were provided to the four coders for analysis.
Most advertisements (22) targeted men and women, five targeted women only, and
three targeted men only. Adults were targeted in all advertisements — most (21)
targeted adults in general, six targeted young adults and three targeted older people.
5.4.1

Advertisement Sponsor and Type

Of these 30 advertisements, 13 had no identifiable advertiser or sponsor, nine were
sponsored by pharmaceutical companies, three by government, three by nongovernment organisations and two by a combination of advertisers (PRL = 0.97).
Most advertisements (19) were classified as DAA, with the remaining 11 classified
as unbranded product advertisements (PRL = 0.80).

Analysis of sponsor by advertisement type showed that most unbranded product
advertisements (7/11) had no identifiable sponsor. These advertisements could be
classified as “advertorials” as they commonly appeared alongside an advertisement
for an over-the-counter product. However, four of the nine industry-sponsored
advertisements were also classified as unbranded product advertisements.
5.4.2

Disease Information

Table 5.3 shows the number of advertisements where the various types of disease
information were present and the reliability scores for each.
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Table 5.3: Presence of different types of disease information in 30 advertisements
in six magazines, April 2006 to March 2007
Number of advertisements

PRL reliability

Disease information type

where present

score

Treatment

28

0.95

Cause/aetiology

21

0.87

Symptoms

21

0.98

Prevention

19

0.85

Risk factor(s)

16

0.78

Prevalence

13

0.92

PRL = proportional reduction in loss.

The most common form of disease information in advertisements was treatment
information, followed by information on the cause or aetiology of the
disease/condition as well as symptom information. PRL reliability scores ranged
from 0.78 for risk factors to 0.98 for symptoms. Analysis of disease information by
sponsor showed that the advertisements sponsored by pharmaceutical companies
more often provided prevalence and treatment information, whereas advertisements
without identifiable sponsors tended to provide information in all areas apart from
prevalence (see Table 5.4).
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Table 5.4: Disease information provided in 30 advertisements in six magazines,
April 2006 to March 2007, by sponsor

Disease
information
type

NonGovernment government
(n = 3)

organisation
(n = 3)

Sponsor

Pharmaceutical Combination
company

of sponsors

(n = 9)

(n = 2)

not
identified
(n = 13)

Treatment

3

3

7

2

13

Cause

3

2

3

0

13

Symptoms

0

2

4

2

13

Prevention

3

1

3

2

10

Risk

3

2

2

0

9

Prevalence

3

2

7

0

1

5.4.3

Persuasive Techniques

Emotional appeals (imagery that aroused feelings) were identified in 22
advertisements (PRL = 0.95. Of these, the most commonly used appeal type (of eight
possibilities) was happiness/healthiness/wellbeing (15), and the second most
common was fear/revulsion/loss (3) (PRL = 0.94). The advertisements containing
fear/revulsion/loss appeals were the melanoma and skin cancer advertisements that
formed part of an Australian Government advertising campaign.

Thematic analysis of coder responses to the implicit intent of the imagery (the
meaning implied by imagery) demonstrated similar themes to the responses for
emotional appeal type. An interesting finding was that the imagery in a series of
genital herpes advertisements conveyed contradictory messages regarding the
prevalence of the condition. Whereas the text stated that “1 in 8” people have genital
herpes, the coders felt that the imagery portrayed much higher prevalence levels. For
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example, one advertisement showed an image of six female symbols, where four
were coloured black and two coloured red. The coders agreed that the implicit
message was that two in six women have genital herpes.

Coders unanimously agreed that 15 advertisements contained a corporate brand or
logo. Fourteen advertisements had other forms of branding present, such as a
campaign name, logo or icon, including seven of the nine industry-sponsored
advertisements. Examples of advertisements examined and their characteristics are
shown in Figure 5.2.

Figure 5.2: Examples of four advertisements and their characteristics
Sponsor

Main image

Photograph of
two bananas
Bayer

side by side,

Healthcare

one pointing
up and one
pointing down
Photograph of

CSL
Laboratories

adolescent girl
leaving home
with a camping
rucksack

Main text

Category

Disease

Target

information

audience appeal

Emotional

“Erection
difficulties? Your

Small image
Unbranded

doctor can point you product
in the right

Branding

from another
Treatment

Men

Humour

advertisement

advertising
campaign and

direction”

flame symbol

“You can’t stop
your daughter from
growing up, but you
can help protect her
from cervical

Disease
awareness
advertisement

Cause;
prevalence;
prevention;

Happiness/
Adults

healthiness/
wellbeing

treatment

Text: “guard
against
cervical
cancer”

cancer”

Not

Photograph of

“Understanding

identified

skeletal spine

osteoporosis”

Disease
awareness
advertisement

Cause; risk
factors;

Older

prevention;

adults

Not present Not present

treatment
Illustrative

Photograph of
Australian

“Not everyone with

surgeon’s hand melanoma dies,

Government cutting skin
with a scalpel

some just go
through hell”

symbols; text:

Cause; risk
Disease

factors;

awareness

prevalence;

advertisement

prevention;
treatment

Young
adults

Fear/

“protect

revulsion/

yourself in

loss

five ways
from skin
cancer”
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5. 5 Discussion
Our results indicate that DAA comprises a small proportion of all therapeutic
advertising in popular Australian magazines, and is sponsored by industry,
government and non-government organisations. Almost half the industry-sponsored
advertisements were classified as “unbranded product advertisements”, which
promote the use or supply of a product without referring directly to a brand
(ANZTPA, 2005). The most common form of disease information in all
advertisements was treatment information, and industry-sponsored advertisements
more often provided information regarding treatment and prevalence.

These results suggest that a primary objective of industry DAA is to provide
information about a treatment in order to sell a product. Although this may appear
logical from a marketing viewpoint, consumer advocates are concerned that the
public is unaware of the profit motive of DAA (Mackenzie et al., 2007; Mintzes,
2006). Further research is required to determine actual responses, but it is possible
that consumers would not recognise the commercial intent of industry DAA, and
perceive it to be a community service, similar to government advertisements. A
possible solution is more transparent disclosure that the advertiser makes a product to
treat or prevent the condition advertised; however, the use of such a disclosure would
require research and testing, as it may act as a form of advertising similar to DTCA,
or have other adverse effects.

The results have implications for health professionals, as industry DAA is required to
include a statement to encourage patients to “ask their doctor” (Medicines Australia,
2006). However, if advertisements focus on treatment and do not include adequate
information on risk factors, doctors may spend more valuable consultation time
responding to inappropriate requests for treatment and re-educating patients (Toop
and Mangin, 2007).

Our results suggest that the pharmaceutical industry could improve DAA through the
provision of more comprehensive disease information, such as symptom and risk
factor information. Medicines Australia could provide more detailed and specific
guidelines for DAA, as recommended in a Council of Australian Governments
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review (Galbally, 2000). Such guidelines are provided by the Medicines and
Healthcare products Regulatory Agency in the United Kingdom. The Agency
guidelines state that information in DAA should be: accurate; current; substantiated;
comprehensive in covering the key characteristics of the disease including
identification of the symptoms and risk factors; and balanced such that treatment
information is not unduly emphasised (MHRA, 2005). The identification of
unbranded product advertisements may also be useful for Medicines Australia for
future revisions to their Code of Conduct, as there is currently no acknowledgement
of, or guidelines for, this form of advertising. This differs from the TGA advertising
code, which recognises unbranded therapeutic product advertisements in relation to
non-prescription medicines (Australian Government Department of Health and
Ageing, 2007).

We found that most industry-sponsored DAA used branding techniques, such as
campaign names, logos or symbols. The use of branding techniques has previously
been identified in Australian DAA as potentially circumventing the prohibition on
DTCA, as companies create a “pseudo brand” that conveys the identity of the
product without naming it (Hall and Jones, 2007). As in studies of DTCA in the US
(Frosch et al., 2007; Welch Cline and Young, 2004), the most prominent emotional
appeal that we found was positive (happiness/healthiness/ wellbeing). An analysis of
visual features in DTCA in the US found that advertisements commonly portray
models with positive personal characteristics. Consumers may associate prescription
drugs with social rewards via observational learning and conclude that “a healthy
appearance and active lifestyle is only a prescription away” (Welch Cline and
Young, 2004).

Our methodology was based on analyses of DTCA conducted in the US (Bell,
Wilkes et al., 2000), and in response to formative industry-focused advertising
regulation in Australia (ANZTPA, 2005). Specific codes relevant to non-profit or
government advertisements were not devised, and therefore recommendations for
these advertisements have not been made. Another limitation of our study is the
small sample of unique advertisements that resulted from the monitoring and
inclusion process. This prevented statistical analysis and comparisons with content
analyses conducted into DTCA.
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Although further research into DAA across a range of media is required, as is
research into behavioural responses to this form of advertising, we have
demonstrated that DAA is present in popular Australian magazines and is sponsored
by profit and non-profit organisations. Most industry DAA contained treatment
information, and almost half were classified as “unbranded product advertisements”.
Medicines Australia could improve the educational value of industry DAA by
providing specific and detailed guidelines to pharmaceutical marketers regarding the
presence of different types of disease information, as well as guidelines on the use of
persuasive techniques.
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6. 1 Abstract
Objective: In countries where direct-to-consumer advertising of prescription
medicines is prohibited, pharmaceutical companies sponsor Disease Awareness
Advertising (DAA) which can provide disease information but cannot directly
promote a prescription medicine product. This study examined the impact of DAA
exposure on women’s reported behavioural intentions.
Design: Participants were recruited via mall-intercept method and were randomly
shown two advertisements, following which they completed a questionnaire.
Setting: A commercial shopping centre in a metropolitan area in NSW, Australia.
Participants: 241 women aged between 48 and 85 years responded to 466
advertisements.
Intervention: The stimuli were print magazine advertisements about osteopenia and
fibromyalgia. Sponsors and the amount of disease information were manipulated.
Results: The majority of participants reported an intention to ask their doctor about
the health condition and to ask about treatments and tests. Participants were more
likely to report an intention to ask their doctor for a prescription or referral if they
saw an advertisement with limited disease information than those viewing
advertisements with more detailed information.
Conclusion: When limited disease information is provided, DAA can stimulate
demand for prescription medicine products. The regulation of industry-sponsored
DAA requires strengthening, with specific guidelines on the inclusion of more
detailed disease information.

116

6. 2 Introduction
There is growing concern in Australia and elsewhere regarding the influence of the
pharmaceutical industry on the prescribing habits of doctors (Angell, 2006;
Moynihan and Cassels, 2005). Concern has centred around marketing practices that
directly influence doctor’s prescribing behaviour (Mansfield et al., 2006), as well as
pharmaceutical promotions that directly target consumers.

Direct-to-consumer advertising (DTCA) of prescription medicines is currently only
legal in the United States (US) and New Zealand, and there is evidence that it
influences consumers to make requests to doctors for prescription medicines (Frosch
et al., 2010; Hoek et al., 2004). DTCA initiated requests from consumers have been
found to influence doctors to prescribe the advertised medicines (Frosch et al., 2010;
Gilbody et al., 2005).

While DTCA is not legal in Australia, pharmaceutical companies can engage in
disease awareness advertising (DAA) which targets consumers via a range of media.
DAA cannot include the name or information about a specific prescription medicine,
however it can include disease information such as the symptoms and prevalence of a
disease, as well as general treatment information (Medicines Australia, 2006). DAA
is utilised in many western nations, and is referred to as ‘help seeking advertising’ in
Canada and the US. Research into the effects of DAA demonstrate that it can
increase consultation rates as well as prescriptions for the advertiser’s product
(Basara, 1996; t'Jong et al., 2004).

Proponents of DTCA and DAA claim that the pharmaceutical industry can provide
valuable information regarding health conditions and help consumers to identify
symptoms and seek help (Auton, 2007; Bonaccorso and Sturchio, 2002). DAA is
considered particularly important for conditions where there are high levels of underdiagnosis, such as diabetes (Wielondek, 2005).
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However, it has been suggested that industry-sponsored DAA in Australia
circumvents regulations that prevent DTCA (Mackenzie et al., 2007), and that some
advertisements promote an association between the disease and a prescription
product, even if the name of the product is not included (Mintzes, 2006). Often there
are concurrent campaigns targeting doctors which use the same creative techniques
but include product information (Hall and Jones, 2007).

Industry-sponsored DAA has been identified as a form of disease mongering or
“widening boundaries of treatable illness in order to expand markets for those who
profit from treatments” (Moynihan, et al., 2002, p.886). There is also concern that
DAA tends to focus on ‘lifestyle conditions’, such as obesity or erectile dysfunction,
where there are lucrative markets (Glatter, 2004). Other DAA has been criticized for
promoting health conditions with vague or non-specific symptoms, or exaggerating
the prevalence of a condition and using fear appeals, such that consumers are
encouraged to identify themselves as suffering with, or consider themselves at
greater risk of contracting, the advertised condition (Moynihan and Cassels, 2005).
Consistent with criticism of DTCA (Bell et al., 2000), it has been found that while
DAA can be eye-catching and emotive, it often provides very limited disease
information (Hall et al., 2009).

DAA in Australia is currently regulated by the industry body, Medicines Australia.
Until recently, guidance for DAA was under Section 9.5, ‘Patient Education’ in the
Code of Conduct Edition 15 (Medicines Australia, 2006). This section stipulated that
educational material should not stimulate the demand for prescription of a particular
product, but should include: a description of the medical condition and general
treatment information; a statement directing patients to seek more information from
their doctor; and balanced information that does not create undue concern or
misunderstanding in the community (Medicines Australia, 2006). Edition 16 of the
Code of Conduct recently came into effect with a specific section (Section 12.7) on
‘Disease Education Activities in Any Media’ (Medicines Australia, 2009). The
guidelines are similar, but state that the advertisement should focus on the condition
itself and its diagnosis rather than treatment, and that key characteristics of the health
conditions should be included (Medicines Australia, 2009).
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The purpose of the current study was to determine the impact of DAA on older
Australian women’s perceptions of their susceptibility to, and the severity of, two
advertised health conditions. We also aimed to determine whether women would
respond differently to a range of behavioural variables (including their intention to
seek further information, talk to their doctor and request a prescription or referral) if
they viewed advertisements for health conditions with differing amounts of
information and differing sponsor logos.

6. 3 Method
The study design included the development of mock DAA for two health conditions
that affect older women. Print magazine advertisements were used as there are high
and growing levels of readership in Australia, particularly among women (Magazine
Publishers of Australia, 2007). The advertisements were developed using marketingcommunication principles (Rossiter and Bellman, 2005; Rossiter and Percy, 1997)
and included similar styles of imagery and quantity of text as found in current DAA
in Australian magazines (Hall et al., 2009). The advertisements provided information
regarding two low profile health conditions: osteopenia, which is a state of early
bone loss which can potentially increase the risk of developing osteoporosis; and
fibromyalgia which is a disorder of the central nervous system associated with
intensified pain due to abnormal sensory processing. Both conditions have been
subject to controversy as to their clinical importance, and there is concern that they
have the potential for disease mongering (Alonso-Coello et al., 2008; Berenson,
2008).The authors could find no evidence of mass media education or
pharmaceutical promotions about these conditions in Australia. This differs from the
US where there has been promotion by pharmaceutical companies of treatments for
these conditions over the past few years (Berenson, 2008; Kelleher, 2005).

Two different manipulations were applied to the advertisements: the amount of
information provided and the sponsor logos1. For the information manipulation,
participants received either limited disease information (brief descriptions of the
1

Refer to Appendix E for examples of stimuli.

119

symptoms, and how to seek further information) or more detailed disease
information (fuller descriptions of the symptoms, disease causation, diagnosis and
management as well as how to seek further information). For the sponsor
manipulation, fictional logos at the bottom of the advertisement varied between nonprofit, pharmaceutical company and a combination of these two (co-sponsored).
Research assistants approached women in a commercial shopping centre within a
metropolitan area in NSW, during retail hours over five consecutive days in
November 2008. Refusals and ineligible respondents were recorded. Consenting
participants were randomly assigned an advertisement for one health condition, and
then received an advertisement for the other health condition with the same sponsor
and information manipulation. For example, if a participant was randomly assigned
the co-sponsored, high information advertisement for fibromyalgia, she would
subsequently be shown the co-sponsored, high information advertisement for
osteopenia. Participants viewed the advertisements and completed the
questionnaires1 independently. All participants read an information sheet2 and
following participation, were debriefed regarding the hypothetical nature of the
advertisements and offered contact details for relevant health support organisations.

Data was analysed using descriptive and non-parametric statistics. Mann-Whitney U
tests were used to identify relationships between variables as this test is considered
more appropriate than t-tests for nominal and scale variables which fail to satisfy the
assumptions of normality (McCrum-Gardner, 2008). A score was created for
perceived severity of the condition, which included responses to three bipolar
adjective scales for how distressing, serious and inconvenient it would be to
experience the condition. Item-to-total correlations were high (>.830) and inter-item
correlations were between .51 and .67, indicating that none of the items were
redundant. The internal consistency of the scale was measured using Principal
Components Analysis. Only one component was extracted with an eigenvalue greater
than one; it explained 73.9% of variance. All items loaded with values greater than
.840. Cronbach’s alpha for the three-item scale was .822, indicating an appropriate
level of internal consistency.

1

Refer to Appendix F

2

Refer to Appendix G
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6. 4 Results
A total of 977 women were approached to participate in the study, with 30%
agreeing, however only 82.5% of those agreeing were eligible. Demographic data
was not collected for the women that refused to participate in the study and as such it
cannot be determined what percentage was eligible1. A total of 241 women aged
between 48 and 85 years (median age of 64) participated in the survey. Sixty seven
percent were born in Australia, and 14.6% were born in the United Kingdom; 93%
spoke English at home. Approximately half had achieved Year 12 or higher
education level, and 54% were retired. The demographic profile of participants is
similar to women in this age group in the local government area, however
participants in the study were found to have higher levels of educational attainment
as an estimated 18% of women in this age group in the local government area have
achieved Year 12 or higher education level.

Participants were asked about where they most often get information regarding
disease or health conditions; while the most nominated source was their doctor
(82%), television (45%), pharmacists (40%), internet (37%) and magazines (36%)
were also cited as sources of health information.

Questionnaires were completed for a total of 466 advertisements; 232 on
fibromyalgia and 234 on osteopenia, and most participants rated the advertisements
as easy to understand. While 36% agreed that they or someone they knew well had
suffered from fibromyalgia, 64% agreed that they or someone they knew well had
suffered from osteopenia.
6.4.1

Behavioural Intentions

Participants were asked, as a result of seeing the advertisement, which of a list of six
actions they would take. Seventy seven percent of the women agreed that they would
talk with their doctor about the condition, 73% agreed they would ask about
treatments or tests, 64% agreed they would look for information as directed by the
advertisement and 55% agreed they would look for information from other sources.
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Close to half (49%) agreed they would ask their doctor for a prescription or a referral
as a result of viewing the advertisement, whereas only 23% agreed they would do
nothing.

Contingency table analysis indicated a statistically different result between reported
behavioural intentions for the two different health conditions, such that participants
were more likely to report an intention to talk to their doctor about the condition
(p=.029) and to ask their doctor about treatments or tests (p=.024), after viewing the
advertisement for osteopenia (see Table 6.1).

1

Refer to Appendix H
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Table 6.1: Percentage of agreement with behavioural intention by condition type
Behavioural intention

Condition Type

2

“As a result of seeing this
advertisement would you…”

Fibromyalgia
(n=232)

Osteopenia
(n=234)

pvalue

Talk to your doctor about the

73.1%

81.7%

.029

68.3%

77.8%

.024

63.1%

65.5%

.596

55.0%

55.5%

.916

45.1%

52.5%

.123

25.0%

20.6%

.291

condition
Ask your doctor about treatments or
tests
Look for information as directed by
the advertisement
Look for information from other
sources
Ask your doctor for a prescription
or a referral
Do nothing

Behavioural intentions did not differ significantly between the sponsor
manipulations. When considering the two information levels between the health
conditions, there were no significant differences for participants viewing high or low
information levels for the advertisements for fibromyalgia (see Table 6.2). However
For the osteopenia advertisements, participants viewing low information
advertisements were more likely to report an intention to ask their doctor for a
prescription or a referral (p=.015) than those viewing high information
advertisements (see Table 6.3). Considering all participants, Mann-Whitney U tests
showed that those who reported an intention to ask for a prescription or referral were
more likely to be older (p<.001), and less educated (p<.001).
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Table 6.2: Percentage of agreement with behavioural intention by
information manipulation: Fibromyalgia
Condition Type

Fibromyalgia
n=232

Behavioural intention

Information level 2

“As a result of seeing this advertisement would

High

Low

p-

you…”

(n=

(n=

value

54)

178)

Talk to your doctor about the condition

71.2%

73.7%

.420

Ask your doctor about treatments or tests

63.5%

69.8%

.245

Look for information as directed by the advertisement

59.6%

64.1%

.333

Look for information from other sources

48.1%

57.1%

.164

Ask your doctor for a prescription or a referral

41.2%

46.3%

.314

Do nothing

28.0%

24.1%

.349
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Table 6.3: Percentage of agreement with behavioural intention by
information manipulation: Osteopenia
Condition Type

Osteopenia
n=234

Behavioural intention

Information level 2

“As a result of seeing this advertisement would

High

Low

p-

you…”

(n=

(n=

value

56)

178)

Talk to your doctor about the condition

76.4%

83.3%

.167

Ask your doctor about treatments or tests

69.8%

80.2%

.082

Look for information as directed by the advertisement

57.4%

68.0%

.103

Look for information from other sources

48.1%

57.8%

.139

Ask your doctor for a prescription or a referral

38.5%

57.0%

.015

Do nothing

23.4%

19.7%

.361

When considering personal experience (if they or someone they knew well had
suffered from the advertised health condition), participants viewing fibromyalgia
advertisements and reporting personal experience were significantly more likely to
report an intention to look for information from other sources and request a
prescription or referral from their doctor than those participants without personal
experience (see Table 6.4). For participants viewing osteopenia advertisements,
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participants reporting personal experience were more likely to report agreement to all
behavioural intentions with the exception of do nothing (see Table 6.5).

Table 6.4: Percentage of agreement with behavioural intention
by personal experience: Fibromyalgia
Condition Type

Fibromyalgia
n = 219 (13 missing responses)

Behavioural intention

With personal

Without personal

experience

experience

n = 79

n = 140

76.3%

71.0%

.251

69.3%

67.6%

.463

64.0%

61.5%

.417

64.4%

49.6%

.028

54.1%

39.4%

.030

20.6%

27.1%

.202

2 pvalue

Talk to your doctor about the
condition
Ask your doctor about treatments
or tests
Look for further information as
directed by the advertisement
Look for further information from
other sources
Ask your doctor for a prescription
or referral
Do nothing
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Table 6.5: Percentage of agreement with behavioural intention
by personal experience: Osteopenia

Condition Type

Osteopenia
n=227 (7 missing responses)

Behavioural intention

With personal

Without personal

experience

experience

n = 146

n = 81

86.7%

72.2%

.007

82.4%

68.8%

.018

71.6%

53.9%

.007

59.9%

48.1%

.064

59.1%

39.2%

.004

14.8%

31.3%

.007

2 pvalue

Talk to your doctor about the
condition
Ask your doctor about treatments
or tests
Look for further information as
directed by the advertisement
Look for further information from
other sources
Ask your doctor for a prescription
or referral
Do nothing

Note that a Bonferroni adjustment of alpha to <.008 to prevent possible T1 errors
associated with multiple tests would render some of these results not significant.
6.4.2

Perceived Severity and Susceptibility

Participants perceived both conditions to be severe (mean score of 4.53 for
fibromyalgia and 4.42 for osteopenia on a six point scale); there was no significant
difference between scores for the two conditions. When asked to rate how likely it
would be that they would experience the advertised conditions (on a six-point scale
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where one was not at all likely and six was very likely), participants perceived
themselves to be susceptible to both conditions (mean score of 3.40 for fibromyalgia
and 3.88 for osteopenia), but significantly more susceptible to osteopenia (p=.007).
No significant differences were found across the sponsor or information
manipulations.

Participants who nominated an intention to ask their doctor for a prescription or a
referral were significantly more likely to perceive higher susceptibility to the health
conditions (mean score of 4.14 compared with 3.12 for participants who did not
intend to ask, p<.001), and have higher severity scores (mean score of 4.77 compared
with 4.28, p<.001).

6. 5 Discussion
The results indicate that participants exposed to the advertisements with less disease
information may be more likely to express an intention to ask their doctor for a
prescription or a referral as a result of seeing those advertisements. This finding is of
concern for general practitioners as requests for prescription medicines or referrals as
a result of viewing DAA may cause tension in their relationship with patients, and
valuable consultation time may be lost responding to inappropriate requests for
treatment and re-educating patients as has been found for DTCA (Murray et al.,
2003). The results have important implications for regulation in Australia, as they
indicate that DAA can stimulate demand for prescription medicine products,
particularly if limited disease information is provided. If the purpose of industrysponsored DAA is to provide education rather than stimulate demand for prescription
medicines, regulators should provide more guidance to advertisers as to what types
of disease information (such as symptom, cause, prevalence and risk factor
information) and what level of detail should be provided. While the effect of the very
recent and more specific guidelines for DAA in Medicines Australia’s Code of
Conduct Edition 16 are yet to be determined, there is potential that even more
prescriptive guidelines are required, such as those made by the Medicines and
Healthcare products Regulatory Agency in the United Kingdom (MHRA, 2005).
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The results demonstrate the importance of providing prevalence and risk factor
information in DAA to assist consumers to more accurately identify their
susceptibility. Just over one quarter of participants estimated that it was very likely
that they would experience fibromyalgia in the future, whereas international data
suggests between 2% and 10% of women have the condition (Wolfe et al., 1995).
Similarly, 36% estimated that it was very likely that they would experience
osteopenia, while an Australian study of women aged over 50 years found a
prevalence of 15% (University of South Australia et al., 2007). These results provide
some support for the notion that DAA can inflate the perceived prevalence of
advertised disease (Moynihan, et al., 2002).

Most participants reported an intention to look for further information, talk to their
doctor about the condition and ask about treatments or tests, however further
research is needed to determine if intentions result in actual behaviour. The high
level of reported intentions following exposure to the DAA has potentially positive
implications for organisations attempting to generate awareness of health conditions
among this group, particularly for under-diagnosed conditions. However, this
potentially also has negative implications, as the advertisements in the study were for
diagnostically controversial conditions, where there is inconclusive evidence for
pharmacological treatment (Alonso-Coello et al., 2008; Berenson, 2008). Participants
with the intention to ask for a prescription or referral perceived a higher level of
susceptibility to, and severity of, the health conditions, and were found to be older
and less educated. While further research is required, this suggests that older and less
educated women are particularly open to the influence of DAA, and would benefit
most from the provision of impartial health information.

These findings are consistent with the Health Belief Model which posits that
perceived susceptibility and perceived severity, along with other factors including
cues to action or media/education, combine to predict the likelihood of behaviour
intention (Janz et al., 2002). The current study, however, did not consider other
factors in the model including perceived benefits and barriers to taking action and
self efficacy.
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The results of the current study can be compared with a study in the US involving
1465 women who were exposed to DTCA in a test magazine (Mehta and Purvis,
2003). The US study found that 43% of participants reported that they would ask
their doctor about a specific medicine they saw advertised (Mehta and Purvis, 2003)
compared with 73% in the current study that reported they would talk with their
doctor about treatments or tests after viewing DAA. In the US study, only 12%
reported that they would ask their doctor to prescribe a medicine that they saw
advertised and these women were more likely to have personal experience with the
medicine (Mehta and Purvis, 2003). In contrast, the current study found that almost
half (49%) reported that they would ask their doctor for a prescription or a referral as
a result of viewing DAA. The higher levels of reported behavioural intentions in the
current study can be attributed to participants having viewed only two advertisements
for health conditions that were targeted to their age and gender (rather than viewing a
wider range of advertisements shown within the context of a magazine).

A limitation of the current study is that participants’ involvement with the stimuli
would be very different to how they would normally view magazine advertisements,
as only single A4-size advertisements were provided. Sampling by intercept method
has limitations including a level of response bias and, because sampling occurred
during business hours over one week in one metropolitan area, it is likely that the
findings are not representative of all Australian women in this age group. Another
limitation is the potential that participants confused the advertised condition
‘osteopenia’ with the better known condition ‘osteoporosis’. This may have led to a
greater perceived severity and susceptibility to the condition, and increased
agreement for personal experience with the condition and intention to take action.

Despite these limitations, the results are important and demonstrate that DAA can
influence women to report an intention to request a prescription medicine or referral
from their doctor. The effects were most pronounced in older, less educated women,
along with those reporting personal experience with the health condition, and those
viewing advertisements with limited disease information. If the pharmaceutical
industry is genuinely concerned about providing education via DAA, rather than
stimulating demand for prescription medicines, then Medicines Australia should
provide detailed guidance regarding the amount and types of disease information to
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be included. Further research is required to determine behavioural effects of DAA in
different media, as well as the potential impact on doctor-patient relationships.
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7. 1 Abstract
Objectives: In Australia, direct-to-consumer advertising of prescription medicines is
not allowed, however pharmaceutical companies can sponsor advertisements about
health conditions or disease. While there is debate about the potential negative
effects of disease awareness advertising, the industry maintains that it serves an
educational function, and is particularly important for new or under-diagnosed
conditions. This study aimed to determine older women’s perceptions of the
adequacy of disease information in advertisements for two health conditions:
fibromyalgia and osteopenia.
Methods: 119 women over 48 years were recruited via mall intercept method in a
metropolitan shopping centre in NSW, Australia. They were randomly allocated
magazine advertisements with either limited or detailed disease information and
completed a questionnaire. The mock advertisements were based on advertisements
found in popular Australian women’s magazines, and complied with current industry
advertising regulation for “Patient Education”.
Results: Overall, participants held very positive attitudes towards the
advertisements. However, participants receiving limited information advertisements
(similar to actual advertisements in Australian magazines) were less likely to
perceive adequate information was provided with respect to the cause, symptoms,
prevalence, risk factors, prevention and treatment of the advertised health conditions.
Conclusions: An increased amount of different types of disease information, similar
to that provided in the more detailed information advertisements used as stimuli, is
more likely to satisfy consumers and increase the educational value of industrysponsored disease advertisements.
Implications: Australian advertising regulation should be strengthened to include
specific guidelines for the provision of different types of disease information in
industry-sponsored disease awareness advertisements.
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7. 2 Background

7.2.1

Direct-to-Consumer Advertising (DTCA) of Prescription Medicine

In the United States (US) and New Zealand, manufacturers of prescriptions
medicines can advertise their products directly to consumers, commonly known as
direct-to-consumer advertising (DTCA). There has been considerable debate in both
countries regarding the potential positive and negative effects of DTCA (Auton,
2007; Hoek, 2008). Proponents of DTCA argue that it provides valuable information
to consumers about health conditions and treatments, that it encourages discussions
with doctors and potentially expedites diagnosis and improves compliance with
treatment regimens (Auton, 2007; Bonaccorso and Sturchio, 2002). Some public
health and consumer advocates however argue that DTCA over-emphasises the
benefits of prescription medicines and encourages consumers to become overly
reliant upon them, potentially to the detriment of behaviour change or other therapies
(Coney, 2002; Mintzes, 2002). It is argued that because DTCA tends to promote the
benefits of treatment, and often omits other health information – such as symptom,
risk-factor and prevention information – it can lead to inappropriate requests for
medicines which can result in unnecessary prescribing or the loss of consultation
time where the doctor has to re-educate patients (Toop and Mangin, 2006).

There is considerable evidence that DTCA promotes consumer requests for
prescription medicines, and results in increased diagnoses as well as increased
prescriptions (Gilbody et al., 2005). Surveys have found that consumers value DTCA
for the information it provides on treatments, and they perceive it helps them in
discussions with their doctors (Hoek et al., 2004; USA Today et al., 2008). However,
New Zealand and US consumers are undecided as to whether DTCA helps them to
make better decisions about their health (Hoek et al., 2004; USA Today et al., 2008).

Several content analyses of DTCA conducted in the US have noted the lack of
disease information and subsequently the limited educational value of advertisements
across a range of media (Bell et al., 2000; Curry et al., 2005; Kaphingst et al., 2004).
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A US study analysed 320 DTC advertisements in 18 consumer magazines from 1989
to 1998 (Bell et al., 2000). They found that most advertisements provided the name
of the condition that the drug was designed to treat, and 60% provided symptom
information. However, less than 30% provided information on precursors to disease,
less than 15% provided information on the prevalence, and very few provided
information on supportive lifestyle/behaviour change to complement treatments (Bell
et al., 2000).
7.2.2

Disease Awareness Advertising (DAA)

A form of DTCA by pharmaceutical companies that is currently permissible in
Australia, as well as in many other western nations, is disease awareness advertising
(DAA). In DAA, pharmaceutical companies are permitted to promote awareness
about diseases or health conditions for which they manufacture a treatment or
vaccine, provided they do not name their product directly and do not encourage
consumers to seek a prescription. There are concerns about potential negative effects
of DAA, similar to those associated with DTCA. Pharmaceutical company-sponsored
DAA has been criticised as a form of “disease mongering”, where consumers are
encouraged to identify themselves as suffering with an advertised condition in order
to increase the potential market for treatments (Hughes and Minchin, 2003;
Moynihan et al., 2002). DAA been criticised for potentially causing consumer fear
and anxiety (Hall, 2008; Mintzes, 2006) and this may result in unnecessary visits to
general practitioners. DAA often coincides with branded advertising campaigns that
target doctors (Glatter, 2004; Hall and Jones, 2007a). However, the pharmaceutical
industry maintains that DAA, like DTCA, serves an important educational function,
that it can help consumers to recognise symptoms and that it encourages early
diagnosis (Bonaccorso and Sturchio, 2002). They argue that DAA can be helpful in
educating and motivating consumers, and has potential to redress under-diagnosis of
health conditions such as high cholesterol and diabetes (Wielondek, 2005).

The small amount of research into DAA suggests that, like DTCA, it can increase
disease-related consultations and prescriptions of the advertiser’s product (Basara,
1996; t'Jong et al., 2004). Similar to responses found for DTCA, Australian
consumers believe that DAA helps to create awareness of disease and different
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treatment options, and helps people to have better discussions with their doctor (Hall
and Jones, 2007b). However a recent content analysis of DAA in popular Australian
magazines found that the industry-sponsored DAA did not provide comprehensive
disease information, and less than half of the pharmaceutical advertisements
contained information on aetiology, risk-factors, symptoms or prevention (Hall et al.,
2009). The authors concluded that current regulation of DAA in Australia could be
strengthened with the inclusion of more specific guidelines as to the types and the
amount of disease information to be included, so as to improve the educational value
of DAA for consumers. A similar recommendation was made following a national
policy review in 2001, that being a specific code of practice be developed to regulate
the content of pharmaceutical company-sponsored DAA, such that benefits for
consumers would be enhanced and risks minimised (Galbally, 2000).
7.2.3

Regulation of DAA in Australia

Pharmaceutical sponsored DAA is self-regulated by Medicines Australia, an industry
body. DAA falls under Section 9.5 (Patient Education) of their Code of Conduct
(Edition 15). The Code allows for information on health conditions and the broad
range of treatments which may be prescribed by doctors providing the material:


is current, accurate, balanced;



does not focus on a specific product or treatment;



includes a statement directing consumers to further information about the
condition/range of treatments;



does not encourage patients to seek a prescription for a product;



does not cause alarm or misunderstanding; and



does not raise the patients’ hopes of successful treatment (Medicines
Australia, 2006).

The current Australian regulation differs from other countries, including the US and
the United Kingdom, which have guidelines specifically for DAA (Food and Drug
Administration, 2004; MHRA, 2005). The Australian regulation is likely to change
in 2010 as the proposed Edition 16 of the Code of Conduct includes a section on
“Disease Awareness Education” (Medicines Australia, 2009). However, unlike the
UK guidelines, the proposed Australian guidelines are not specific with respect to the
types of disease information required in DAA.
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The current study sought to determine consumer responses to hypothetical DAA
based on recent examples found in Australian magazines (Hall et al., 2009). The
hypothetical DAA were for two relatively unknown health conditions: fibromyalgia
and osteopenia. Specifically, the study investigated older Australian women’s
attitudes toward the advertisements, including what they perceived to be the intent of
the advertisement, and whether they felt adequate disease information was provided.

7. 3 Method
Print magazine DAA were devised as the stimuli and provided information regarding
two health conditions: fibromyalgia and osteopenia1. Fibromyalgia is a condition
where sufferers experience muscle stiffness and generalised pain as well as extreme
fatigue and sleep disturbances. Osteopenia refers to a state of lower bone density
which can potentially increase the risk of developing osteoporosis. These conditions
were selected as they are relatively low profile in Australia, and they have not been
the subject of any mass media education or pharmaceutical promotions as has
occurred in the US (Berenson, 2008; Kelleher, 2005).

The advertisements contained factual disease information; however the sponsor logos
(including a pharmaceutical company and a health foundation) and the contact details
were hypothetical. Information levels were manipulated such that participants
received either high information advertisements or low information advertisements.
The high information advertisements contained more detailed information on the
symptoms and aetiology of the conditions, and provided information under
subheadings on how they are diagnosed, managed, and treated. The low information
advertisements gave a more a general descriptions of the symptoms and brief
information about seeking diagnosis or treatment. The design of the advertisements
was informed by marketing-communication principles (Rossiter and Bellman, 2005;
Rossiter and Percy, 1997), and the amount of information provided in the low
information advertisements was similar to industry-sponsored DAA identified in a
content analysis of popular Australian magazines (Hall et al., 2009).
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The survey was conducted by intercept method over five days in a commercial
shopping centre in a metropolitan area in NSW, Australia and was part of a broader
survey into consumers reported behavioural intentions after viewing DAA, and
attitudes to varying sponsors of DAA, results of which have been reported elsewhere
(Hall, Jones and Iverson, 2010a, Hall Jones and Iverson, 2010b). Research assistants
approached women in the target group and consenting participants were randomly
assigned an advertisement using a freely available, web-based instrument (Urbaniak
and Plous, 2008). After viewing the advertisement for one health condition and
completing a one-page questionnaire2, participants received the advertisement for the
other health condition with the same information manipulation. For example, if a
participant completed a questionnaire after viewing the high information
advertisement for osteopenia, they would then be given the high information
advertisement for fibromyalgia. Once participants had completed the questionnaires,
the research assistants explained that while the information in the advertisements was
factual, the advertisements and the sponsors were hypothetical.

Responses were entered into SPSS version 15, and initially analysed using
descriptive statistics. Five bi-polar adjective items were used to determine attitude to
the advertisement based on established measures of attitude to and perceived
credibility of advertisements (MacKenzie et al., 1986). An attitude to the
advertisement scale was created from these items, however inter-item correlations
were above the .85 level for three items, suggesting that they measured the same
construct; thus two items were removed. A revised scale was created with the
remaining three items and item-to-total and inter-item correlations were calculated to
determine reliability. Inter-item correlations were between .582 and .856, and itemto-total correlations were above .850. Principal Components Analysis was performed
with one component extracted with an eigenvalue greater than one. All items loaded
with values greater than .82. Cronbach’s alpha for the three item scale was .86.

1

Refer to Appendix E for examples

2

Refer to Appendix F
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Questions relating to the types of disease information were based on disease
information codes used in a content analysis of DTCA in the US to determine
medical condition information (Bell et al., 2000) as well as the types of disease
information currently recommended for DAA in the UK (MHRA, 2005). The attitude
to the advertisements scale failed to satisfy the assumptions of normality, and as
such, Kruskal-Wallis and Mann-Whitney U tests were used to determine
relationships with other variables (McCrum-Gardner, 2008).

7. 4 Results
A total of 119 women aged between 48 and 85 years (median age of 65 years)
responded to 230 advertisements. Sixty two percent of the women were born in
Australia and 94% spoke English at home. Approximately 55% had achieved an
education level of Year 12 or higher. Over half of the participants were retired, 17%
were occupied with home duties, 11% were professionals and 6% were managers.

The majority of participants (85%) agreed that their doctor was their regular source
of health information; however, many also agreed that television (45%), their
pharmacist (41%), the internet (37%), magazines (36%) and newspapers (33%) were
regular sources of health information.

Of the 230 responses collected, 113 were for fibromyalgia advertisements and 117
were for osteopenia advertisements. One hundred and ten responses were collected
for the high information advertisements and 120 for the low information
advertisements, and these were almost evenly split between the two health
conditions. On a six-point scale where one was difficult and six was easy, the mean
rating of understanding for all advertisements was 5.49. There were no significant
differences in understanding between information level, or health condition. There
was a significant difference between participant responses to the health conditions
for personal experience – while only 35% of participants agreed that they or someone
they knew well had suffered from fibromyalgia, 64% agreed that they or someone
they knew well had experienced osteopenia (2 (DF = 1, n=224) = 18.33, p<.001).
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7.4.1

Perceived Intent and Attitude to the Advertisement

Participants were asked to identify what they perceived the advertisement was trying
to do by selecting one of six options. Forty five percent perceived the intent of the
advertisement was to provide information about a health condition, 18% to
encourage them to talk to their doctor, 15% to encourage them to be more proactive
about their health, 12% to provide information about a treatment, 8% to sell a
product, service or treatment, and 2% to encourage them to ask for a prescription or
referral. There were no significant differences in perceived intent between
participants viewing different information levels, however there were significant
differences between the two health conditions. Participants were more likely to
perceive the advertisement for fibromyalgia was trying to provide information about
a treatment (17% for fibromyalgia vs. 6% for osteopenia) and were more likely to
perceive the advertisement for osteopenia was trying to sell a product, service or
treatment (12% for osteopenia vs. 5% for fibromyalgia) 2 (DF = 5, n=208) = 13.67,
p = .018.

Attitude toward the advertisement scores were high (mean score of 5.2 on a six-point
scale), and there were no significant differences between participants viewing
advertisements with different condition types or information levels. A KruskalWallis test was conducted with attitude to the advertisement as the test variable and
the perceived intent of the advertisement as the grouping variable to determine if
there were any significant differences in participants’ attitude scores relevant to their
perceived intent. The six groups were found to significantly differ 2 (DF = 5,
n=187) = 18.607, p = .002. Post-hoc comparisons were conducted using MannWhitney U tests with a Bonferroni adjustment of alpha to  = .00083. Participants
who perceived the intent of the advertisement was to provide information about a
health condition or to encourage them to be more proactive about their health had
significantly more positive attitude toward the advertisement scores than those who
perceived the intent was to sell a product, service or treatment.
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7.4.2

Information Adequacy

Participants were asked whether they perceived that enough information was
provided with regard to the aetiology, symptoms, and prevalence of the condition as
well as who is most at risk, how the condition can be prevented and treated, and
where to get more information.

When considering all participant responses with regard to adequacy of information,
there were statistically significant differences between the two health conditions for
all questions with the exception of information on what causes the condition and
where you can get more information. Participants were more likely to agree that
there was adequate information for the osteopenia advertisements, with the exception
of symptom information (see Table 7.1).
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Table 7.1: Percent agreement that enough information was provided
by condition type
Do you think enough information

Fibromyalgia Osteopenia 2

p-

was provided with regard to:

(n=113)

(n=117)

value

What causes the disease/condition

35%

44%

2.24

77%

52%

14.48 <.001

65%

84%

10.53 .001

27%

42%

4.98

.018

27%

41%

4.34

.026

59%

70%

3.31

.046

91%

90

0.15

.437

What the symptoms of the disease/
condition are
Who is most at risk of getting the
disease/condition
The prevalence of (or how many
people have) the disease/condition
How the disease/condition can be
prevented
How the disease/condition can be
treated
Where you can get more information
about the disease/condition

.087

When considering all advertisements for both health conditions a comparison of
means revealed statistically significant differences in responses between the two
information levels (p<.001), with the exception of “where you can get more
information about the disease/condition”. Participants receiving the high information
advertisements were more likely to agree that adequate information was provided
than those receiving the limited information advertisements.

When considering participants that viewed advertisements for fibromyalgia only,
those receiving high information advertisements were significantly more likely to
perceive that adequate information was provided regarding “what the symptoms of
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the disease/condition are”, “who is most at risk of getting the disease/condition” and
“how the disease/condition can be treated” than those receiving low information
advertisements (see Table 7.2)

Table 7.2: Percent agreement that enough information was provided
by information type: Fibromyalgia
Condition Type

Fibromyalgia
n=113

Do you think enough

High

Low

information was provided with

information

information

regard to:

advertisement advertisement

What causes the disease/condition 48.1%
What the symptoms of the
disease/condition are
Who is most at risk of getting the
disease/condition

2

pvalue

22%

8.507 .003

83%

70.7%

2.347 .095

76.9%

53.4%

6.602 .008

35.3%

20%

3.115 .061

34.6%

20.7%

2.681 .077

69.8%

48.3%

5.293 .017

92.6%

89.7%

.297

The prevalence of (or how many
people have) the
disease/condition
How the disease/condition can be
prevented
How the disease/condition can be
treated
Where you can get more
information about the

.418

disease/condition

When considering participants that viewed advertisements for osteopenia only, those
receiving high information advertisements were significantly more likely to perceive
that there was adequate information than those receiving low information
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advertisements for all variables with the exception of “where you can get more
information about the disease/condition” (see Table 7.3)

Table 7.3: Percent agreement that enough information was provided
by information type: Osteopenia
Condition Type

Osteopenia
n=117

Do you think enough

High

Low

information was provided with

information

information

regard to:

advertisement advertisement

What causes the
disease/condition
What the symptoms of the
disease/condition are
Who is most at risk of getting the
disease/condition

2

pvalue

56.6%

33.3%

6.177

.011

69.8%

36.7%

12.390 <.001

92.7%

75%

6.538

69.2%

17.2%

30.459 <.001

59.6%

23.7%

14.767 <.001

85.5%

55.9%

11.854 <.001

90.7%

88.5%

.151

.009

The prevalence of (or how many
people have) the
disease/condition
How the disease/condition can
be prevented
How the disease/condition can
be treated
Where you can get more
information about the

.469

disease/condition

When considering perceived adequacy of information for participants with previous
personal experience with the condition (where they or someone they knew well had
suffered with the condition), there were significant differences for perceived
adequacy of information on aetiology and prevention. For these types of disease
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information, participants with personal experience were significantly more likely to
perceive that there was adequate information (p=.006).

7. 5 Discussion
The majority of women had very positive attitudes towards the DAA and this did not
differ between those viewing the high or low information advertisements. Most
women perceived that the intention of the advertisements was to provide
information, encourage them to talk to their doctor or to be proactive about their
health, which suggests that they did not perceive a commercial intent. Only 10%
perceived a direct commercial intent (to encourage them to ask for a prescription or
to sell a product or treatment), while a further 12% perceived the intent to be to
provide information about a treatment. Those that perceived the intent was to sell a
product, service or treatment held less positive views of the advertisement than those
that perceived the intent to be informational or to encourage them to be more
proactive about their health. This suggests that the small group of women that
attributed a direct commercial intent were generally more sceptical about the
advertisement overall.

The results demonstrate that participants receiving the high information
advertisements were more satisfied that adequate information was provided for all
disease information types.. This suggests that consumers would prefer more detailed
information from DAA similar to that provided in the high information
advertisements, and potentially even more detailed information on prevalence,
aetiology and (where appropriate) prevention.

It should be noted that the limited information advertisements used as stimuli in the
current study had approximately 85 words in the body text, which is similar to wordcounts of the same sized, pharmaceutical company-sponsored DAA found in
Australian magazines (Hall et al., 2009). The high information advertisements had
word counts approximately two and a half times greater (around 225 words), and
contained headings to guide consumers. Interestingly, greater amounts of information
(up to 250 words of body copy) are recommended for magazine advertisements for
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products where critical decisions are required, and the consumer’s motivation is to
avoid or solve a problem (as would normally be the case for disease information)
(Rossiter and Percy, 1997).

The findings of the current study indicate that consumers would prefer more disease
information in industry-sponsored DAA than is currently being provided by most
advertisers. DAA could potentially be improved if the regulating body, Medicines
Australia, provided more specific guidance as to what types of disease information
should be included in advertisements, as well as examples of acceptable amounts of
information for different media. In the UK, the Medicines and Healthcare products
Regulatory Agency (MHRA) disease awareness campaign guidelines state that
advertisements should be comprehensive and cover the key characteristics of the
disease, including information on the aetiology, risk-factors, symptoms and
preventive measures (MHRA, 2005, p.54).

When considering differences between the two health conditions, participants were
more likely to agree that there was adequate information for osteopenia than for
fibromyalgia, with the exception of symptom information. This was expected as
osteopenia does not have identifiable symptoms, and as such symptom information
was not included in either the low or high information advertisements. The greater
perceived adequacy of the other types of disease information for the osteopenia
advertisements could be attributed to greater familiarity with this condition (as a
higher percentage identified as having suffered or knowing someone who suffered
with osteopenia) or existing knowledge regarding the related condition
(osteoporosis). This has implications for advertisers of rare or relatively unknown
health conditions, as it appears consumers desire even more detailed information for
such conditions.

There are several limitations of the current study including the sampling by intercept
method which could attract a level of response bias. Because sampling occurred
during business hours over one week in one metropolitan area, it is likely that the
findings are not representative of all Australian women in this age group. The
viewing and consideration of advertisements in the study setting would be very
different to how advertisements might be viewed in a natural setting. The study was
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limited to magazine advertisements which potentially have a different capacity to
provide disease information than broadcast or digital media. Questions only asked
about whether enough information was provided, and did not explore participants’
retention or comprehension of the information in the advertisements. Other
potentially important considerations in developing DAA that were not considered in
the current study include the presentation of risk information, message framing and
other persuasive techniques.

Older Australian women perceived there was inadequate disease information in the
advertisements which reflect current magazine DAA. While the type of disease
information would potentially vary depending on disease or condition being
advertised and the personal experience of the consumer, it appears that more detailed
disease information, similar to that provided in the high information advertisements,
would satisfy consumers. Medicines Australia has the potential to improve the
educational value of industry-sponsored DAA in Australia via the provision of
specific guidelines regarding the types and amount of disease information to be
included in advertisements.
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CHAPTER 8: CONSUMER PERCEPTIONS OF SPONSORS OF
DISEASE AWARENESS ADVERTISING

Based on article submitted to Health Education, February 2010
Hall, D.V., Jones, S.C. and Iverson, D.C. (submitted), ‘Consumer perceptions of
sponsors of disease awareness advertising’, Health Education
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8. 1 Abstract
Purpose: In many countries there is emerging concern regarding alliances between
the pharmaceutical industry and health non-profit organisations (NPOs), and the
increase of co-sponsored marketing activities such as disease awareness advertising.
The current study explored Australian women’s perceptions of disease awareness
advertising with differing sponsors, to determine whether their attitudes toward the
sponsor and their reported behavioural intentions differed as a function of the
sponsor (or co-sponsor).
Methodology: Older women (aged 50+) were approached by mall-intercept method
in a metropolitan area in New South Wales, Australia. Consenting participants were
randomly assigned an advertisement with either a NPO sponsor, pharmaceutical
company sponsor, or a combination of the two (co-sponsored). Each participant
viewed advertisements for two health conditions (fibromyalgia and osteopenia) with
the same sponsor manipulation, and completed a one-page questionnaire after
reading each advertisement.
Findings: Participants had significantly more positive attitudes towards the NPOsponsored advertisement than the pharmaceutical company-sponsored advertisement
or the co-sponsored advertisement. Participants with more positive attitudes towards
the sponsor were significantly more likely to report an intention to take action such
as look for more information or talk to their doctor.
Implications: The results suggest that a NPO-sponsored advertisement promoting
awareness about a disease or health condition is more effective without the cosponsorship of a pharmaceutical company.
Originality/Value: This is the only identified research into attitudes towards
sponsors of disease awareness advertising that considers pharmaceutical companies
and health NPOs and is important given the increasing trend of disease advertising
and cause-related marketing in Australia and internationally.
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8. 2 Introduction
Over the past three decades there has been an increase in corporations engaging in
socially responsible marketing activities including corporate sponsorship of, and
partnering with, Non Profit Organisations (NPOs) (Dibb et al., 2001; Kotler et al.,
2003). This can benefit corporations through enhanced corporate identity and
stakeholder relations as well as improved brand equity, and ultimately increased
profit (Smith, 1994; Webb and Mohr, 1998). These alliances can also benefit NPOs
through increased exposure, awareness, support and funds for their activities
(Polonsky and Wood, 2001; Varadarajan and Menon, 1988). Health NPOs may
consider entering a CRM alliance with a pharmaceutical company in an effort to
increase public awareness regarding a disease or health conditions. However there is
increasing criticism of pharmaceutical industry involvement with, and influence over
health NPOs in western nations (Angell, 2006; Jacobson, 2005; Moynihan and
Cassels, 2005), and cases of co-sponsored advertisements in Australia have attracted
consumer scepticism (Hughes and Minchin, 2003). For NPOs embarking on disease
awareness advertising (DAA), it is important to consider what effects co-sponsorship
with industry may have on consumer attitudes towards the sponsors and consumer
intentions to take health seeking behaviours.
8.2.1

Cause-Related Marketing

Cause-related marketing (CRM) is a recognised form of corporate philanthropy
(Brønn and Vrioni, 2001; Mullen, 1997; Varadarajan and Menon, 1988). Similar
concepts include mission marketing (Brønn and Vrioni, 2001), cause marketing
alliances (Nowak and Washburn, 2000) and joint issue promotions (Wymer and
Samu, 2003). Original definitions of CRM focussed on the exchange of revenue,
where a corporate organisation donates a percentage of profit from the sale of
product to a charity or cause (Polonsky and Wood, 2001). More recent definitions
appear broader and incorporate any efforts that increase awareness and revenue for
both corporate and charity partner (Lafferty et al., 2004). Berglind and Nakata
(2005), for example, state that CRM is “the practice of marketing a product, service,
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brand or company through a mutually beneficial relationship with a non-profit or
social cause organisation” (p. 444).

Corporate organisations engage in CRM for a range of reasons, including increasing
competitiveness or differentiation for their product, improving brand recognition or
image, increasing or gaining access to a customer base, increasing sales, increasing
publicity, enhancing corporate image, diverting attention from or countering negative
publicity, and improving employee morale (Polonsky and Wood, 2001; Varadarajan
and Menon, 1988). CRM can contribute to brand equity (value of the brand) and can
strengthen relationships with a range of stakeholders, as well as improve message
believability in marketing activities (Brønn and Vrioni, 2001).

For the NPO or charity partners, involvement with a corporate organisation often
brings needed support including financial and other resources, such as personnel who
may act as volunteers. Partnerships may also lend legitimacy or substantiate the
cause, as well as increase opportunities for publicity (Polonsky and Wood, 2001).
Further, nonprofits can benefit from partnership with well-respected corporations as
their reputation may enhance the credibility of the NPO (Nowak and Washburn,
2000). While medium to longer-term associations are generally considered most
beneficial for NPOs, it is important that the relationship does not create restrictive
practices such as exclusivity arrangements where the NPO is restricted to only one
corporate partner (Polonsky and Wood, 2001).

For consumers, CRM can provide greater choice and additional perceived value for a
product. There is evidence that CRM promotions can enhance consumer perceptions
regarding the cause, the corporation and the non-profit partner, particularly if there is
a perceived “natural fit” between the corporate company and the cause (Lafferty et
al., 2004; Simmons and Becker-Olsen, 2006). However, there is potential for
controversy and negative effects from CRM activities, particularly if the corporate
organisation overplays its involvement or support as this can lead to consumer
scepticism (Brønn and Vrioni, 2001; Drumwright and Murphy, 2001). In a
qualitative study considering United States (US) consumers’ attitudes towards CRM
advertisers and their motives, Webb and Mohr (1998) found that the majority of
participants felt more favourably towards NPOs and most participants identified
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NPO motives in CRM as to help others. However their attitudes towards corporate
organisations were less favourable, and they perceived that corporations’ motive for
involvement in CRM was either to help themselves or to help themselves and others
(Webb and Mohr, 1998). Brønn and Vrioni (2001) state that “honesty, long-term
commitment to a cause and involvement of non-profit organisation are factors that
help to overcome customers’ scepticism towards CRM” (p.219).
8.2.2

Non-Profits and Pharmaceutical Industry Marketing Relationships

In the US and other nations of the Organisation of Economic Cooperative
Development, there has been increased concern on the part of consumer and public
health advocates regarding pharmaceutical industry alliances with health NPOs
(Angell, 2006; Jacobson, 2005; Moynihan and Cassels, 2005). In Ireland, a recent
survey of 112 health activist organisations found that almost half received funding or
support from the pharmaceutical industry. Qualitative research with a smaller sample
of organisations, including interviews with key staff and analyses of organisational
documents, demonstrated that medical research charities tended to value and be quite
reliant upon industry research (O'Donovan, 2007). Jacobson (2005) was critical of a
range of American health NPOs that appeared to be influenced by their relationships
with (and funding received from) industry groups. He argued that “charities
generally portray themselves as vigorous proponents of the public interest, helping
victims, seeking cures and investigating preventive measures. But taking corporate
donations puts enormous constraints on an organisation’s activities and raises
questions about a group’s objectivity and independence” (Jacobson, 2005 pp. 351352). It has been suggested that such alliances can cause health NPOs to shield
industry in times of crisis, and can turn the focus of the NPOs towards medicinal
treatments rather than behaviour change or prevention (Jacobson, 2005; Moynihan
and Cassels, 2005).

Moynihan et al (2005) described that while many health NPOs work with the
pharmaceutical industry to gain greater recognition for their particular cause, the
pharmaceutical companies may use the relationship to create stronger links between
their product and the disease itself, a phenomenon described as ‘condition branding’.
Parry (2003) stated that “if you can define a particular condition and its associated
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symptoms in the minds of physicians and patients, you can also predicate the best
treatment for that condition” (p.43). Condition branding has been considered a
socially responsible action for the pharmaceutical industry that aims to generate
awareness of a disease or condition in order to improve its recognition and treatment
(Angelmar et al., 2007). However, others argue that condition branding is not a form
of corporate social responsibility as its primary purpose is to increase brand share for
products and the total number of prescriptions (Consumers International, 2006; Hall
and Jones, 2008b). For pharmaceutical companies, it is considered particularly
effective for brands where a company has the only treatment for that condition or a
large market share (Angelmar et al., 2007). In condition branding, one form of
promotion used by pharmaceutical companies is disease awareness advertising
(DAA).
8.2.3

Disease Awareness Advertising (DAA)

In countries where direct-to-consumer advertising of prescription medicine is
prohibited - such as Australia, Canada, Europe and the United Kingdom pharmaceutical manufacturers are permitted to sponsor DAA, also known as helpseeking advertising (Hall and Jones, 2007; Mintzes, 2006). Companies usually
sponsor DAA for conditions for which they manufacture a treatment or prevention
product. DAA cannot include the name or brand of a prescription medicine product,
but can provide information on the disease or health condition (such as prevalence or
symptom information) and the suggestion to “ask your doctor”. In many instances,
companies co-sponsor DAA with health NPOs, similar to CRM arrangements. A
recent Australian example is an advertising campaign to promote bone density
testing by Osteoporosis Australia with the pharmaceutical company Merck Sharp &
Dohme who manufacture Fosamax, a product used to treat osteoporosis by
increasing bone density.

Even though DAA does not directly promote a branded product, there is evidence
that advertisements have increased prescriptions and sales of the advertiser’s product
(Basara, 1996; t'Jong et al., 2004). Literature on the effectiveness, or consumer
perceptions, of co-sponsored DAA is extremely limited. The only identified, and
somewhat dated, study was conducted with 264 volunteers in the US (Hammond,
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1987). This research was supported by the National Cancer Institute which is a
government entity but often referred to in the research as a NPO. The Institute was
conducting an advertising campaign with a well known food manufacturer
(Kellogg’s Company) on nutrition and cancer, and wanted to determine if perceived
corporate credibility differed for advertisements sponsored by profit, NPO or a
combination of profit and NPO. Participants were shown print, radio and television
advertisements with a health promotion message (to increase dietary fibre) where the
sponsor was manipulated. The sponsor varied between a fictional NPO (the United
Cancer Foundation) and a fictional profit entity (the Wellness Marketing
Association) and a combination of the two. Hammond (1987) found that the
combination sponsor or the NPO sponsor alone were perceived as significantly more
credible by participants than the profit sponsor alone. There was no significant
difference in perceived source credibility between the NPO and combination
sponsor. In a commentary on the actual advertising campaign that followed,
sponsored by the National Cancer Institute and Kellogg’s, Freimuth, Hammond and
Stein (1988) reported improvements in consumer health knowledge and behaviour,
as well as an increased market share for Kellogg’s.
8.2.4

Advertising Effectiveness and Source Credibility

While there are many factors that contribute to advertising effectiveness, one area
research has focussed on is consumers’ cognitive responses to persuasive messages
(Belch and Belch, 2001). There is considerable evidence that the use of a highly
credible source within an advertisement will increase persuasion (Petty and
Cacioppo, 1986; Pornpitakpan, 2004). Two forms of source credibility can be
influential: that of the endorser or presenter (such as a celebrity); and that of the
company or organisation identified with the product (Lafferty et al., 2002;
Pornpitakpan, 2004). This latter form of source credibility is commonly called
corporate credibility, and includes the dimensions of expertise and trustworthiness
(Goldsmith et al., 2000; Newell and Goldsmith, 2001). Expertise refers to a
company’s capacity or competency in producing and delivering a product, whereas
trustworthiness refers to whether or not a company can be relied upon (Newell and
Goldsmith, 2001).
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While studies have demonstrated that endorser credibility has its strongest influence
on attitude to the advertisement, corporate credibility has a stronger impact on
attitude to the brand. Corporate credibility, however, has also been found to impact
on attitude to the advertisement as well as purchase intention (Goldsmith et al., 2000;
Lafferty et al., 2002). In the Hammond (1987) study previously described, while
there was no significant relationship found between corporate credibility and
message acceptance, corporate credibility did affect behaviour intention.

While the evidence from the Hammond (1987) study suggests that co-sponsorship
with a for-profit organisation (such as the Wellness Marketing Association) will not
significantly effect the source credibility of the NPO sponsor, there is no identified
research into the effects of co-sponsorship of DAA with pharmaceutical companies.
There is potential that growing scepticism regarding pharmaceutical industry
influence over health NPOs may impact on consumer attitudes towards NPO
sponsors in joint promotions. NPOs considering a CRM arrangement with a
pharmaceutical company to promote awareness about a health condition should
consider whether consumers perceive NPOs to have greater corporate credibility than
pharmaceutical companies in sponsoring DAA, and whether this differs again for cosponsored arrangements. They should also consider whether a co-sponsored disease
awareness advertisement will be more or less effective than an NPO-sponsored
advertisement in influencing consumer intentions towards health seeking behaviours.

8. 3 Methodology
The current study aimed to determine how older Australian women perceived mock
print advertisements for two relevant health conditions which were sponsored by a
fictional pharmaceutical company, a fictional NPO, or a combination of the two. The
survey explored who participants perceived the advertiser or sponsor to be, their
attitude towards the sponsor, and their reported behavioural intentions.
8.3.1

Stimuli and Survey Questionnaire

Print magazine advertisements were considered appropriate for stimuli as there are
high and growing levels of magazine readership among Australian women
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(Magazine Publishers of Australia, 2007). Mock advertisements were developed
about two relatively unknown health conditions: fibromyalgia and osteopenia1.
Fibromyalgia is a condition characterized by widespread pain and tenderness, and
other symptoms including sleep disorders. Osteopenia is a state of lower bone
mineral density and is often considered a precursor to developing osteoporosis and
bone fractures. While there is evidence of pharmaceutical company promotions for
these conditions occurring in the US in recent years (Berenson, 2008; Kelleher,
2005), there is no evidence of consumer-targeted promotions in Australia.

Sponsor logos that appeared at the bottom of each advertisement were manipulated
such that three different sponsor conditions existed for each condition type:
cosponsored, pharmaceutical industry-sponsored and NPO-sponsored. The sponsors
were fictional, but were pre-tested, and the names of the NPO sponsors were directly
related to the health condition. The NPO sponsor for the fibromyalgia advertisement
was the “Fibromyalgia Foundation of Australia” and the NPO sponsor for the
osteopenia advertisement was the “Osteopenia Foundation”. Note that in Australia,
there are considerably fewer private foundations than in the US (Asia-Pacific Centre
for Philanthropy and Social Justice, 2005) and, as such, the term “foundation” is
usually associated with a public foundation or charitable organisation.

Marketing-communication principles considered appropriate for high-involvement
and informational advertisements in magazines were used in the design and
development of the advertisement stimuli (Rossiter and Bellman, 2005; Rossiter and
Percy, 1997). The advertisements gave a brief description of each health condition
and encouraged readers to contact their doctor regarding treatments or tests. The
advertisements were checked for accuracy of content by health professionals, and
were pre-tested with a snowball sample of 31 participants in the target group. Pre-test
results demonstrated that participants found the advertisements to be believable
(82%) and easy to understand (86%).

The questionnaire was based on previous questionnaires used to determine
consumers’ behavioural intentions in relation to direct-to-consumer advertising and
1

Refer to Appendix I for examples of advertisements
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DAA (Hall and Jones, 2008a; Hoek et al., 2004). Participants were asked who they
thought the advertiser or sponsor was, and to rate their attitude toward the sponsor on
bipolar adjective scales1. The scales were based on instruments described in relevant
studies considering corporate credibility (Lafferty et al., 2002; Newell and
Goldsmith, 2001). Additional questions captured the demographic information of
participants.
8.3.2

Participants, Sampling and Random Assignment

Women were selected as the target group for the study as they generally have greater
involvement in their own and their families’ health information seeking and decision
making behaviour (Commonwealth Office of the Status of Women, 2003). The
survey was conducted during weekday retail hours in a commercial shopping centre
within a metropolitan area in New South Wales, Australia. Research assistants
approached women in the target group and consenting participants were randomly
assigned an advertisement using a computer random allocation resource (Urbaniak
and Plous, 2008). After completing the first advertisement questionnaire they then
received the advertisement for the other condition with the same sponsor
manipulation. For example, if a participant was randomly assigned the co-sponsored
advertisement for fibromyalgia, they would subsequently be shown the co-sponsored
advertisement for osteopenia. Following completion of the second advertisement
questionnaire, participants completed the demographic questionnaire and were then
provided with a gift voucher worth AU$5 as a thank you for their participation.
Participants were advised at this stage that although information in the
advertisements was factual, the advertisements themselves and the sponsors were
fictional.

This study was part of a broader survey into consumers reported behavioural
intentions after viewing DAA, the results of which have been reported elsewhere
(Hall, Jones and Iverson, 2010a, Hall Jones and Iverson, 2010b).

1

Refer to Appendix F.
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8.3.3

Data Analysis

Data was analysed using descriptive statistics. A score was created for attitude
toward the sponsor, which included responses to bipolar adjective scales for
trustworthiness, expertise, reliability, honesty and believability of the advertiser or
sponsor. Item-to-item correlations for trustworthiness, reliability and honesty were
greater than .8 suggesting that these items were measuring the same construct. A new
scale was then created (sponsor score) for responses to trustworthiness, expertise and
believability; inter-item correlations ranged between .560 and .782. Item-to-total
correlations were greater than .838. Principal Components Analysis was performed
with one component extracted with an eigenvalue greater than one. All items loaded
with values greater than .814. Cronbach’s alpha for the sponsor score was .922. The
scale variable failed to satisfy the assumptions of normality and as such, MannWhitney U tests were used to identify relationships with other variables.

8. 4 Results
A total of 185 women aged between 48 and 85 years (median age of 64 years)
participated in the study (response rate of 30%). Sixty nine percent of participants
were born in Australia, and 12% were born in the United Kingdom. Ninety three
percent of participants spoke English at home. Participants had a similar
demographic profile to women in the local government area, but had higher
educational attainment as approximately half had achieved at least 12 years of
schooling, and for local women in this age group approximately 18% had completed
Year 12 or equivalent..

A total of 178 advertisement questionnaires were completed for each health
condition. There were 120 advertisements questionnaires completed for each of the
pharmaceutical and combination sponsors, and 116 completed for the NPO sponsor.
On a six-point scale (1 = difficult and 6 = easy) the mean rating of understanding for
the advertisements was 5.46.
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8.4.1

Identification of Advertiser

When asked who they thought the advertiser was, written responses were categorised
into five generic categories and compared with the actual sponsor on the
advertisement allocated to the participant. Overall, only 51% correctly identified the
category of sponsor. The most predicted sponsor was pharmaceutical company
(47%), followed by NPO (31%) followed by government/research/medical (G/R/M)
(8%). Table 8.1 shows the predicted sponsor by actual sponsor allocated. Participants
viewing the pharmaceutical sponsored advertisements were most likely to correctly
identify that sponsor (83%), whereas only 66% of participants viewing the NPOsponsored advertisements correctly identified that sponsor. Participants viewing the
combination sponsor were more likely to predict a pharmaceutical company (49%) or
NPO (21%) than to correctly identify the combination of sponsors (11%) (2 =
141.318, p<.001).

Table 8.1: Percentage of actual sponsor by predicted sponsor
Actual

Predicted sponsor

sponsor

Pharmaceutical NPO Combination G/R/M Unknown Other

Pharmaceutical

83%

6%

0%

2%

4%

5%

NPO

12%

66%

1%

12%

4%

5%

Combination

49%

21%

11%

8%

3%

8%

8.4.2

Attitude to the Sponsor

Mean sponsor scores for the actual sponsors allocated to participants were high (over
four on a six-point scale) (see Table 8.2). Scores were similar for pharmaceutical and
combination sponsors, however Mann-Whitney U tests showed that participants
receiving NPO-sponsored advertisements gave significantly higher sponsor scores
than those receiving either combination sponsored advertisements (p<.001) or
pharmaceutical sponsored advertisements (p<.001). There were no significant
differences between the two health conditions (fibromyalgia or osteopenia).
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Table 8.2: Mean sponsor score for actual sponsor
Actual sponsor

Mean*

N

Std. Deviation

Pharmaceutical

4.422

101

1.115

NPO

4.994

106

976

Combination

4.418

103

1.160

*6-point scale

For predicted sponsors (where participants identified who they thought the advertiser
was), Mann-Whitney U tests showed that NPO sponsors were rated significantly
higher than pharmaceutical sponsors (p<.001). Comparisons could not be made with
other categories due to sample size limitations (see Table 8.3).

Table 8.3: Mean sponsor score for predicted sponsor
Predicted sponsor

Mean*

N

Std. Deviation

Pharmaceutical

4.209

137

1.155

NPO

5.125

90

.837

Combination

4.436

13

1.322

Government/research/medical

4.698

21

.983

Unknown

4.833

6

1.095

Other

4.854

16

1.124

*6-point scale

Paired comparisons were considered appropriate for 171 of the women that
completed two advertisements, to examine how their sponsor scores varied between
advertisements for the two health conditions. A Wilcoxon signed-rank test was
conducted with sponsor score as the dependent variable measured for the
fibromyalgia advertisement and osteopenia advertisement viewed by each woman. A
significant difference was found between the fibromyalgia advertisement (median =
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4.67) and the osteopenia advertisement (median = 5.0) indicating that regardless of
sponsor type, the sponsor of the osteopenia advertisement was rated more positively
(z = -2.031, p = .042).
8.4.3

Reported Behavioural Intentions

A one-way ANOVA test of actual sponsor against behavioural intentions found no
significant differences in behavioural intentions between the groups viewing
different sponsors. This was also the case for the predicted sponsor. However, MannWhitney U tests showed significant differences for each of the behavioural variables
when considering the sponsor scores (or attitude towards the sponsor). Participants
agreeing with each of the behavioural variables had significantly higher mean ranks
for sponsor scores with the exception of “do nothing” where participants that agreed
had a lower mean rank (see Table 8.4).

Table 8.4: Agreement with behavioural intention by sponsor score

Behavioural intention

Sponsor score

Z

p

172.95 110.10

-5.936

<.000

Look for information from other sources

167.43 130.61

-3.641

<.000

Talk to your doctor about the condition

167.63 108.70

-4.947

<.000

Ask your doctor about treatments or tests

167.69 109.98

-5.083

<.000

Ask your doctor for a prescription or a referral

170.79 126.51

-4.488

<.000

Do nothing

101.10 153.12

-4.501

<.000

“As a result of seeing this advertisement would Mean Rank
you…”
Agree
Look for information as directed by the
advertisement

Disagree
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8. 5 Discussion
The results show that only half of the participants were able to correctly identify the
sponsor of the DAA despite clear corporate branding at the bottom of each
advertisement. Almost half of the participants perceived the advertiser to be a
pharmaceutical company regardless of the corporate logo displayed on their
advertisement. Participants that were allocated co-sponsored advertisements were
least likely to correctly identify the sponsors, and were more likely to identify a
pharmaceutical company sponsor. This has implications for NPOs that are
considering co-sponsoring DAA, as the involvement of the pharmaceutical company
may be perceived as dominant, regardless of the equality of corporate branding on
the actual advertisement. If the company is perceived as dominant, this may also
have negative repercussions for the reputation of the NPO (Brønn and Vrioni, 2001;
Drumwright and Murphy, 2001). In a recent US study of attitudes and behavioural
intentions following exposure to CRM advertisements and co-sponsored public
service announcements, Samu and Wymer (2009) concluded that while perceived fit
of the cause and brand are important, perceived sponsor dominance is also important.
In their study, participants had more positive attitudes towards the NPO and
corporate sponsor, as well as stronger behavioural intentions, when the NPO was
dominant in the advertisement and there was a high level of perceived fit (Samu and
Wymer, 2009). Co-sponsored DAA may benefit from increased dominance of the
NPO partner in corporate branding as well as a presence in the lead text and headline
of advertisements.

Considering attitude toward the sponsor (sponsor scores) in the current study, the
only significant difference for the sponsors predicted by participants was between the
NPO and the pharmaceutical sponsor. This provides support for the notion that NPO
(and government) sources are generally perceived by consumers to be more credible
than commercial sources (Hayley, 1996). However, for the actual sponsors allocated
to participants, the NPO-sponsored advertisements received significantly higher
scores than those viewing the pharmaceutical sponsor or the combination sponsor.
This differs to the Hammond (1987) study where both the NPO and combination
sponsor were rated more highly, and suggests that consumers feel less favourably
towards the involvement of pharmaceutical companies in DAA (as the corporate

168

sponsor in the Hammond study was a more generic “marketing association”). Further
research is required as to whether consumers perceive a positive fit between
pharmaceutical companies and health NPOs in the sponsorship in DAA. Future
studies should also measure whether co-sponsorship of DAA by NPOs and
pharmaceutical companies has an effect the perceived credibility or reputation of the
individual organisations.

In the current study, there is potential that participants felt less positive attitudes
towards pharmaceutical companies because there was no acknowledgement of the
benefit to the companies. In DAA, pharmaceutical companies do not disclose their
commercial intent to sell prescription medicine products, and often position
advertisements as “community service announcements” (Medicines Australia, 2006).
Recent research indicates that consumers can become sceptical of corporate societal
marketing if the consumer perceives that the advertiser is deceiving them as to the
commercial or other benefits accrued by the corporation in undertaking the
marketing activity (Forehand and Grier, 2003).

While the advertisement sponsor did not show any significant influence on reported
behavioural intentions, participants agreeing they would take action as a result of
viewing the advertisements were significantly more likely to hold favourable
attitudes towards the sponsor. This result was expected as it has been demonstrated
that corporate credibility can influence purchase intention (Goldsmith et al., 2000;
Lafferty et al., 2002), and it was also found in the Hammond (1987) study that
corporate credibility had an effect on reported behaviour intention.

There are some limitations in the current study including that recruitment by
intercept method can result in a level of response bias. Sampling occurred during
retail hours over one week in a metropolitan shopping centre and may not be
representative of all Australian women in this age group. Participants’ viewing of
advertisements in the study environment would be different to how they would
normally view magazine advertisements and responses may have been affected by
social desirability bias, as women were completing surveys after being approached
by research assistants within a shopping mall. Finally, the survey questionnaire did
not ask participants about whether they perceived a level of fit between the sponsors
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and the cause, which is an important consideration when determining consumer
attitudes towards CRM activities.

While further research is required with larger sample sizes, and a wider range of
advertisements, the current study found that NPO sponsors alone attracted higher
sponsor scores, and that higher sponsor scores were found for participants with an
intention to take action after viewing the advertisement. These results suggest that
NPO-sponsored DAA is more effective without the co-sponsorship of a
pharmaceutical company. The growing concern about pharmaceutical involvement
with health NPOs may also detract from potential partnerships with industry in
promoting awareness about disease. However, if NPOs choose to enter a cosponsored arrangement in DAA, they may benefit from increasing their corporate
branding, and ensuring that their involvement is perceived to be dominant over that
of their pharmaceutical industry partners.
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9

CHAPTER 9: CONCLUSION

9. 1 Introduction
The objectives of the National Medicines Policy in 1999 called for accurate
information and education about medicines to be made available for consumers,
including responsible advertising that enhances public health. The results reported in
the previous chapters provide insight into current pharmaceutical companysponsored advertising to Australian consumers, including the provision of
information about medicines and health conditions. The results are summarised and
compared under three headings and implications for regulation are discussed. First,
the differing types of advertisements sponsored by pharmaceutical companies,
including Disease Awareness Advertising (DAA), Direct-to-Consumer Advertising
(DTCA), and unbranded product advertisements are considered. Second, results
relating to the content of advertisements are summarised, including persuasive and
informational content. Third, the effect of advertisements on consumers’ reported
behavioural intentions is discussed. The results suggest that while consumers have
positive perceptions of DAA provided by pharmaceutical companies, some
advertisements do not contain adequate disease information, are misleading, and may
encourage consumers to request a prescription from their doctors. This concluding
chapter also describes how this research informed the Medicines Australia (MA)
Code of Conduct Review in 2009 and discusses implications of the research for
advertisers, health professionals and consumers. It also provides recommendations
for future research to further understanding, and improve the regulation, of
pharmaceutical industry advertising in Australia.

9. 2 Types of Advertisements
Advertising for prescription medicines predominantly targets health professionals in
Australia, however pharmaceutical companies also target the general public with
different types of advertising including DAA. An initial aim of this research was to
determine the extent and nature of advertisements targeting the general public in the
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Australian mass media. Chapter 2 described cases of pharmaceutical companysponsored unbranded product advertising for prescription medicines that have
occurred in both print and broadcast media in Australia (Barry, 2000; Hughes and
Minchin, 2003). Unbranded product advertisements can stimulate demand for a
product, while not naming the product directly (ANZTPA, 2005). There is criticism
of unbranded product advertising in Australia, as these advertisements are considered
to circumvent the laws that prevent DTCA (Mackenzie et al., 2007; Vitry, 2004), and
the National Review conducted in 2000 (Galbally, 2000) concluded that unbranded
product advertising for prescription medicines could have similar negative
consequences as DTCA for public health.

Independent coders in the content analysis (Chapter 5) considered a sample of 30
advertisements that appeared in popular Australian magazines over a twelve month
period. They classified one third of the advertisements as unbranded product
advertisements, using the ANZTPA definition (ANZTPA, 2005). This definition
states that unbranded product advertisements “promotes the use and supply of a
product by inviting the consumer to seek information about symptoms or conditions
and/or their treatment or management while not referring overtly to any particular
branded product,” (ANZTPA, 2005 p. 9). While unbranded product advertising for
prescription medicine evidently exists in Australia, there is no specific clause to
prevent or regulate this type of advertising in the current Medicine Australia (MA)
Code of Conduct, Edition 16 (Medicines Australia, 2009). The term ‘unbranded’ is
misleading, as while the name of the product is not included, the content analysis
demonstrated that many other elements of branding are present in these
advertisements. Further research is required into the presence of unbranded product
advertising in Australia across a range of mediums, including the internet, and should
consider the potential effects of this advertising on quality use of medicines (QUM).

The content analysis (Chapter 5) also found that the majority of advertisements
identified during the monitoring period were for over-the-counter (OTC) products.
DAA accounted for approximately 8% of therapeutic advertisements and was found
to be sponsored by pharmaceutical companies, government entities, non-profit
organisations (NPOs) as well as a combination of advertisers.
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9.2.1

Consumers’ Perceptions of Different Types of Advertisements

An important objective of the research was to determine Australian consumer
responses to DAA including their perceptions of DAA generally, and their
perceptions of DAA compared with their perceptions of DTCA. Results described in
Chapters 3, 4, 6, 7 and 8 suggest that most consumers have favourable perceptions of
DAA, but feel less favourably towards DTCA and unbranded product
advertisements. The mail survey (Chapter 4) elicited Australian consumer responses
to actual New Zealand DTCA, and a matched Australian disease awareness
advertisement and an unbranded product advertisement. Participants were more
likely to find the disease awareness advertisement to be valuable than the unbranded
product advertisement or the DTCA. In the intercept survey (Chapter 7), older
Australian women were shown hypothetical DAA for two health conditions, and the
majority of participants held positive attitudes towards the advertisements.

In Chapter 3, Australian participants were asked about their general perceptions of
DAA, and this was compared with New Zealanders’ general perceptions of DTCA.
The majority of participants in both countries agreed that these advertisements make
people aware of different diseases or health conditions, and different treatment
options. Similar proportions also agreed that these advertisements helped them in
their discussions with doctors. Australian participants were ambivalent as to whether
DAA helped them to make better health decisions. New Zealanders held some
negative perceptions of DTCA including a perceived lack of balanced information in
advertisements, and the potential for advertisements to create an increased reliance
on medicines, or influence consumers to make inappropriate requests to their doctors
for medicines that may not suit them.
9.2.2

Consumers’ Perceptions of the Intent of Advertisements

The research aimed to explore consumer attitudes toward the sponsors of DAA,
including their perceptions of the intent of the advertisement and advertiser. In the
mail survey (Chapter 4) participants (including male and female over the age of 18)
were shown one of four different types of pharmaceutical company-sponsored
advertisements and asked what they thought the advertisement was trying to do.
Participants were more likely to perceive the intent of the disease awareness
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advertisement as being to provide information about a medical condition, whereas
for the unbranded product advertisement and the DTCA, they were more likely to
perceive the intent as being to sell a product or treatment. These results were
expected, as the participants that received the more product-focussed advertisements
recognised the commercial intent to sell a therapeutic product.

In Chapter 3, Australian participants were asked about their general perceptions of
advertisements for health conditions that require prescription medicines, 72% agreed
that advertisements alert people to disease in order to sell more medicine or medical
products, whereas 62% perceived advertisements were designed to increase positive
health behaviours.

In the intercept survey (Chapter 7), older Australian women were shown DAA for
two health conditions and were asked to identify what they perceived the
advertisement was trying to do by selecting one of six options. The most commonly
selected purpose was to provide information about a health condition (45%),
followed by to encourage them to talk to their doctor (18%), to encourage them to be
more proactive about their health (15%), and to provide information about a
treatment (12%). Only 10% perceived a direct commercial intent (to sell a product,
service or treatment, or to encourage them to ask for a prescription or referral).

The results regarding perceived intent of the advertisement from the two studies
described in Chapters 3 and 7 appear to be conflicting. This may be attributed to
methodological differences, as for Chapter 3, the original question referred to
advertisements for diseases or conditions that require prescription medicines, and this
may have suggested the commercial motive to participants. Further, participants
rated their agreement on a five-point scale (from strongly agree to strongly agree)
and were given the opportunity to respond to each and every statement. In Chapter 7,
however, participants were shown DAA as stimuli and were asked to select only one
of six options to identify what they perceived the advertisement was trying to do. The
differing results regarding perceived intent in these two studies may also be
attributed to sample differences, as the mail survey included male and female adult
participants, whereas the intercept survey included older (48+yrs) female
participants. This suggests that older women may be less sceptical regarding the
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intent of DAA. Further, the intercept survey (Chapter 8) found no significant
differences in women’s perceptions of the intent of DAA between advertisements
with commercial and non-commercial sponsors. This suggests that participants did
not identify the sponsor or did not consider sponsor motives when responding about
the intent of the advertisement.

Further research is required to determine consumers’ perceptions of the intent of
DAA, including consumers that are potentially more vulnerable such as older
consumers or those with lower literacy. From the current research, it appears that
when exposed to actual or hypothetical pharmaceutical company-sponsored DAA (as
described in Chapters 4 and 7) consumers do not recognise the commercial intent of
the advertisers. This is concerning as if consumers do not readily recognise the
commercial intent of industry-sponsored DAA then they may be less objective in
evaluating the information provided. This issue has been raised previously in
Australia, as well as in Canada and Europe, as an important matter for consumer
protection (Mackenzie et al., 2007; Mintzes, 1998, 2006).

9. 3 Content of Advertisements
For the past two decades, there has been increasing criticism of pharmaceutical
industry advertising of prescription medicines, particularly in countries that allow for
DTCA including the United States (US) and New Zealand (Coney, 2002; Mintzes,
2002; Woloshin et al., 2001). Much of the criticism is around the provision of very
persuasive yet potentially misleading information in advertisements, and the
potential negative effect this may have for public health. This research aimed to
explore the persuasive content of pharmaceutical company-sponsored advertising
targeting Australian consumers. It also aimed to determine the informational content
of advertisements, including the amount and types of disease information provided.
Consumer perceptions of advertising content for these two areas are described, and
implications for regulation discussed.
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9.3.1

Persuasive Content

The research aimed to determine the use of branding and other persuasive techniques
in pharmaceutical company-sponsored advertisements in the Australian mass media,
and specifically in Australian magazines. Chapter 2 describes the range of brand
building activities that can be employed by pharmaceutical companies including the
emerging practice of condition branding. This Chapter also provides cases of
pharmaceutical companies that use pseudo brands (where the identity of a product is
conveyed without actually naming it) to promote prescription medicines directly to
consumers. The content analysis (Chapter 5) found that most pharmaceutical
company-sponsored DAA utilised techniques such as campaign names, logos or
symbols. In the mail survey (reported in Chapter 2), where participants received one
of four different types of advertisements, they were asked to identify who they
thought the advertiser was. From the results, it appears that participants perceived the
text in the most prominent logo or symbol in the advertisement to be the advertiser.
Further research is required to determine how consumers perceive branding
techniques such as campaign names, spokes-characters, logos and symbols used in
pharmaceutical advertising, and whether they associate them with a prescription
medicine product. Research should also determine whether these techniques are
simultaneously being used in advertising to doctors, as is described for some of the
cases in Chapter 2, and whether they increase consumer intentions to seek a
prescription for a specific product.

In the content analysis (Chapter 5) the most prominent emotional appeal found in the
advertising imagery was positive (happiness/healthiness/wellbeing). The analysis
also found examples of pharmaceutical company-sponsored advertisements where
the advertising visuals conveyed an implicit message of inflated prevalence of a
health condition, and this differed to the explicit message of the text which conveyed
the actual prevalence. Future content analyses of pharmaceutical advertising in a
range of mediums should include more detailed analyses of the advertising visuals
and emotional appeals and, ideally consumer responses to such appeals should be
tested.
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As described in Chapter 8, the credibility of an advertisement sponsor can affect the
persuasiveness of an advertisement. An aim of the research project was to determine
Australian consumer responses to advertisements, including their attitudes towards
the sponsors of DAA. Only half of the older Australian women in the intercept
survey (Chapter 8) were able to correctly identify the sponsor despite clear corporate
branding on the bottom of each advertisement. Women receiving advertisements
with the NPO sponsor held significantly more favourable views towards the
advertiser than those viewing advertisements with a pharmaceutical company
sponsor or a combination of the two. For the predicted sponsor however,
significantly more positive scores were only found for the NPO advertiser when
compared with the pharmaceutical company sponsor. Further research could explore
consumers’ capacity to identify different sponsors of DAA, and the effect of cosponsored arrangements on perceived credibility of individual sponsors.
9.3.2

Informational Content

The research aimed to determine the provision of disease information in DAA in
Australian magazines. In the content analysis of DAA (Chapter 5) the most common
form of disease information found in all advertisements was treatment information,
followed by information on the cause of the condition and symptom information. For
pharmaceutical company-sponsored advertisements, treatment and prevalence
information were most commonly identified. This has implications for both
consumers and general practitioners. If advertisements focus on prevalence and
treatment of a condition and do not educate consumers regarding the aetiology,
symptoms, risk factors or prevention, then consumers may worry unnecessarily that
they are susceptible, and make inappropriate requests to their general practitioner for
medicines. Following exposure to the DAA in the intercept study (Chapter 6)
participants perceived much greater susceptibility to the advertised health conditions
than the actual prevalence rates for those health conditions.

In the content analysis (Chapter 5), of the advertisements included that were found to
be in breach of the Medicines Australia Code of Conduct, one was due to “the lack of
balance of information and that the information was intended to encourage a patient
to ask their doctor to prescribe a product” (complaint #810) (Medicines Australia,
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2006), and another because the information on treatments was not balanced
(complaint #866) (Medicines Australia, 2007). As previously mentioned, two other
pharmaceutical company-sponsored advertisements for genital herpes portrayed
inflated prevalence of the condition via the advertising imagery. These results
provide support for the notion that pharmaceutical company-sponsored DAA often
provides unbalanced information (Mintzes, 2006; Moynihan and Cassels, 2005).

The research aimed to determine consumer perceptions regarding the adequacy of
disease information in range of pharmaceutical company-sponsored advertisements.
In the mail survey (Chapter 4) participants found it easier to make sense of the
Alzheimer’s advertisements which were more text dominant, and felt the weight loss
advertisements which were more visually dominant provided insufficient information
regarding the condition itself and treatments available. The results from the intercept
study (Chapter 7) are similar to those for the direct mail survey (Chapter 4).
Participants that received the more detailed information advertisements were more
likely to be satisfied that adequate information was provided for all disease
information types than those receiving limited disease information advertisements.
For participants receiving the limited information advertisements, 64% agreed there
was adequate information on who was most at risk of getting the disease/condition,
just over half perceived adequate symptom or treatment information, and less than a
third perceived adequate prevalence, aetiology or prevention information.

The pharmaceutical industry has the opportunity to provide more comprehensive
disease information in DAA to better satisfy and educate consumers regarding health
conditions. The most recent Medicines Australia Code of Conduct guidelines state
that “disease education activities should cover the key characteristics of the disease”
(Medicines Australia, 2009), however this could be more prescriptive, such as the
guidelines used by the Medicines and Healthcare products Regulatory Agency
(MHRA) in the United Kingdom which stipulate that DAA should include
information on the aetiology, risk-factors, symptoms and preventive measures
(MHRA, 2005 p.54).

The research did not examine actual understanding of advertisements but the results
from Chapter 3 provide an indication of perceived understanding of different types of
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advertising. Almost half of the New Zealand participants thought that most people
felt confused by the information in DTCA which may be attributed to the requisite
product information. For Australian participants considering advertisements about
diseases/health conditions, one quarter felt that advertisements were difficult to
understand.

9. 4 Reported behavioural intentions
An important aim of the research project was to determine Australian consumer
behavioural intentions as a result of viewing pharmaceutical company-sponsored
advertisements. In the mail survey (Chapter 4) the behavioural intentions of
participants varied depending on which health condition was advertised. Participants
were asked if they would take specific actions after reading the advertisement
envisaging that the condition was relevant to them personally, or to a family member.
Participants viewing the Alzheimer’s advertisements were significantly more likely
to report an intention to talk with their doctor about the condition and about the
treatment, and to seek a prescription, than those viewing the weight-loss
advertisements. A similar response was found for the intercept survey (Chapter 6)
with participants more likely to report an intention to talk to their doctor, and ask
their doctor about treatments and tests after viewing the advertisement for
osteopenia, than those viewing the advertisement for fibromyalgia. These results
demonstrate that consumer’s involvement with the advertised health condition will
affect their reported behavioural intentions. Future studies should consider pretesting consumer perceptions and behavioural intentions for different health
conditions to ensure they do not differ significantly prior to conducting research with
advertising stimuli.

The majority of participants in the mail survey (Chapter 4) expressed an intention to
talk about the condition with their doctor and talk about the treatment with their
doctor, however less than 40% reported an intention to seek a prescription. Similarly
in the intercept survey (Chapter 6), the majority of participants agreed they would
talk to their doctor about the condition and about treatments. However, 49% of
participants in the intercept survey agreed they would ask their doctor for a
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prescription or referral after exposure to the hypothetical DAA. Potentially the higher
rate of agreement to request a prescription in the intercept survey is related to greater
relevance of the health conditions to participants in that study, as the advertised
health conditions were selected for their relevance to older women. The higher rate
of agreement for the intercept survey may also be attributed to sample differences, as
there is potential that older women are more likely to report an intention to request a
prescription or referral than the general population after viewing DAA. Further,
responses from the intercept survey may have been affected by social desirability
bias, as women were completing surveys after being approached by research
assistants within a shopping mall.

The high level of reported intention to request a prescription following exposure to
the DAA in the intercept survey has potentially negative implications, as the
advertisements for this study were for diagnostically controversial conditions, where
there is inconclusive evidence for pharmacological treatment. This is also concerning
from a public health perspective, as it demonstrates that such advertisements
encourage consumer demand for new pharmacological treatments which may not be
as effective or as safe as existing medications, or other non-pharmacological
therapies. Of particular concern is the result reported in Chapter 6, that women
viewing low information advertisements were more likely to report an intention to
ask their doctor for a prescription or referral than those viewing high information
advertisements. This has implications for regulation, as it appears that DAA can
stimulate demand for prescription medicine products, particularly if limited disease
information is provided. As previously suggested, Medicines Australia should
provide more guidance to pharmaceutical advertisers as to what types of disease
information (such as symptom, cause, prevalence and risk factor information) should
be included in DAA and what level of detail should be provided.

9. 5 Implications
This research has raised a number of important issues which are relevant to
regulators of pharmaceutical product advertising in Australia including Medicines
Australia and the Therapeutic Goods Administration, as well as the Australian New
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Zealand Therapeutic Products Authority if it is reinstated. The results have
implications for health professions, and may also be of interest to organisations such
as the National Prescribing Service and the Australian Medical Association. Some of
results have implications for consumers which may also be of interest to consumer
advocacy groups. Finally, there are implications for advertisers of disease including
pharmaceutical companies, NPOs and government entities, and recommendations to
improve advertisements to better educate consumers and benefit public health.
9.5.1

Implications for Regulation

An aim of this research project was to generate new information to inform future
regulation of pharmaceutical company-sponsored advertising in Australia. Within
this concluding chapter, several issues with implications for regulation of advertising
have been discussed, including the presence of unbranded product advertisements,
use of branding techniques to convey a product identity and the lack of disease
information in advertisements, and, of particular significance, the potential for DAA
with limited disease information to stimulate demand for a prescription product.
These results informed a submission by the Centre for Health Initiatives at the
University of Wollongong to the Medicines Australia Code of Conduct Review in
2009. The Review Committee took some points raised in the submission into account
and a new section ‘Disease Education Activities in Any Media’ (Section 12.7) has
appeared in Edition 16 of the Code, effective 1 January 2010 (Medicines Australia,
2009). However, the results of the intercept study indicate that even more detailed
guidelines regarding the amount and types of disease information to be included in
DAA are required. Guidelines regarding the accuracy of disease information would
also be beneficial, such as those suggested by Health on the Net Foundation for
accreditation of web-based health information (Health on the Net Foundation 2010).
Their Code principles recommend including the author and their qualifications, as
well citing sources of published information. The new Medicines Australia Code of
Conduct does not recognise the presence of, or specifically prohibit, unbranded
product advertising (or the use of pseudo-branding) in Australia despite evidence
reported in Chapters 2 and 5 that this exists.
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MA has also failed to address concerns regarding consumer vulnerability to DAA as
consumers do not readily recognise its commercial intent and may confuse it with
government or NPO-sponsored advertising. Medicines Australia continue to refer to
pharmaceutical company-sponsored DAA as a “community service” in the new Code
of Conduct (Medicines Australia, 2009). The lack of disclosure of the commercial
motive of pharmaceutical company-sponsored DAA (to sell prescription medicine
products) is potentially unethical, particularly when considering more vulnerable
groups such as older and less educated consumers. The World Health Organisation
Ethical Criteria for Medicinal Drug Promotion (1988) specifically states that
promotional material should not be designed so as to disguise its real nature, and
advertisements targeting the general public should not take advantage of consumers’
concern for their health. Further research is required into potential options to redress
the lack of disclosure of commercial intent in DAA, and it is hoped this may inform
future revisions to the Medicines Australia Code of Conduct.

In the systematic monitoring and selection of advertisements for the content analysis
(Chapter 5), nine unique pharmaceutical company-sponsored advertisements were
identified. It is concerning that three of these were found in breach of the Medicines
Australia Code of Conduct Edition 15. Potentially two advertisements for genital
herpes with misleading images would also be considered in breach had complaints
been submitted. This suggests a considerable proportion of industry-sponsored DAA
appearing in popular Australian magazines is not compliant, and that self-regulation
requires review. Edition 16 of the Medicines Australia Code of Conduct has only
recently come into effect, and the success of its revised guidelines and more
substantial sanctions is yet to be determined. Ongoing research is required to assess
current practices of pharmaceutical advertisers and to determine the effectiveness of
Australia’s industry-regulation of advertising. The lack of consumer complaints to
Medicines Australia regarding advertisements also requires investigation, including
whether consumers are aware of Code of Conduct and the Medicines Australia
complaints process. Ideally, independent monitoring of advertisements in
mainstream and digital media will occur, including monitoring the extent and nature
of unbranded product advertisements. While further research is required, including
analyses of advertisements in other media, other regulatory options should also be
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considered such as government regulation, or co-regulation by industry and
government.
9.5.2

Implications for Health Professionals

The research results have implications for health professionals as it was found that
pharmaceutical company-sponsored DAA in Australian magazines focuses on
treatment and prevalence information, and includes advice to speak with a doctor. It
is apparent that the commercial motive of pharmaceutical company-sponsored DAA
is to encourage conversations about health conditions between patients and doctors,
to increase the potential that the company’s product will be prescribed. The results of
this research suggest that consumers may perceive inflated severity of, and
susceptibility to, advertised health conditions. Further, advertisements with limited
disease information are likely to encourage patients to ask their doctor for a treatment
or referral. Health professionals should be aware of the potential influence that DAA
has on consumers, which may in turn exert an influence on their decision to prescribe
a therapeutic product. Because advertisements commonly omit important disease
information including risk factors and preventive measures, doctors may be required
to provide this information to their patients. Finally, health professionals should be
aware that pharmaceutical company-sponsored advertisements targeting consumers
often concurrently target doctors, but with a branded promotion, and that this has the
potential to influence their prescribing behaviours.
9.5.3

Implications for Consumers

Consumers have generally positive perceptions regarding DAA and their sponsors,
but are less aware of the commercial motive of pharmaceutical company-sponsored
advertisements. While implications for regulation have already been discussed, there
is also potential that consumers generally (and particularly more vulnerable groups)
would benefit from media literacy regarding DAA, to help them to correctly identify
the sponsors of advertisements and consider the sponsor motives. Such media
literacy may help consumers to identify persuasive techniques used in advertisements
and understand their potential effects. It could also help them to identify accurate and
credible sources of health information to guide their help seeking behaviours. The
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results indicate that consumers perceived inadequate disease information in DAA
and would benefit from the provision of more comprehensive disease information.
9.5.4

Implication for Advertisers

Many of the recommendations made for improvements to regulation of
pharmaceutical advertising in Australia could be independently adopted by
pharmaceutical advertisers – such as ensuring that comprehensive, balanced and
accurate disease information is provided to consumers, including information on
aetiology, prevalence, symptoms, risk-factors, treatment and prevention (where
relevant to the health condition advertised). As well as these recommendations and
local regulations, pharmaceutical companies should abide by the World Health
Organisation Ethical Criteria for Medicinal Drug Promotion (1988) previously
described. Results from the intercept survey (Chapter 8) suggest that other
advertisers of health conditions, including the government or NPOs, should consider
clearly differentiating their advertisements from those of pharmaceutical companies
in order to increase positive perceptions of the advertiser and advertisement, and
increase the likelihood of influencing behavioural intentions.

9. 6 Future Research
A number of areas for future research have already been identified in this concluding
chapter, including content analyses of DAA in other media, studies into the
effectiveness of different persuasive techniques in pharmaceutical companysponsored advertising, and further research into consumer perceptions and
behavioural intentions following exposure to a range of DAA for varying health
conditions in varying media. An area of growing interest is disease awareness
websites, as Australian consumers are increasingly turning to the Internet as their
preferred source of health information. The presence of pharmaceutical companysponsored disease awareness websites appears to be increasing in Australia, and a
recent study of Australian general practitioners found that close to half had
recommended such websites to their patients after receiving incentives or
enticements from pharmaceutical companies (Wayne and James, 2009).
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Broader research should also be considered regarding the increasing medicalisation
of western nations and consumer demand for pharmacological treatments, and the
longer term implications for public health. Research should explore the influence of a
range of agents for this change, including the pharmaceutical industry, and the
effects on public health. To provide accurate information about medicines and their
use, as set out in the National Medicines Policy, it would be important to assess the
effectiveness of a variety of providers of information to determine what most
benefits consumers from a public health perspective. Potentially, the provision of
information about health conditions and treatments, including non-pharmacological
treatments, from an independent or neutral service may be most beneficial.

9. 7 Conclusion
This research has extended knowledge regarding the types and content of
pharmaceutical company-sponsored advertisements that directly target consumers in
Australia and has provided evidence that unbranded product advertising for
prescriptions medicines does occur. Results from the direct and intercept surveys
indicate that consumers hold positive attitudes towards DAA and their sponsors, but
often feel that advertisements provide insufficient disease information. The results
suggest that when exposed to an actual disease awareness advertisement, consumers
do not readily recognise its commercial intent, but are often motivated by it to speak
with their doctor regarding the health condition and discuss potential treatments.
DAA that contains limited disease information is more likely to encourage
consumers to make requests for prescription medicines. This is potentially also the
case for DAA that provides unbalanced information or uses misleading imagery.
Such advertising may have negative consequences for consumers (such as
heightened anxiety), and their doctors (such as dealing with inappropriate requests
for medicines and spending consultation time re-educating patients). Further research
is required into pharmaceutical company-sponsored advertising in Australia,
including research into unbranded product advertisements and disease awareness
websites. It is important that regulation of pharmaceutical company-sponsored DAA
is strengthened to include guidelines regarding the amount and types of disease
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information to be provided, and to prohibit or provide specific guidelines for
unbranded product advertisements.
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Appendix A. Questionnaire for direct mail survey reported in Chapters 3 and 4
1.

When you first looked at the advertisement, what did you think stood out the
most? (please tick one box only)
Pictures
Title
Advertiser logo
Other logo
Product information
Sources for more information
Other (please write)

2.

Do you feel the advertisement is (Please rate on the following scale):

Extremely Valuable

Valuable

Neutral

Not very valuable

Not valuable at all

Please provide a reason for your response:

3.

What do you think this advertisement is trying to do?
(please tick one box only)
Provide information about a medical condition
Provide information about a treatment
Sell a product or treatment
Encourage me to talk to my doctor
Encourage me to ask for a prescription
Other (please write)

4.

How easy was it to make sense of the information written under the picture in
the advertisement? (please tick one box only)
Very easy
Quite easy
Neither easy nor difficult
Quite difficult
Very difficult
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5.

After reading the advertisement, do you feel adequate information was
provided regarding (please tick either Yes or No for each)
The medical condition itself
The treatments available
The benefits of treatments
Risks associated with treatments
How/where to obtain the treatment
How/where to get further information

6.

Yes
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No
No

Imagine this condition was relevant to you personally, as a result of reading
the advertisement would you… (please tick either Yes or No for each)
Talk about the condition with your doctor
Talk about the treatment with your doctor
Seek a prescription from your doctor
Other (please write)

7.

Yes
Yes
Yes

No
No
No

Imagine this condition was relevant to someone close to you, as a result of
reading the advertisement would you …
(please tick either Yes or No for each)
Disucss the condition with them
Talk about the potential treatment with them
Encourage them to discuss the condition with their doctor
Encourage them to discuss the treatment with their doctor
Encourage them to seek a prescription from their doctor
Other (please write)

Yes
Yes
Yes
Yes
Yes

No
No
No
No
No

8.

Who do you think the advertiser is?

9.

How reliable you think this advertiser is in providing information regarding
this condition or disease? (please tick one box only)
Very reliable
Quite reliable
Not very reliable
Not at all reliable
Not sure
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10. Have you recently seen or heard any other advertising about diseases or
conditions that require prescription medicines (medicines prescribed only by a
doctor)?
Yes
No
Not sure

Please go to question 13

11. Where did you see or hear advertisements about diseases/conditions that require
prescription medicines? (please tick as many boxes as you need to)
On television
On the radio
In a magazine
In a newspaper
On the Internet
On a billboard
In a letter or leaflet that came in the mail
Other (please write)

12. Which of the following diseases or conditions do you recall seeing/hearing an
advertisement for? Please tick as many boxes as you need to.
Osteoporosis

Alzheimer’s

Heart disease

Erectile dysfunction

Weight loss

Arthritis

Genital herpes

Diabetes

Asthma

Meningococcal C

Chlamydia

Cholesterol

Vaccination/Immunisation

Other (please write)
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13.

Please read the statements below and then tick a box beside each statement to
show how much you agree or disagree with that statement (please tick ONE
box for each statement).
Strongly
Agree

Agree

Neither
agree nor
disagree

Disagree Strongly
disagree

Advertisements help make
people aware of
diseases/conditions and
different treatment options











Advertisements about
diseases/ conditions help
people make better decisions
about their health











Advertisements about
diseases/ conditions help
people have better discussions
with their doctor











Advertisements about
diseases/ conditions confuse
people about what disease they
may be at risk of developing











Advertisements about
diseases/ conditions are often
difficult to understand











Advertisements alert people to
disease in order to make the
disease itself more important











Advertisements alert people to
disease in order to sell more
medicine or medical products











Advertisements alert people to
disease in order to increase
positive health behaviours
such as diet or exercise











Advertisements alert people to
disease in order to increase
visits to doctors or other health
professionals
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14.

How knowledgeable would you say you are about health and medicines?
(please tick one box only)
Very knowledgeable
Quite knowledgeable
Not very knowledgeable
Not at all knowledgeable

15.

How would you rate your own health over the last twelve months?
(please tick one box only)
Excellent
Very good
Good
Fair
Poor

16.

Have you or a family member experienced any of the following conditions:

Overweight

You
Yes

No

Alzheimer’s

Yes

No

Yes

No

Heart disease

Yes

No

Yes

No

Asthma

Yes

No

Yes

No

Arthritis

Yes

No

Yes

No

17.

In what year were you born? 19 ______

18.

What is your country of birth? (please write)

Family Member
Yes
No

__________________________________
19.

Which of these categories best describes your highest formal qualification?
Still attending school
Year 11 or less (did not complete HSC or equivalent)
Completed High School Certificate (Year 12 or equivalent)
Trade Certificate
Other Certificate
Associate or Undergraduate Diploma
Bachelor’s Degree or higher
Other (please write)
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20.

What is your gender?
Female
Male
__ __ __ __

21.

What is your postcode?

22.

Are you an Aboriginal or Torres Strait Islander?
Yes
No

198

Appendix B. Participant information sheet for direct mail survey reported in
Chapters 3 and 4

Research Study into Peoples’ Responses to Advertisements about Disease.

Chief Investigators:

A/Prof Sandra Jones and Danika Hall
University of Wollongong

RESEARCH STUDY INFORMATION

The University of Wollongong is conducting research into peoples’ attitudes towards
magazine advertisements for diseases or health conditions and the impact of such
advertisements on consumer behaviour.
We request that a person in your household over the age of 18 completes the
questionnaire. If that person sends the completed questionnaire in the enclosed reply
paid envelope along with the separate consent form, they will go into the draw to win
one of six $100.00 ‘Coles Myer’ vouchers.
Please note that consent forms and surveys will be separated on receipt at the
University of Wollongong so that questionnaire responses remain confidential.
Participation in this research study is entirely voluntary and you are free to choose to
participate or not participate. However, due to the confidential nature of the
questionnaire once it has been completed and returned you will not be able to
withdraw as the data cannot be identified.
If you have any questions regarding the study itself before or after you have
completed the questionnaire or would like a copy of the results once the information
has been completed you can contact Associate Professor Sandra Jones on 4221 4209.
If you have any concerns or complaints regarding how the research is or has been
conducted you can contact the Ethics Officer, Human Research Ethics Committee,
University of Wollongong 4221 4457.
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Appendix C: Advertisement stimuli for mail survey reported in Chapter 4
On this page, there is an advertisement about weight loss.
We know that this may not be relevant to you personally, but we would like you to
read the advertisement as though it was relevant to you. Once you have read the
advertisement, please answer questions on the following pages.
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On this page, there is an advertisement about weight loss.
We know that this may not be relevant to you personally, but we would like you to
read the advertisement as though it was relevant to you. Once you have read the
advertisement, please answer questions on the following pages.
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On this page, there is an advertisement about Alzheimer’s Disease.
We know that this may not be relevant to you personally, but we would like you to
read the advertisement as though it was relevant to you. Once you have read the
advertisement, please answer questions on the following pages.
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On this page, there is an advertisement about Alzheimer’s Disease.
We know that this may not be relevant to you personally, but we would like you to
read the advertisement as though it was relevant to you. Once you have read the
advertisement, please answer questions on the following pages.

Appendix D: Coding sheet for content analysis reported in Chapter 5
1. Ad number

2. Coder initials

3. Advertiser

4. Advertiser type

Government or

Non Government

Pharmaceutical

Combination of

government agency

Organisation

company

advertisers

Unbranded product

Generic advertisement

Other (please state)

5. What do you think this ad is trying to do?

6. Ad type (see guide)

Disease
awareness

Other (please state)

(please state)

7. Disease/condition

8. Disease information (see guide – select one of the four options for each)

None

Mention &

Focus of the

discussion

ad

Comments

Mention

a. Cause/Aetiology
b. Symptoms
c. Risk factor(s)
d. Prevalence
e. Treatment
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f. Prevention
g. Supportive behaviours
h. Other (please state)

9. Further information (select
which apply)
10. Target audience:
Who do you think the
advertisement is talking to?
Note that this may be different
to the person at risk of (or
experiencing) the
disease/condition.

Website

Telephone

a. What gender group
(select one only)

b. What age group
(select one only)

Talk to

Talk to doctor

pharmacist

Other (please state)

Male

Female

Both male and
female

Children/Teens

Young adults

Adults

Older people

11. Advertising visuals.
a. Does the visual imagery contain an

Y/N

emotional appeal (see guide)
b. If applicable, what is the dominant type of
emotional appeal in the main image of the
advertisement
(select one only)

Happiness, healthiness,
wellbeing
Fear, revulsion,
potential loss

Success, social approval

Humour

Sex

Guilt, regret

Frustration

Other emotion (please state)

c. What does the main image of the
advertisement contain (see guide –select

Two or more people

Single person

Part of person/ people

Other (please state)
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one only)

204

d. If one or more person used, what

Expert

type of person (select one only)
e. Image setting for main image of the
advertisement (if applicable)
f. Image type for main image of the
advertisement (select one only)
g. Size of the main image of the
advertisement
11. Advertising visuals
continued…

Person at risk of

Person experiencing

disease/condition

disease/condition

Lifestyle

Photo

Clinical

Icon/symbol

¼ page or less

Diagram
¼ page to
½ page

Other (please state)

Other (please state)

Cartoon

Other (please state)

½ page to ¾ page

More than ¾ page

h. Explicit message of imagery
(please state)

(what actually appears in the main image in
the advertisement)
i. Implicit message of imagery
(please state)

(what meaning is implied by the main image
of the advertisement)
Present

Size (relative to size of page)

j. Corporate brand/logo
Y/N
Present
Y/N

Small (<5%)

Medium (5-15%)

Large (15%+)

Size (relative to size of page)
Small (<5%)

Medium (5-15%)

Large (15%+)

k. Campaign name/brand/symbol/logo
if YES, please state the name and/or describe the brand/symbol/logo
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12. Advertising text
Present

(If YES, please state title/headline)

a. Title/headline of the advertisement
Y/N
b. Does the main title/headline contain an

Y/N

emotional appeal (see guide)

Happiness, healthiness,
c. What is the dominant type of emotional

wellbeing

appeal in the main title/ headline (select one

Fear, revulsion,

only)

potential loss

d. Does the body text of the advertisement

Success, social approval

Humour

Guilt, regret

Frustration

Sex
Other emotion (please
state)

Y/N

contain a rational appeal (see guide)
(if YES, please state)

e. Is there a call to action/
tagline to be remembered (see guide)

Y/N

13. Which of the following “motives” are demonstrated in the advertisement (see definitions below)
13a. Primary (choose one)

13b. Secondary (Answer yes or no to all. Answer no if you have already selected as your primary motive):

problem removal

problem removal

Yes

No

problem avoidance

problem avoidance

Yes

No

incomplete satisfaction

incomplete satisfaction

Yes

No

mixed approach-avoidance

mixed approach-avoidance

Yes

No

normal depletion

normal depletion

Yes

No

sensory gratification

sensory gratification

Yes

No
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intellectual stimulation or mastery

intellectual stimulation or mastery

Yes

No

social approval

social approval

Yes

No

Motivation

Definition

Example(s) of products

Problem removal

eliminate/reduce a current problem

OTC analgesics

Problem avoidance

avoid a potential future problem

health insurance

Incomplete satisfaction

current product doesn’t fully meet needs, so looking for something better

“more thirst-quenching” soft drink, “stronger” painkiller

Mixed approach-avoidance

product has negatives as well as positives, so seeking to gain positives while
reducing/avoiding negatives

low-calorie soft drinks, low-fat cookies

Normal depletion

have/could run out of product

stocking up on batteries

Sensory gratification

something that makes you feel good

candy, alcohol, luxury cars

Intellectual stimulation or
mastery

attain a sense of accomplishment

university course, sky-diving

Social approval

make people like you/approve of you more

fashion (especially for young people), some food products (especially children and
mothers)

Estimate time taken to complete coding this advertisement (mins)
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Appendix E: Examples of stimuli used in intercept survey reported in
Chapters 6, 7 and 8

Fibromyalgia: co-sponsored; low information.
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Osteopenia: co-sponsored; low information.
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Fibromyalgia: co-sponsored; high information.
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Osteopenia: co-sponsored; high information.
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Appendix F: Advertisement questionnaire for intercept survey reported in
Chapters 6, 7 and 8
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Appendix G: Participant information sheet for intercept survey reported in
Chapters 6, 7 and 8

Participant Information Sheet
Australian Women’s Perceptions of Health Advertisements

Purpose of Research
This project is researching adult women’s attitudes towards advertisements for two
health conditions: Fibromyalgia and Osteopenia. It aims to determine what type of
advertisement they find most valuable, what information they find most useful and
how they perceive the advertisements might affect their behaviour.

Participant Involvement
Once you have read this sheet, the researcher will separately show you two
advertisements and ask you to answer a one-page questionnaire on each.
Participation in this study should take approximately ten minutes of your time. Your
involvement in this study is voluntary and you are free to discontinue at any stage.
Your responses will not be identifiable, and as such, once you have submitted
completed questionnaires they cannot be withdrawn.

Researchers:
This study is part of a PhD undertaken by Ms Danika Hall of the Centre for Health
Initiatives (Tel: 4221 5811) and supervised by the Director of that Centre, Professor
Sandra Jones (Tel: 4221 4209). The study has been reviewed by the University of
Wollongong Human Ethics Committee, and if you have any concerns regarding the
way this research is conducted you can contact the Ethics Officer (Tel: 4221 4457).
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Appendix H: Number of women completing questionnaires,
reported in Chapter 6

Women
approached:
977

Agreed:
293

Eligible:
247

Usable:
241

Completed one
advertisement:
16
(16 ads)

Completed two
advertisements:
225
(450 ads)

Not Useable:
6

Not Eligible:
46

Refused:
684
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APPENDIX I: Samples of stimuli used in intercept study reported in Chapter 8

Osteopenia: pharma-sponsored
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Osteopenia: foundation-sponsored
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Osteopenia: co-sponsored

